{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import os\n",
    "import re\n",
    "import requests as req\n",
    "import urllib.request\n",
    "from dotenv import load_dotenv\n",
    "from IPython.display import display, Markdown\n",
    "\n",
    "import chromadb\n",
    "import nest_asyncio\n",
    "\n",
    "nest_asyncio.apply()\n",
    "\n",
    "from llama_index.core import Document, Settings, StorageContext, VectorStoreIndex\n",
    "from llama_index.core.memory import ChatMemoryBuffer\n",
    "from llama_index.core.node_parser import SentenceSplitter\n",
    "from llama_index.core.response.notebook_utils import display_response\n",
    "from llama_index.core.schema import MetadataMode\n",
    "#from llama_index.embeddings.nomic import NomicEmbedding\n",
    "from llama_index.embeddings.openai import OpenAIEmbedding\n",
    "from llama_index.llms.openai import OpenAI\n",
    "from llama_index.vector_stores.chroma import ChromaVectorStore\n",
    "\n",
    "import openai\n",
    "\n",
    "from utils_17 import extract_from_json, flatten_dict, replace_double_newline, format_flattened_dict, pfizer_ncts\n",
    "from loader_utils import *\n",
    "load_dotenv() \n",
    "# nomic_api_key = os.getenv(\"NOMIC_API_KEY\")\n",
    "openai_api_key = os.getenv(\"OPENAI_API_KEY\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "%%bash\n",
    "find ./ -type f -name \"*.json\" -delete"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "%%bash\n",
    "rm -rf chroma_db"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "list_of_nct_id = pfizer_ncts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "247"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# fetch the JSON data for the trials\n",
    "downloaded_json = get_downloaded_json(list_of_nct_id)\n",
    "# downloaded_json[0] # check\n",
    "len(downloaded_json) # check"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "247"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents_list = list_from_extracted_json(downloaded_json)\n",
    "len(documents_list) # check"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "68"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_keys = max_keys(documents_list)\n",
    "len(all_keys)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "62"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "llm_keys_to_incude = [\n",
    "    \"National Clinical Identification NCT ID\",\n",
    "    \"Brief title\",\n",
    "    \"Condition\",\n",
    "    \"Conditions keywords\",\n",
    "    \"Lead sponsor\",\n",
    "    \"Arms group 0 intervention names\",\n",
    "]\n",
    "\n",
    "# to exclude the keys not used by LLM\n",
    "llm_keys_to_exclude = adjust_metadata_keys(all_keys, llm_keys_to_incude)\n",
    "len(llm_keys_to_exclude)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "62"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "embedding_keys_to_incude = [\n",
    "    \"National Clinical Identification NCT ID\",\n",
    "    \"Brief title\",\n",
    "    \"Condition\",\n",
    "    \"Conditions keywords\",\n",
    "    \"Lead sponsor\",\n",
    "    \"Arms group 0 intervention names\",\n",
    "]\n",
    "\n",
    "# to exclude the keys not used by embedding\n",
    "embedding_keys_to_exclude = adjust_metadata_keys(all_keys, llm_keys_to_incude)\n",
    "len(embedding_keys_to_exclude)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "embed_model = OpenAIEmbedding(model=\"text-embedding-ada-002\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "llm3 = OpenAI(temperature=0.001, model=\"gpt-3.5-turbo\", max_tokens=512)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "# NOTE:  metata data must be one of (str, int, float, None)\n",
    "def create_llama_docs(documents_list):\n",
    "    \"\"\"\n",
    "    Converts a list of trial documents into LlamaIndex Document objects.\n",
    "    \"\"\"\n",
    "    \n",
    "    llama_documents = []  \n",
    "    for trial in documents_list:\n",
    "        # apply functions from utils to flatten JSON and create content similar to the example above\n",
    "        content_text = format_flattened_dict(flatten_dict(trial))\n",
    "\n",
    "        llama_document = Document(\n",
    "            text=content_text, \n",
    "            metadata=trial, \n",
    "            excluded_llm_metadata_keys=llm_keys_to_exclude, #<== adjust?, TBD\n",
    "            excluded_embed_metadata_keys=embedding_keys_to_exclude , #<== adjust?, TBD\n",
    "            metadata_template=\"{key}=>{value}\",\n",
    "            text_template=\"Metadata:\\n{metadata_str}\\n===========================\\nContent: \\n{content}\"\n",
    "        )\n",
    "        llama_documents.append(llama_document)  \n",
    "    return llama_documents\n",
    "\n",
    "llama_documents = create_llama_docs(documents_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_nodes(llama_documents):\n",
    "    \"\"\"\n",
    "    Generates and embeds nodes from Llama documents.\n",
    "    \"\"\"\n",
    "    parser = SentenceSplitter(chunk_size=1024,chunk_overlap=20) # <== adjust from default\n",
    "    nodes = parser.get_nodes_from_documents(llama_documents)\n",
    "    for node in nodes:\n",
    "        node_embedding = embed_model.get_text_embedding(\n",
    "            node.get_content(metadata_mode=MetadataMode.EMBED)\n",
    "        )\n",
    "        node.embedding = node_embedding\n",
    "    return nodes\n",
    "\n",
    "nodes = create_nodes(llama_documents)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Looking for the CLINICAL_RAG collection in the database...\n",
      "CLINICAL_RAG collection WAS NOT FOUND in Chroma DB, creating...\n",
      "Creating vector store...\n",
      "Creating vector store index\n",
      "record count: 700\n"
     ]
    }
   ],
   "source": [
    "# Chroma DB collection name\n",
    "COLLECTION_NAME = \"CLINICAL_RAG\"\n",
    "\n",
    "db = chromadb.PersistentClient(path=\"chroma_db\")\n",
    "print(f\"Looking for the {COLLECTION_NAME} collection in the database...\" )\n",
    "if COLLECTION_NAME not in [col.name for col in db.list_collections()]:\n",
    "    print(f\"{COLLECTION_NAME} collection WAS NOT FOUND in Chroma DB, creating...\")\n",
    "    chroma_collection = db.create_collection(COLLECTION_NAME)\n",
    "    print(\"Creating vector store...\")\n",
    "    vector_store = ChromaVectorStore(chroma_collection=chroma_collection)\n",
    "    storage_context = StorageContext.from_defaults(vector_store=vector_store)\n",
    "    print(\"Creating vector store index\")\n",
    "    VectorStoreIndex(\n",
    "        nodes=nodes,\n",
    "        storage_context=storage_context,\n",
    "        store_nodes_override=True\n",
    "    )\n",
    "    record_count = chroma_collection.count()\n",
    "    print(f\"record count: {record_count}\")   \n",
    "    \n",
    "else:\n",
    "    print(f\"{COLLECTION_NAME} collection WAS FOUND in Chroma DB\")\n",
    "    COLLECTION_NAME = db.get_collection(COLLECTION_NAME)\n",
    "    vector_store = ChromaVectorStore(chroma_collection=COLLECTION_NAME)\n",
    "    print(\"Restoring vector store index from the collection...\")\n",
    "    index = VectorStoreIndex.from_vector_store(\n",
    "        vector_store=vector_store,\n",
    "        embed_model=embed_model,\n",
    "        store_nodes_override=True\n",
    "    )\n",
    "    record_count = COLLECTION_NAME.count()\n",
    "    print(f\"record count: {record_count}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Start of Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "llm4 = OpenAI(model=\"gpt-4\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "vector_index = VectorStoreIndex.from_vector_store(vector_store)  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "query_engine = vector_index.as_query_engine(llm=llm3)\n",
    "\n",
    "response_vector = query_engine.query(\"What were the primary inclusion criteria for neonates in the study evaluating the safety and efficacy of IV sildenafil in the treatment of persistent pulmonary hypertension of the newborn?\")\n",
    "response_vector_1 = query_engine.query(\"What are the inclusion criteria for patients participating in the study, specifically regarding their breast cancer diagnosis and treatment history?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(Response(response='The primary inclusion criteria for neonates in the study were: they had to have persistent pulmonary hypertension of the newborn, be less than or equal to 96 hours old and more than or equal to 34 weeks gestational age, have an Oxygenation Index greater than 15 and less than 60, and be undergoing concurrent treatment with inhaled nitric oxide and at least 50% oxygen.', source_nodes=[NodeWithScore(node=TextNode(id_='bc90b2bd-c2c7-4cc5-9593-bcbff30f82f6', embedding=None, metadata={'National Clinical Identification NCT ID': 'NCT01720524', 'Organization study identification': 'A1481316', 'EudraCT number': '2012-002619-24', 'Organization': 'Pfizer', 'Organization class': 'INDUSTRY', 'Brief title': 'A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn', 'Official title': 'A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT', 'Overall status': 'COMPLETED', 'Start date': '2013-08-05', 'Primary completion date': '2018-10-17', 'Completion date': '2020-09-28', 'Verification date': '2021-08', 'Study first submitted date': '2012-09-17', 'Results first submitted date': '2019-10-16', 'Last update submitted date': '2021-08-12', 'Last update posted date': '2021-08-16', 'Lead sponsor': \"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.\", 'Lead sponsor class': 'INDUSTRY', 'Brief summary': 'This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.', 'Detailed description': 'oof, this data not available', 'Condition': \"['Pulmonary Hypertension, Familial Persistent, of the Newborn']\", 'Conditions keywords': \"['persistent pulmonary hypertension', 'newborn', 'neonates', 'iv sildenafil', 'hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn']\", 'Study type': 'INTERVENTIONAL', 'Phases': \"['PHASE3']\", 'Allocation': 'RANDOMIZED', 'Intervention model': 'PARALLEL', 'Primary purpose': 'TREATMENT', 'Masking': 'DOUBLE', 'Who is masked': \"['PARTICIPANT', 'INVESTIGATOR']\", 'Enrollment count': '59', 'Enrollment type': 'ACTUAL', 'Arms group 0 label': 'placebo', 'Arms group 0 type': 'PLACEBO_COMPARATOR', 'Arms group 0 description': 'iv placebo of normal saline or 10% dextrose', 'Arms group 0 intervention names': \"['Drug: placebo']\", 'Arms group 1 label': 'sildenafil', 'Arms group 1 type': 'EXPERIMENTAL', 'Arms group 1 description': 'Active study drug', 'Arms group 1 intervention names': \"['Drug: iv sildenafil']\", 'Arms group 0 intervention type': 'DRUG', 'Arms group 0 intervention name': 'placebo', 'Arms group 0 intervention description': 'IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.', 'Arms group 0 intervention labels': \"['placebo']\", 'Arms group 1 intervention type': 'DRUG', 'Arms group 1 intervention name': 'iv sildenafil', 'Arms group 1 intervention description': 'loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.', 'Arms group 1 intervention labels': \"['sildenafil']\", 'Primary outcome': 'Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure', 'Primary outcome description': 'Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.', 'Primary outcome time frame': '14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)', 'Eligibility criteria': 'Inclusion Criteria:\\n\\n* Neonates with persistent pulmonary hypertension of the newborn\\n* Age \\\\<=96 hours and \\\\>=34 weeks gestational age\\n* Oxygenation Index \\\\>15 and \\\\<60\\n* Concurrent treatment with inhaled nitric oxide and \\\\>=50% oxygen\\n\\nExclusion Criteria:\\n\\n* Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation\\n* Expected duration of mechanical ventilation \\\\<48 hours\\n* Profound hypoxemia\\n* Life-threatening or lethal congenital anomaly', 'Eligibility of healthy volunteer': 'False', 'Eligibility sex': 'ALL', 'Eligibility minimum age': '0 Days', 'Eligibility standard age': \"['CHILD']\", 'Pre-assignment details': 'Neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure (HRF) and at risk of PPHN who were receiving inhaled nitric oxide (iNO) treatment were evaluated in this study.', 'Recruitment details': 'This study was planned in two parts Part A (double-blind phase) and Part B (long-term, non-intervention phase).', 'Recruitment group 0 id': 'FG000', 'Recruitment group 0 title': 'IV Sildenafil', 'Recruitment group 0 description': \"Part A: Participants received sildenafil intravenously based on their body weight at a loading dose of 0.1 milligrams per kg (mg/kg) for 30 minutes on Day 1 followed by a maintenance dose of 0.03 milligrams per kg per hour (mg/kg/hr), for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Recruitment group 1 id': 'FG001', 'Recruitment group 1 title': 'Placebo', 'Recruitment group 1 description': \"Participants received placebo (0.9 % normal saline or dextrose 10%) at a rate matched to sildenafil infusion, intravenously, based on participant's weight, for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Group IDs': \"[{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.9850', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least square (LS) mean difference', 'paramValue': '0.0', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2.08', 'ciUpperLimit': '2.04', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.02'}]\", 'p-value': '0.9850', 'Statistical Method': 'ANCOVA', 'Limitations and caveats': '', 'Has results': 'True'}, excluded_embed_metadata_keys=['Organization study identification', 'EudraCT number', 'Organization', 'Organization class', 'Official title', 'Overall status', 'Start date', 'Primary completion date', 'Completion date', 'Verification date', 'Study first submitted date', 'Results first submitted date', 'Last update submitted date', 'Last update posted date', 'Lead sponsor class', 'Brief summary', 'Detailed description', 'Study type', 'Phases', 'Allocation', 'Intervention model', 'Primary purpose', 'Masking', 'Who is masked', 'Enrollment count', 'Enrollment type', 'Arms group 0 label', 'Arms group 0 type', 'Arms group 0 description', 'Arms group 1 label', 'Arms group 1 type', 'Arms group 1 description', 'Arms group 1 intervention names', 'Arms group 0 intervention type', 'Arms group 0 intervention name', 'Arms group 0 intervention description', 'Arms group 0 intervention labels', 'Arms group 1 intervention type', 'Arms group 1 intervention name', 'Arms group 1 intervention description', 'Arms group 1 intervention labels', 'Primary outcome', 'Primary outcome description', 'Primary outcome time frame', 'Eligibility criteria', 'Eligibility of healthy volunteer', 'Eligibility sex', 'Eligibility minimum age', 'Eligibility standard age', 'Pre-assignment details', 'Recruitment details', 'Recruitment group 0 id', 'Recruitment group 0 title', 'Recruitment group 0 description', 'Recruitment group 1 id', 'Recruitment group 1 title', 'Recruitment group 1 description', 'Group IDs', 'p-value', 'Statistical Method', 'Limitations and caveats', 'Has results'], excluded_llm_metadata_keys=['Organization study identification', 'EudraCT number', 'Organization', 'Organization class', 'Official title', 'Overall status', 'Start date', 'Primary completion date', 'Completion date', 'Verification date', 'Study first submitted date', 'Results first submitted date', 'Last update submitted date', 'Last update posted date', 'Lead sponsor class', 'Brief summary', 'Detailed description', 'Study type', 'Phases', 'Allocation', 'Intervention model', 'Primary purpose', 'Masking', 'Who is masked', 'Enrollment count', 'Enrollment type', 'Arms group 0 label', 'Arms group 0 type', 'Arms group 0 description', 'Arms group 1 label', 'Arms group 1 type', 'Arms group 1 description', 'Arms group 1 intervention names', 'Arms group 0 intervention type', 'Arms group 0 intervention name', 'Arms group 0 intervention description', 'Arms group 0 intervention labels', 'Arms group 1 intervention type', 'Arms group 1 intervention name', 'Arms group 1 intervention description', 'Arms group 1 intervention labels', 'Primary outcome', 'Primary outcome description', 'Primary outcome time frame', 'Eligibility criteria', 'Eligibility of healthy volunteer', 'Eligibility sex', 'Eligibility minimum age', 'Eligibility standard age', 'Pre-assignment details', 'Recruitment details', 'Recruitment group 0 id', 'Recruitment group 0 title', 'Recruitment group 0 description', 'Recruitment group 1 id', 'Recruitment group 1 title', 'Recruitment group 1 description', 'Group IDs', 'p-value', 'Statistical Method', 'Limitations and caveats', 'Has results'], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='b176b5aa-cb7c-4598-83b6-358020237e97', node_type=<ObjectType.DOCUMENT: '4'>, metadata={'National Clinical Identification NCT ID': 'NCT01720524', 'Organization study identification': 'A1481316', 'EudraCT number': '2012-002619-24', 'Organization': 'Pfizer', 'Organization class': 'INDUSTRY', 'Brief title': 'A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn', 'Official title': 'A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT', 'Overall status': 'COMPLETED', 'Start date': '2013-08-05', 'Primary completion date': '2018-10-17', 'Completion date': '2020-09-28', 'Verification date': '2021-08', 'Study first submitted date': '2012-09-17', 'Results first submitted date': '2019-10-16', 'Last update submitted date': '2021-08-12', 'Last update posted date': '2021-08-16', 'Lead sponsor': \"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.\", 'Lead sponsor class': 'INDUSTRY', 'Brief summary': 'This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.', 'Detailed description': 'oof, this data not available', 'Condition': \"['Pulmonary Hypertension, Familial Persistent, of the Newborn']\", 'Conditions keywords': \"['persistent pulmonary hypertension', 'newborn', 'neonates', 'iv sildenafil', 'hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn']\", 'Study type': 'INTERVENTIONAL', 'Phases': \"['PHASE3']\", 'Allocation': 'RANDOMIZED', 'Intervention model': 'PARALLEL', 'Primary purpose': 'TREATMENT', 'Masking': 'DOUBLE', 'Who is masked': \"['PARTICIPANT', 'INVESTIGATOR']\", 'Enrollment count': '59', 'Enrollment type': 'ACTUAL', 'Arms group 0 label': 'placebo', 'Arms group 0 type': 'PLACEBO_COMPARATOR', 'Arms group 0 description': 'iv placebo of normal saline or 10% dextrose', 'Arms group 0 intervention names': \"['Drug: placebo']\", 'Arms group 1 label': 'sildenafil', 'Arms group 1 type': 'EXPERIMENTAL', 'Arms group 1 description': 'Active study drug', 'Arms group 1 intervention names': \"['Drug: iv sildenafil']\", 'Arms group 0 intervention type': 'DRUG', 'Arms group 0 intervention name': 'placebo', 'Arms group 0 intervention description': 'IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.', 'Arms group 0 intervention labels': \"['placebo']\", 'Arms group 1 intervention type': 'DRUG', 'Arms group 1 intervention name': 'iv sildenafil', 'Arms group 1 intervention description': 'loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.', 'Arms group 1 intervention labels': \"['sildenafil']\", 'Primary outcome': 'Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure', 'Primary outcome description': 'Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.', 'Primary outcome time frame': '14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)', 'Eligibility criteria': 'Inclusion Criteria:\\n\\n* Neonates with persistent pulmonary hypertension of the newborn\\n* Age \\\\<=96 hours and \\\\>=34 weeks gestational age\\n* Oxygenation Index \\\\>15 and \\\\<60\\n* Concurrent treatment with inhaled nitric oxide and \\\\>=50% oxygen\\n\\nExclusion Criteria:\\n\\n* Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation\\n* Expected duration of mechanical ventilation \\\\<48 hours\\n* Profound hypoxemia\\n* Life-threatening or lethal congenital anomaly', 'Eligibility of healthy volunteer': 'False', 'Eligibility sex': 'ALL', 'Eligibility minimum age': '0 Days', 'Eligibility standard age': \"['CHILD']\", 'Pre-assignment details': 'Neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure (HRF) and at risk of PPHN who were receiving inhaled nitric oxide (iNO) treatment were evaluated in this study.', 'Recruitment details': 'This study was planned in two parts Part A (double-blind phase) and Part B (long-term, non-intervention phase).', 'Recruitment group 0 id': 'FG000', 'Recruitment group 0 title': 'IV Sildenafil', 'Recruitment group 0 description': \"Part A: Participants received sildenafil intravenously based on their body weight at a loading dose of 0.1 milligrams per kg (mg/kg) for 30 minutes on Day 1 followed by a maintenance dose of 0.03 milligrams per kg per hour (mg/kg/hr), for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Recruitment group 1 id': 'FG001', 'Recruitment group 1 title': 'Placebo', 'Recruitment group 1 description': \"Participants received placebo (0.9 % normal saline or dextrose 10%) at a rate matched to sildenafil infusion, intravenously, based on participant's weight, for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Group IDs': \"[{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.9850', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least square (LS) mean difference', 'paramValue': '0.0', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2.08', 'ciUpperLimit': '2.04', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.02'}]\", 'p-value': '0.9850', 'Statistical Method': 'ANCOVA', 'Limitations and caveats': '', 'Has results': 'True'}, hash='45caf72b6b3268b03f0ed08145ae4c3161cea08a1422a1cadc23590398091313'), <NodeRelationship.PREVIOUS: '2'>: RelatedNodeInfo(node_id='cbb99564-a42d-48b6-8e31-fc15f6dc0e64', node_type=<ObjectType.TEXT: '1'>, metadata={'National Clinical Identification NCT ID': 'NCT01701362', 'Organization study identification': 'A0081279', 'EudraCT number': '2012-003304-12', 'Organization': 'Pfizer', 'Organization class': 'INDUSTRY', 'Brief title': 'Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain', 'Official title': 'A Randomized Double Blind Placebo Controlled Parallel Group Study Of The Efficacy And Safety Of Pregabalin (Bid) In Subjects With Post-traumatic Peripheral Neuropathic Pain', 'Overall status': 'COMPLETED', 'Start date': '2012-10', 'Primary completion date': '2015-08', 'Completion date': '2015-08', 'Verification date': '2017-04', 'Study first submitted date': '2012-10-03', 'Results first submitted date': '2016-07-20', 'Last update submitted date': '2021-01-26', 'Last update posted date': '2021-01-28', 'Lead sponsor': \"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.\", 'Lead sponsor class': 'INDUSTRY', 'Brief summary': 'This study is designed to investigate if pregabalin is effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma due to a traumatic or surgical event such as, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns or crush injury.', 'Detailed description': 'oof, this data not available', 'Condition': \"['Neuropathic Pain']\", 'Conditions keywords': \"['post-traumatic peripheral neuropathic pain']\", 'Study type': 'INTERVENTIONAL', 'Phases': \"['PHASE3']\", 'Allocation': 'RANDOMIZED', 'Intervention model': 'PARALLEL', 'Primary purpose': 'TREATMENT', 'Masking': 'DOUBLE', 'Who is masked': \"['PARTICIPANT', 'INVESTIGATOR']\", 'Enrollment count': '542', 'Enrollment type': 'ACTUAL', 'Arms group 0 label': 'pregabalin', 'Arms group 0 type': 'ACTIVE_COMPARATOR', 'Arms group 0 description': '', 'Arms group 0 intervention names': \"['Drug: pregabalin']\", 'Arms group 1 label': 'placebo', 'Arms group 1 type': 'PLACEBO_COMPARATOR', 'Arms group 1 description': '', 'Arms group 1 intervention names': \"['Drug: placebo']\", 'Arms group 0 intervention type': 'DRUG', 'Arms group 0 intervention name': 'pregabalin', 'Arms group 0 intervention description': 'capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization', 'Arms group 0 intervention labels': \"['pregabalin']\", 'Arms group 1 intervention type': 'DRUG', 'Arms group 1 intervention name': 'placebo', 'Arms group 1 intervention description': 'capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization', 'Arms group 1 intervention labels': \"['placebo']\", 'Primary outcome': 'Baseline Mean Pain Score', 'Primary outcome description': 'This is based on the daily pain dairy and is defined as the baseline mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 (\"no pain\") to 10 (\"worst possible pain\"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.', 'Primary outcome time frame': 'Baseline', 'Eligibility criteria': 'Inclusion Criteria:\\n\\n* Subjects must have chronic peripheral neuropathic pain present for than 6 months after a traumatic or surgical event such as, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns or crush injury.\\n* Subjects must be literate and have the ability (unaided) to understand and use the interactive voice response system (IVRS), have daily access to a telephone in order to complete the IVRS assessments each day, perform telephone visits and complete all required assessments/forms.\\n* Subjects must have sufficient post-traumatic neuropathic pain at screening and baseline.\\n\\nExclusion Criteria:\\n\\n* Subjects with neuropathic pain due to diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), HIV, trigeminal neuralgia (TGN), carpal tunnel syndrome (CTS) or with central neuropathic pain (for example, due to spinal cord injury) or with Complex Regional Pain Syndrome (CRPS, Type I or Type II).\\n* Subjects with other pain that may confound assessment or self-evaluation of the peripheral neuropathic pain.\\n* Subjects who have failed pregabalin treatment due to lack of efficacy with an adequate course of therapy at doses greater than or equal to 150 mg/day, who have previously participated in a pregabalin clinical trial or who have been treated with pregabalin at any time during the 6 month period prior to screening.\\n* Subjects with epilepsy; pernicious anemia; hematological illnesses; known HIV infection; any clinically unstable cardiovascular (including a myocardial infarction \\\\[heart attack\\\\] in the 3 months prior to screening), hematological, autoimmune, endocrine, renal, hepatic (including chronic hepatitis B, hepatitis B within the 3 months prior to screening) respiratory, or gastrointestinal disease; symptomatic peripheral vascular disease including intermittent claudication; uncontrolled diabetes mellitus; untreated hypothyroidism.\\n* Subjects with a diagnosis of DSM-IV TR Axis I disorder (including, for example, schizophrenia, bipolar disorder) with the exceptions of Generalized Anxiety Disorder (GAD) or major depression that is clinically stable.\\n* Subjects considered at risk of suicide or self-harm based on investigator judgment and/or details of a risk assessment.\\n* Use of prohibited medications in the absence of appropriate washout periods.', 'Eligibility of healthy volunteer': 'False', 'Eligibility sex': 'ALL', 'Eligibility minimum age': '18 Years', 'Eligibility standard age': \"['ADULT', 'OLDER_ADULT']\", 'Pre-assignment details': 'Participants had clinic visits at screening, randomization, and during the treatment period, and a phone contact for follow-up after the last taper dose. All the eligible participants were randomly assigned (1:1) to 15 weeks of treatment with Pregabalin or Placebo.', 'Recruitment details': 'A total of 187 centers participated in the study in 14 countries.\\n\\nDuring screening, with the exception of daily pain score data that was collected to determine participants eligibility, no participants were treated with active drug and no efficacy data were collected. Only safety and no efficacy data was collected during the taper period.', 'Recruitment group 0 id': 'FG000', 'Recruitment group 0 title': 'Pregabalin', 'Recruitment group 0 description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.', 'Recruitment group 1 id': 'FG001', 'Recruitment group 1 title': 'Placebo', 'Recruitment group 1 description': 'Participants randomized to receive placebo', 'Group IDs': 'oof, this data not available', 'p-value': 'oof, this data not available', 'Statistical Method': 'oof, this data not available', 'Limitations and caveats': '', 'Has results': 'True'}, hash='e815c31d49b3e76a6dd0d2fc60dfc54b0ba4a2496080db2b7f3f06fc67f46c67'), <NodeRelationship.NEXT: '3'>: RelatedNodeInfo(node_id='cf94d0df-b0b3-4ffa-82bb-3457eefcdab3', node_type=<ObjectType.TEXT: '1'>, metadata={}, hash='c094f9d3aefdf34e834e04f061091509a1ce33bcb27a39eecf91ae728619d46a')}, text='\"National Clinical Identification NCT ID\": \"NCT01720524\",\\n\"Organization study identification\": \"A1481316\",\\n\"EudraCT number\": \"2012-002619-24\",\\n\"Organization\": \"Pfizer\",\\n\"Organization class\": \"INDUSTRY\",\\n\"Brief title\": \"A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn\",\\n\"Official title\": \"A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT\",\\n\"Overall status\": \"COMPLETED\",\\n\"Start date\": \"2013-08-05\",\\n\"Primary completion date\": \"2018-10-17\",\\n\"Completion date\": \"2020-09-28\",\\n\"Verification date\": \"2021-08\",\\n\"Study first submitted date\": \"2012-09-17\",\\n\"Results first submitted date\": \"2019-10-16\",\\n\"Last update submitted date\": \"2021-08-12\",\\n\"Last update posted date\": \"2021-08-16\",\\n\"Lead sponsor\": \"Pfizer\\'s Upjohn has merged with Mylan to form Viatris Inc.\",\\n\"Lead sponsor class\": \"INDUSTRY\",\\n\"Brief summary\": \"This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.\",\\n\"Detailed description\": \"oof, this data not available\",\\n\"Condition\": \"[\\'Pulmonary Hypertension, Familial Persistent, of the Newborn\\']\",\\n\"Conditions keywords\": \"[\\'persistent pulmonary hypertension\\', \\'newborn\\', \\'neonates\\', \\'iv sildenafil\\', \\'hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn\\']\",\\n\"Study type\": \"INTERVENTIONAL\",\\n\"Phases\": \"[\\'PHASE3\\']\",\\n\"Allocation\": \"RANDOMIZED\",\\n\"Intervention model\": \"PARALLEL\",\\n\"Primary purpose\": \"TREATMENT\",\\n\"Masking\": \"DOUBLE\",\\n\"Who is masked\": \"[\\'PARTICIPANT\\', \\'INVESTIGATOR\\']\",\\n\"Enrollment count\": \"59\",\\n\"Enrollment type\": \"ACTUAL\",\\n\"Arms group 0 label\": \"placebo\",\\n\"Arms group 0 type\": \"PLACEBO_COMPARATOR\",\\n\"Arms group 0 description\": \"iv placebo of normal saline or 10% dextrose\",\\n\"Arms group 0 intervention names\": \"[\\'Drug: placebo\\']\",\\n\"Arms group 1 label\": \"sildenafil\",\\n\"Arms group 1 type\": \"EXPERIMENTAL\",\\n\"Arms group 1 description\": \"Active study drug\",\\n\"Arms group 1 intervention names\": \"[\\'Drug: iv sildenafil\\']\",\\n\"Arms group 0 intervention type\": \"DRUG\",\\n\"Arms group 0 intervention name\": \"placebo\",\\n\"Arms group 0 intervention description\": \"IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.\",\\n\"Arms group 0 intervention labels\": \"[\\'placebo\\']\",\\n\"Arms group 1 intervention type\": \"DRUG\",\\n\"Arms group 1 intervention name\": \"iv sildenafil\",\\n\"Arms group 1 intervention description\": \"loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.', start_char_idx=0, end_char_idx=3009, text_template='Metadata:\\n{metadata_str}\\n===========================\\nContent: \\n{content}', metadata_template='{key}=>{value}', metadata_seperator='\\n'), score=0.8471484331951007), NodeWithScore(node=TextNode(id_='cf94d0df-b0b3-4ffa-82bb-3457eefcdab3', embedding=None, metadata={'National Clinical Identification NCT ID': 'NCT01720524', 'Organization study identification': 'A1481316', 'EudraCT number': '2012-002619-24', 'Organization': 'Pfizer', 'Organization class': 'INDUSTRY', 'Brief title': 'A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn', 'Official title': 'A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT', 'Overall status': 'COMPLETED', 'Start date': '2013-08-05', 'Primary completion date': '2018-10-17', 'Completion date': '2020-09-28', 'Verification date': '2021-08', 'Study first submitted date': '2012-09-17', 'Results first submitted date': '2019-10-16', 'Last update submitted date': '2021-08-12', 'Last update posted date': '2021-08-16', 'Lead sponsor': \"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.\", 'Lead sponsor class': 'INDUSTRY', 'Brief summary': 'This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.', 'Detailed description': 'oof, this data not available', 'Condition': \"['Pulmonary Hypertension, Familial Persistent, of the Newborn']\", 'Conditions keywords': \"['persistent pulmonary hypertension', 'newborn', 'neonates', 'iv sildenafil', 'hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn']\", 'Study type': 'INTERVENTIONAL', 'Phases': \"['PHASE3']\", 'Allocation': 'RANDOMIZED', 'Intervention model': 'PARALLEL', 'Primary purpose': 'TREATMENT', 'Masking': 'DOUBLE', 'Who is masked': \"['PARTICIPANT', 'INVESTIGATOR']\", 'Enrollment count': '59', 'Enrollment type': 'ACTUAL', 'Arms group 0 label': 'placebo', 'Arms group 0 type': 'PLACEBO_COMPARATOR', 'Arms group 0 description': 'iv placebo of normal saline or 10% dextrose', 'Arms group 0 intervention names': \"['Drug: placebo']\", 'Arms group 1 label': 'sildenafil', 'Arms group 1 type': 'EXPERIMENTAL', 'Arms group 1 description': 'Active study drug', 'Arms group 1 intervention names': \"['Drug: iv sildenafil']\", 'Arms group 0 intervention type': 'DRUG', 'Arms group 0 intervention name': 'placebo', 'Arms group 0 intervention description': 'IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.', 'Arms group 0 intervention labels': \"['placebo']\", 'Arms group 1 intervention type': 'DRUG', 'Arms group 1 intervention name': 'iv sildenafil', 'Arms group 1 intervention description': 'loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.', 'Arms group 1 intervention labels': \"['sildenafil']\", 'Primary outcome': 'Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure', 'Primary outcome description': 'Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.', 'Primary outcome time frame': '14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)', 'Eligibility criteria': 'Inclusion Criteria:\\n\\n* Neonates with persistent pulmonary hypertension of the newborn\\n* Age \\\\<=96 hours and \\\\>=34 weeks gestational age\\n* Oxygenation Index \\\\>15 and \\\\<60\\n* Concurrent treatment with inhaled nitric oxide and \\\\>=50% oxygen\\n\\nExclusion Criteria:\\n\\n* Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation\\n* Expected duration of mechanical ventilation \\\\<48 hours\\n* Profound hypoxemia\\n* Life-threatening or lethal congenital anomaly', 'Eligibility of healthy volunteer': 'False', 'Eligibility sex': 'ALL', 'Eligibility minimum age': '0 Days', 'Eligibility standard age': \"['CHILD']\", 'Pre-assignment details': 'Neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure (HRF) and at risk of PPHN who were receiving inhaled nitric oxide (iNO) treatment were evaluated in this study.', 'Recruitment details': 'This study was planned in two parts Part A (double-blind phase) and Part B (long-term, non-intervention phase).', 'Recruitment group 0 id': 'FG000', 'Recruitment group 0 title': 'IV Sildenafil', 'Recruitment group 0 description': \"Part A: Participants received sildenafil intravenously based on their body weight at a loading dose of 0.1 milligrams per kg (mg/kg) for 30 minutes on Day 1 followed by a maintenance dose of 0.03 milligrams per kg per hour (mg/kg/hr), for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Recruitment group 1 id': 'FG001', 'Recruitment group 1 title': 'Placebo', 'Recruitment group 1 description': \"Participants received placebo (0.9 % normal saline or dextrose 10%) at a rate matched to sildenafil infusion, intravenously, based on participant's weight, for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Group IDs': \"[{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.9850', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least square (LS) mean difference', 'paramValue': '0.0', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2.08', 'ciUpperLimit': '2.04', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.02'}]\", 'p-value': '0.9850', 'Statistical Method': 'ANCOVA', 'Limitations and caveats': '', 'Has results': 'True'}, excluded_embed_metadata_keys=['Organization study identification', 'EudraCT number', 'Organization', 'Organization class', 'Official title', 'Overall status', 'Start date', 'Primary completion date', 'Completion date', 'Verification date', 'Study first submitted date', 'Results first submitted date', 'Last update submitted date', 'Last update posted date', 'Lead sponsor class', 'Brief summary', 'Detailed description', 'Study type', 'Phases', 'Allocation', 'Intervention model', 'Primary purpose', 'Masking', 'Who is masked', 'Enrollment count', 'Enrollment type', 'Arms group 0 label', 'Arms group 0 type', 'Arms group 0 description', 'Arms group 1 label', 'Arms group 1 type', 'Arms group 1 description', 'Arms group 1 intervention names', 'Arms group 0 intervention type', 'Arms group 0 intervention name', 'Arms group 0 intervention description', 'Arms group 0 intervention labels', 'Arms group 1 intervention type', 'Arms group 1 intervention name', 'Arms group 1 intervention description', 'Arms group 1 intervention labels', 'Primary outcome', 'Primary outcome description', 'Primary outcome time frame', 'Eligibility criteria', 'Eligibility of healthy volunteer', 'Eligibility sex', 'Eligibility minimum age', 'Eligibility standard age', 'Pre-assignment details', 'Recruitment details', 'Recruitment group 0 id', 'Recruitment group 0 title', 'Recruitment group 0 description', 'Recruitment group 1 id', 'Recruitment group 1 title', 'Recruitment group 1 description', 'Group IDs', 'p-value', 'Statistical Method', 'Limitations and caveats', 'Has results'], excluded_llm_metadata_keys=['Organization study identification', 'EudraCT number', 'Organization', 'Organization class', 'Official title', 'Overall status', 'Start date', 'Primary completion date', 'Completion date', 'Verification date', 'Study first submitted date', 'Results first submitted date', 'Last update submitted date', 'Last update posted date', 'Lead sponsor class', 'Brief summary', 'Detailed description', 'Study type', 'Phases', 'Allocation', 'Intervention model', 'Primary purpose', 'Masking', 'Who is masked', 'Enrollment count', 'Enrollment type', 'Arms group 0 label', 'Arms group 0 type', 'Arms group 0 description', 'Arms group 1 label', 'Arms group 1 type', 'Arms group 1 description', 'Arms group 1 intervention names', 'Arms group 0 intervention type', 'Arms group 0 intervention name', 'Arms group 0 intervention description', 'Arms group 0 intervention labels', 'Arms group 1 intervention type', 'Arms group 1 intervention name', 'Arms group 1 intervention description', 'Arms group 1 intervention labels', 'Primary outcome', 'Primary outcome description', 'Primary outcome time frame', 'Eligibility criteria', 'Eligibility of healthy volunteer', 'Eligibility sex', 'Eligibility minimum age', 'Eligibility standard age', 'Pre-assignment details', 'Recruitment details', 'Recruitment group 0 id', 'Recruitment group 0 title', 'Recruitment group 0 description', 'Recruitment group 1 id', 'Recruitment group 1 title', 'Recruitment group 1 description', 'Group IDs', 'p-value', 'Statistical Method', 'Limitations and caveats', 'Has results'], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='b176b5aa-cb7c-4598-83b6-358020237e97', node_type=<ObjectType.DOCUMENT: '4'>, metadata={'National Clinical Identification NCT ID': 'NCT01720524', 'Organization study identification': 'A1481316', 'EudraCT number': '2012-002619-24', 'Organization': 'Pfizer', 'Organization class': 'INDUSTRY', 'Brief title': 'A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn', 'Official title': 'A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT', 'Overall status': 'COMPLETED', 'Start date': '2013-08-05', 'Primary completion date': '2018-10-17', 'Completion date': '2020-09-28', 'Verification date': '2021-08', 'Study first submitted date': '2012-09-17', 'Results first submitted date': '2019-10-16', 'Last update submitted date': '2021-08-12', 'Last update posted date': '2021-08-16', 'Lead sponsor': \"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.\", 'Lead sponsor class': 'INDUSTRY', 'Brief summary': 'This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.', 'Detailed description': 'oof, this data not available', 'Condition': \"['Pulmonary Hypertension, Familial Persistent, of the Newborn']\", 'Conditions keywords': \"['persistent pulmonary hypertension', 'newborn', 'neonates', 'iv sildenafil', 'hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn']\", 'Study type': 'INTERVENTIONAL', 'Phases': \"['PHASE3']\", 'Allocation': 'RANDOMIZED', 'Intervention model': 'PARALLEL', 'Primary purpose': 'TREATMENT', 'Masking': 'DOUBLE', 'Who is masked': \"['PARTICIPANT', 'INVESTIGATOR']\", 'Enrollment count': '59', 'Enrollment type': 'ACTUAL', 'Arms group 0 label': 'placebo', 'Arms group 0 type': 'PLACEBO_COMPARATOR', 'Arms group 0 description': 'iv placebo of normal saline or 10% dextrose', 'Arms group 0 intervention names': \"['Drug: placebo']\", 'Arms group 1 label': 'sildenafil', 'Arms group 1 type': 'EXPERIMENTAL', 'Arms group 1 description': 'Active study drug', 'Arms group 1 intervention names': \"['Drug: iv sildenafil']\", 'Arms group 0 intervention type': 'DRUG', 'Arms group 0 intervention name': 'placebo', 'Arms group 0 intervention description': 'IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.', 'Arms group 0 intervention labels': \"['placebo']\", 'Arms group 1 intervention type': 'DRUG', 'Arms group 1 intervention name': 'iv sildenafil', 'Arms group 1 intervention description': 'loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.', 'Arms group 1 intervention labels': \"['sildenafil']\", 'Primary outcome': 'Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure', 'Primary outcome description': 'Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.', 'Primary outcome time frame': '14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)', 'Eligibility criteria': 'Inclusion Criteria:\\n\\n* Neonates with persistent pulmonary hypertension of the newborn\\n* Age \\\\<=96 hours and \\\\>=34 weeks gestational age\\n* Oxygenation Index \\\\>15 and \\\\<60\\n* Concurrent treatment with inhaled nitric oxide and \\\\>=50% oxygen\\n\\nExclusion Criteria:\\n\\n* Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation\\n* Expected duration of mechanical ventilation \\\\<48 hours\\n* Profound hypoxemia\\n* Life-threatening or lethal congenital anomaly', 'Eligibility of healthy volunteer': 'False', 'Eligibility sex': 'ALL', 'Eligibility minimum age': '0 Days', 'Eligibility standard age': \"['CHILD']\", 'Pre-assignment details': 'Neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure (HRF) and at risk of PPHN who were receiving inhaled nitric oxide (iNO) treatment were evaluated in this study.', 'Recruitment details': 'This study was planned in two parts Part A (double-blind phase) and Part B (long-term, non-intervention phase).', 'Recruitment group 0 id': 'FG000', 'Recruitment group 0 title': 'IV Sildenafil', 'Recruitment group 0 description': \"Part A: Participants received sildenafil intravenously based on their body weight at a loading dose of 0.1 milligrams per kg (mg/kg) for 30 minutes on Day 1 followed by a maintenance dose of 0.03 milligrams per kg per hour (mg/kg/hr), for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Recruitment group 1 id': 'FG001', 'Recruitment group 1 title': 'Placebo', 'Recruitment group 1 description': \"Participants received placebo (0.9 % normal saline or dextrose 10%) at a rate matched to sildenafil infusion, intravenously, based on participant's weight, for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Group IDs': \"[{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.9850', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least square (LS) mean difference', 'paramValue': '0.0', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2.08', 'ciUpperLimit': '2.04', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.02'}]\", 'p-value': '0.9850', 'Statistical Method': 'ANCOVA', 'Limitations and caveats': '', 'Has results': 'True'}, hash='45caf72b6b3268b03f0ed08145ae4c3161cea08a1422a1cadc23590398091313'), <NodeRelationship.PREVIOUS: '2'>: RelatedNodeInfo(node_id='bc90b2bd-c2c7-4cc5-9593-bcbff30f82f6', node_type=<ObjectType.TEXT: '1'>, metadata={'National Clinical Identification NCT ID': 'NCT01720524', 'Organization study identification': 'A1481316', 'EudraCT number': '2012-002619-24', 'Organization': 'Pfizer', 'Organization class': 'INDUSTRY', 'Brief title': 'A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn', 'Official title': 'A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT', 'Overall status': 'COMPLETED', 'Start date': '2013-08-05', 'Primary completion date': '2018-10-17', 'Completion date': '2020-09-28', 'Verification date': '2021-08', 'Study first submitted date': '2012-09-17', 'Results first submitted date': '2019-10-16', 'Last update submitted date': '2021-08-12', 'Last update posted date': '2021-08-16', 'Lead sponsor': \"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.\", 'Lead sponsor class': 'INDUSTRY', 'Brief summary': 'This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.', 'Detailed description': 'oof, this data not available', 'Condition': \"['Pulmonary Hypertension, Familial Persistent, of the Newborn']\", 'Conditions keywords': \"['persistent pulmonary hypertension', 'newborn', 'neonates', 'iv sildenafil', 'hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn']\", 'Study type': 'INTERVENTIONAL', 'Phases': \"['PHASE3']\", 'Allocation': 'RANDOMIZED', 'Intervention model': 'PARALLEL', 'Primary purpose': 'TREATMENT', 'Masking': 'DOUBLE', 'Who is masked': \"['PARTICIPANT', 'INVESTIGATOR']\", 'Enrollment count': '59', 'Enrollment type': 'ACTUAL', 'Arms group 0 label': 'placebo', 'Arms group 0 type': 'PLACEBO_COMPARATOR', 'Arms group 0 description': 'iv placebo of normal saline or 10% dextrose', 'Arms group 0 intervention names': \"['Drug: placebo']\", 'Arms group 1 label': 'sildenafil', 'Arms group 1 type': 'EXPERIMENTAL', 'Arms group 1 description': 'Active study drug', 'Arms group 1 intervention names': \"['Drug: iv sildenafil']\", 'Arms group 0 intervention type': 'DRUG', 'Arms group 0 intervention name': 'placebo', 'Arms group 0 intervention description': 'IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.', 'Arms group 0 intervention labels': \"['placebo']\", 'Arms group 1 intervention type': 'DRUG', 'Arms group 1 intervention name': 'iv sildenafil', 'Arms group 1 intervention description': 'loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.', 'Arms group 1 intervention labels': \"['sildenafil']\", 'Primary outcome': 'Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure', 'Primary outcome description': 'Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.', 'Primary outcome time frame': '14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)', 'Eligibility criteria': 'Inclusion Criteria:\\n\\n* Neonates with persistent pulmonary hypertension of the newborn\\n* Age \\\\<=96 hours and \\\\>=34 weeks gestational age\\n* Oxygenation Index \\\\>15 and \\\\<60\\n* Concurrent treatment with inhaled nitric oxide and \\\\>=50% oxygen\\n\\nExclusion Criteria:\\n\\n* Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation\\n* Expected duration of mechanical ventilation \\\\<48 hours\\n* Profound hypoxemia\\n* Life-threatening or lethal congenital anomaly', 'Eligibility of healthy volunteer': 'False', 'Eligibility sex': 'ALL', 'Eligibility minimum age': '0 Days', 'Eligibility standard age': \"['CHILD']\", 'Pre-assignment details': 'Neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure (HRF) and at risk of PPHN who were receiving inhaled nitric oxide (iNO) treatment were evaluated in this study.', 'Recruitment details': 'This study was planned in two parts Part A (double-blind phase) and Part B (long-term, non-intervention phase).', 'Recruitment group 0 id': 'FG000', 'Recruitment group 0 title': 'IV Sildenafil', 'Recruitment group 0 description': \"Part A: Participants received sildenafil intravenously based on their body weight at a loading dose of 0.1 milligrams per kg (mg/kg) for 30 minutes on Day 1 followed by a maintenance dose of 0.03 milligrams per kg per hour (mg/kg/hr), for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Recruitment group 1 id': 'FG001', 'Recruitment group 1 title': 'Placebo', 'Recruitment group 1 description': \"Participants received placebo (0.9 % normal saline or dextrose 10%) at a rate matched to sildenafil infusion, intravenously, based on participant's weight, for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Group IDs': \"[{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.9850', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least square (LS) mean difference', 'paramValue': '0.0', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2.08', 'ciUpperLimit': '2.04', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.02'}]\", 'p-value': '0.9850', 'Statistical Method': 'ANCOVA', 'Limitations and caveats': '', 'Has results': 'True'}, hash='04f116725b7e71410fa2e31122478d71c9272c19c42a01c66e541e678c765584'), <NodeRelationship.NEXT: '3'>: RelatedNodeInfo(node_id='d6c27d04-6820-43e7-ab67-e2a4b17bb67d', node_type=<ObjectType.TEXT: '1'>, metadata={}, hash='d580293bd41ca27d5b2bfbdf8ddc7f858d0ff76948dffeee896e86c12cd40591')}, text='To infuse minimum 48 hours and maximum of 14 days.\",\\n\"Arms group 1 intervention labels\": \"[\\'sildenafil\\']\",\\n\"Primary outcome\": \"Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure\",\\n\"Primary outcome description\": \"Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.\",\\n\"Primary outcome time frame\": \"14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)\",\\n\"Eligibility criteria\": \"Inclusion Criteria:\\n* Neonates with persistent pulmonary hypertension of the newborn\\n* Age \\\\<=96 hours and \\\\>=34 weeks gestational age\\n* Oxygenation Index \\\\>15 and \\\\<60\\n* Concurrent treatment with inhaled nitric oxide and \\\\>=50% oxygen\\nExclusion Criteria:\\n* Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation\\n* Expected duration of mechanical ventilation \\\\<48 hours\\n* Profound hypoxemia\\n* Life-threatening or lethal congenital anomaly\",\\n\"Eligibility of healthy volunteer\": \"False\",\\n\"Eligibility sex\": \"ALL\",\\n\"Eligibility minimum age\": \"0 Days\",\\n\"Eligibility standard age\": \"[\\'CHILD\\']\",\\n\"Pre-assignment details\": \"Neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure (HRF) and at risk of PPHN who were receiving inhaled nitric oxide (iNO) treatment were evaluated in this study.\",\\n\"Recruitment details\": \"This study was planned in two parts Part A (double-blind phase) and Part B (long-term, non-intervention phase).\",\\n\"Recruitment group 0 id\": \"FG000\",\\n\"Recruitment group 0 title\": \"IV Sildenafil\",\\n\"Recruitment group 0 description\": \"Part A: Participants received sildenafil intravenously based on their body weight at a loading dose of 0.1 milligrams per kg (mg/kg) for 30 minutes on Day 1 followed by a maintenance dose of 0.03 milligrams per kg per hour (mg/kg/hr), for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants\\' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\",\\n\"Recruitment group 1 id\": \"FG001\",\\n\"Recruitment group 1 title\": \"Placebo\",\\n\"Recruitment group 1 description\": \"Participants received placebo (0.9 % normal saline or dextrose 10%) at a rate matched to sildenafil infusion, intravenously, based on participant\\'s weight, for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants\\' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.', start_char_idx=2959, end_char_idx=6043, text_template='Metadata:\\n{metadata_str}\\n===========================\\nContent: \\n{content}', metadata_template='{key}=>{value}', metadata_seperator='\\n'), score=0.843885902809184)], metadata={'bc90b2bd-c2c7-4cc5-9593-bcbff30f82f6': {'National Clinical Identification NCT ID': 'NCT01720524', 'Organization study identification': 'A1481316', 'EudraCT number': '2012-002619-24', 'Organization': 'Pfizer', 'Organization class': 'INDUSTRY', 'Brief title': 'A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn', 'Official title': 'A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT', 'Overall status': 'COMPLETED', 'Start date': '2013-08-05', 'Primary completion date': '2018-10-17', 'Completion date': '2020-09-28', 'Verification date': '2021-08', 'Study first submitted date': '2012-09-17', 'Results first submitted date': '2019-10-16', 'Last update submitted date': '2021-08-12', 'Last update posted date': '2021-08-16', 'Lead sponsor': \"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.\", 'Lead sponsor class': 'INDUSTRY', 'Brief summary': 'This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.', 'Detailed description': 'oof, this data not available', 'Condition': \"['Pulmonary Hypertension, Familial Persistent, of the Newborn']\", 'Conditions keywords': \"['persistent pulmonary hypertension', 'newborn', 'neonates', 'iv sildenafil', 'hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn']\", 'Study type': 'INTERVENTIONAL', 'Phases': \"['PHASE3']\", 'Allocation': 'RANDOMIZED', 'Intervention model': 'PARALLEL', 'Primary purpose': 'TREATMENT', 'Masking': 'DOUBLE', 'Who is masked': \"['PARTICIPANT', 'INVESTIGATOR']\", 'Enrollment count': '59', 'Enrollment type': 'ACTUAL', 'Arms group 0 label': 'placebo', 'Arms group 0 type': 'PLACEBO_COMPARATOR', 'Arms group 0 description': 'iv placebo of normal saline or 10% dextrose', 'Arms group 0 intervention names': \"['Drug: placebo']\", 'Arms group 1 label': 'sildenafil', 'Arms group 1 type': 'EXPERIMENTAL', 'Arms group 1 description': 'Active study drug', 'Arms group 1 intervention names': \"['Drug: iv sildenafil']\", 'Arms group 0 intervention type': 'DRUG', 'Arms group 0 intervention name': 'placebo', 'Arms group 0 intervention description': 'IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.', 'Arms group 0 intervention labels': \"['placebo']\", 'Arms group 1 intervention type': 'DRUG', 'Arms group 1 intervention name': 'iv sildenafil', 'Arms group 1 intervention description': 'loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.', 'Arms group 1 intervention labels': \"['sildenafil']\", 'Primary outcome': 'Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure', 'Primary outcome description': 'Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.', 'Primary outcome time frame': '14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)', 'Eligibility criteria': 'Inclusion Criteria:\\n\\n* Neonates with persistent pulmonary hypertension of the newborn\\n* Age \\\\<=96 hours and \\\\>=34 weeks gestational age\\n* Oxygenation Index \\\\>15 and \\\\<60\\n* Concurrent treatment with inhaled nitric oxide and \\\\>=50% oxygen\\n\\nExclusion Criteria:\\n\\n* Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation\\n* Expected duration of mechanical ventilation \\\\<48 hours\\n* Profound hypoxemia\\n* Life-threatening or lethal congenital anomaly', 'Eligibility of healthy volunteer': 'False', 'Eligibility sex': 'ALL', 'Eligibility minimum age': '0 Days', 'Eligibility standard age': \"['CHILD']\", 'Pre-assignment details': 'Neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure (HRF) and at risk of PPHN who were receiving inhaled nitric oxide (iNO) treatment were evaluated in this study.', 'Recruitment details': 'This study was planned in two parts Part A (double-blind phase) and Part B (long-term, non-intervention phase).', 'Recruitment group 0 id': 'FG000', 'Recruitment group 0 title': 'IV Sildenafil', 'Recruitment group 0 description': \"Part A: Participants received sildenafil intravenously based on their body weight at a loading dose of 0.1 milligrams per kg (mg/kg) for 30 minutes on Day 1 followed by a maintenance dose of 0.03 milligrams per kg per hour (mg/kg/hr), for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Recruitment group 1 id': 'FG001', 'Recruitment group 1 title': 'Placebo', 'Recruitment group 1 description': \"Participants received placebo (0.9 % normal saline or dextrose 10%) at a rate matched to sildenafil infusion, intravenously, based on participant's weight, for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Group IDs': \"[{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.9850', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least square (LS) mean difference', 'paramValue': '0.0', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2.08', 'ciUpperLimit': '2.04', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.02'}]\", 'p-value': '0.9850', 'Statistical Method': 'ANCOVA', 'Limitations and caveats': '', 'Has results': 'True'}, 'cf94d0df-b0b3-4ffa-82bb-3457eefcdab3': {'National Clinical Identification NCT ID': 'NCT01720524', 'Organization study identification': 'A1481316', 'EudraCT number': '2012-002619-24', 'Organization': 'Pfizer', 'Organization class': 'INDUSTRY', 'Brief title': 'A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn', 'Official title': 'A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT', 'Overall status': 'COMPLETED', 'Start date': '2013-08-05', 'Primary completion date': '2018-10-17', 'Completion date': '2020-09-28', 'Verification date': '2021-08', 'Study first submitted date': '2012-09-17', 'Results first submitted date': '2019-10-16', 'Last update submitted date': '2021-08-12', 'Last update posted date': '2021-08-16', 'Lead sponsor': \"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.\", 'Lead sponsor class': 'INDUSTRY', 'Brief summary': 'This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.', 'Detailed description': 'oof, this data not available', 'Condition': \"['Pulmonary Hypertension, Familial Persistent, of the Newborn']\", 'Conditions keywords': \"['persistent pulmonary hypertension', 'newborn', 'neonates', 'iv sildenafil', 'hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn']\", 'Study type': 'INTERVENTIONAL', 'Phases': \"['PHASE3']\", 'Allocation': 'RANDOMIZED', 'Intervention model': 'PARALLEL', 'Primary purpose': 'TREATMENT', 'Masking': 'DOUBLE', 'Who is masked': \"['PARTICIPANT', 'INVESTIGATOR']\", 'Enrollment count': '59', 'Enrollment type': 'ACTUAL', 'Arms group 0 label': 'placebo', 'Arms group 0 type': 'PLACEBO_COMPARATOR', 'Arms group 0 description': 'iv placebo of normal saline or 10% dextrose', 'Arms group 0 intervention names': \"['Drug: placebo']\", 'Arms group 1 label': 'sildenafil', 'Arms group 1 type': 'EXPERIMENTAL', 'Arms group 1 description': 'Active study drug', 'Arms group 1 intervention names': \"['Drug: iv sildenafil']\", 'Arms group 0 intervention type': 'DRUG', 'Arms group 0 intervention name': 'placebo', 'Arms group 0 intervention description': 'IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.', 'Arms group 0 intervention labels': \"['placebo']\", 'Arms group 1 intervention type': 'DRUG', 'Arms group 1 intervention name': 'iv sildenafil', 'Arms group 1 intervention description': 'loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.', 'Arms group 1 intervention labels': \"['sildenafil']\", 'Primary outcome': 'Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure', 'Primary outcome description': 'Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.', 'Primary outcome time frame': '14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)', 'Eligibility criteria': 'Inclusion Criteria:\\n\\n* Neonates with persistent pulmonary hypertension of the newborn\\n* Age \\\\<=96 hours and \\\\>=34 weeks gestational age\\n* Oxygenation Index \\\\>15 and \\\\<60\\n* Concurrent treatment with inhaled nitric oxide and \\\\>=50% oxygen\\n\\nExclusion Criteria:\\n\\n* Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation\\n* Expected duration of mechanical ventilation \\\\<48 hours\\n* Profound hypoxemia\\n* Life-threatening or lethal congenital anomaly', 'Eligibility of healthy volunteer': 'False', 'Eligibility sex': 'ALL', 'Eligibility minimum age': '0 Days', 'Eligibility standard age': \"['CHILD']\", 'Pre-assignment details': 'Neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure (HRF) and at risk of PPHN who were receiving inhaled nitric oxide (iNO) treatment were evaluated in this study.', 'Recruitment details': 'This study was planned in two parts Part A (double-blind phase) and Part B (long-term, non-intervention phase).', 'Recruitment group 0 id': 'FG000', 'Recruitment group 0 title': 'IV Sildenafil', 'Recruitment group 0 description': \"Part A: Participants received sildenafil intravenously based on their body weight at a loading dose of 0.1 milligrams per kg (mg/kg) for 30 minutes on Day 1 followed by a maintenance dose of 0.03 milligrams per kg per hour (mg/kg/hr), for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Recruitment group 1 id': 'FG001', 'Recruitment group 1 title': 'Placebo', 'Recruitment group 1 description': \"Participants received placebo (0.9 % normal saline or dextrose 10%) at a rate matched to sildenafil infusion, intravenously, based on participant's weight, for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.\", 'Group IDs': \"[{'groupIds': ['OG000', 'OG001'], 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.9850', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least square (LS) mean difference', 'paramValue': '0.0', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-2.08', 'ciUpperLimit': '2.04', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.02'}]\", 'p-value': '0.9850', 'Statistical Method': 'ANCOVA', 'Limitations and caveats': '', 'Has results': 'True'}}),\n",
       " 'The primary inclusion criteria for neonates in the study were: they had to have persistent pulmonary hypertension of the newborn, be less than or equal to 96 hours old and more than or equal to 34 weeks gestational age, have an Oxygenation Index greater than 15 and less than 60, and be undergoing concurrent treatment with inhaled nitric oxide and at least 50% oxygen.')"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response_vector,response_vector.response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\"National Clinical Identification NCT ID\": \"NCT01720524\",\\n\"Organization study identification\": \"A1481316\",\\n\"EudraCT number\": \"2012-002619-24\",\\n\"Organization\": \"Pfizer\",\\n\"Organization class\": \"INDUSTRY\",\\n\"Brief title\": \"A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn\",\\n\"Official title\": \"A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT\",\\n\"Overall status\": \"COMPLETED\",\\n\"Start date\": \"2013-08-05\",\\n\"Primary completion date\": \"2018-10-17\",\\n\"Completion date\": \"2020-09-28\",\\n\"Verification date\": \"2021-08\",\\n\"Study first submitted date\": \"2012-09-17\",\\n\"Results first submitted date\": \"2019-10-16\",\\n\"Last update submitted date\": \"2021-08-12\",\\n\"Last update posted date\": \"2021-08-16\",\\n\"Lead sponsor\": \"Pfizer\\'s Upjohn has merged with Mylan to form Viatris Inc.\",\\n\"Lead sponsor class\": \"INDUSTRY\",\\n\"Brief summary\": \"This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.\",\\n\"Detailed description\": \"oof, this data not available\",\\n\"Condition\": \"[\\'Pulmonary Hypertension, Familial Persistent, of the Newborn\\']\",\\n\"Conditions keywords\": \"[\\'persistent pulmonary hypertension\\', \\'newborn\\', \\'neonates\\', \\'iv sildenafil\\', \\'hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn\\']\",\\n\"Study type\": \"INTERVENTIONAL\",\\n\"Phases\": \"[\\'PHASE3\\']\",\\n\"Allocation\": \"RANDOMIZED\",\\n\"Intervention model\": \"PARALLEL\",\\n\"Primary purpose\": \"TREATMENT\",\\n\"Masking\": \"DOUBLE\",\\n\"Who is masked\": \"[\\'PARTICIPANT\\', \\'INVESTIGATOR\\']\",\\n\"Enrollment count\": \"59\",\\n\"Enrollment type\": \"ACTUAL\",\\n\"Arms group 0 label\": \"placebo\",\\n\"Arms group 0 type\": \"PLACEBO_COMPARATOR\",\\n\"Arms group 0 description\": \"iv placebo of normal saline or 10% dextrose\",\\n\"Arms group 0 intervention names\": \"[\\'Drug: placebo\\']\",\\n\"Arms group 1 label\": \"sildenafil\",\\n\"Arms group 1 type\": \"EXPERIMENTAL\",\\n\"Arms group 1 description\": \"Active study drug\",\\n\"Arms group 1 intervention names\": \"[\\'Drug: iv sildenafil\\']\",\\n\"Arms group 0 intervention type\": \"DRUG\",\\n\"Arms group 0 intervention name\": \"placebo\",\\n\"Arms group 0 intervention description\": \"IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.\",\\n\"Arms group 0 intervention labels\": \"[\\'placebo\\']\",\\n\"Arms group 1 intervention type\": \"DRUG\",\\n\"Arms group 1 intervention name\": \"iv sildenafil\",\\n\"Arms group 1 intervention description\": \"loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.'"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response_vector.source_nodes[0].get_text()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Creating a Question / Context Dataset for Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|| 700/700 [19:45<00:00,  1.69s/it]\n"
     ]
    }
   ],
   "source": [
    "from llama_index.core.evaluation import generate_question_context_pairs\n",
    "qa_dataset = generate_question_context_pairs(\n",
    "    nodes,\n",
    "    llm=llm3,\n",
    "    num_questions_per_chunk=2\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "qa_dataset.save_json(\"pg_eval_dataset.json\")\n",
    "#qa_dataset = EmbeddingQAFinetuneDataset.from_json(\"pg_eval_dataset.json\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Describe the treatment regimens for the two recruitment groups in the study, including dosages, administration methods, and cycle durations.\n"
     ]
    }
   ],
   "source": [
    "queries = qa_dataset.queries.values()\n",
    "print(list(queries)[19])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['What is the primary purpose of the study described in the context information?',\n",
       " 'How many arms groups were involved in the study, and what were the interventions for each group?',\n",
       " 'Explain the primary outcome of the study comparing adjuvant treatment with exemestane versus tamoxifen therapy in postmenopausal, receptor positive, node negative or node positive breast cancer patients. What is the time frame for assessing this outcome?',\n",
       " 'Discuss the eligibility criteria for inclusion and exclusion of patients in the study comparing exemestane and tamoxifen therapy for adjuvant treatment of breast cancer. Why were patients with ER and PR negative primary tumors or unknown ER/PR status excluded from the study?',\n",
       " 'What was the primary purpose of the randomized trial conducted by Pfizer in postmenopausal women with early breast cancer who had already received adjuvant tamoxifen for 2-3 years?',\n",
       " 'Describe the primary outcome measured in the study, including how Disease-Free Survival (DFS) was defined and what events were considered as relapse.',\n",
       " 'What were the inclusion criteria for postmenopausal women participating in the study, and how long were they required to have been continuously treated with tamoxifen before being eligible for enrollment?',\n",
       " 'What was the statistical method used to analyze the data in the study, and what was the p-value obtained for the comparison between the two recruitment groups?',\n",
       " 'What was the primary objective of the study evaluating Interferon and CCI-779 in advanced renal cell carcinoma, and what was the primary efficacy endpoint of the study?',\n",
       " 'Describe the treatment arms in the study, including the interventions used, the number of participants in each arm, and the primary outcome measured in the study.',\n",
       " 'What are the inclusion criteria for participants in this study on advanced RCC who have not received prior systemic therapy for their disease?',\n",
       " 'What is the statistical method used to analyze the data in this study, and what was the p-value obtained for the comparison between the temsirolimus and Interferon Alfa treatment groups?',\n",
       " 'What was the primary purpose of the study mentioned in the context information?',\n",
       " 'How was the primary outcome of the study defined and assessed according to the details provided?',\n",
       " 'What are the key inclusion criteria for patients to be eligible for this study on sunitinib treatment for malignant GIST?',\n",
       " 'Describe the recruitment details and timeline of the study, including the start and end dates of the double-blind treatment phase and the option for subjects to crossover to open-label treatment.',\n",
       " 'What is the primary purpose of the study described in the context information?',\n",
       " 'Describe the intervention for Arms group 1 in the study, including the dosage and treatment schedule.',\n",
       " 'What were the eligibility criteria for patients to participate in the study on renal cell carcinoma treatment, including specific requirements related to histology, disease status, and performance status?',\n",
       " 'Describe the treatment regimens for the two recruitment groups in the study, including dosages, administration methods, and cycle durations.',\n",
       " 'Explain the significance of the hazard ratio value of 0.5136 in the context of the study results. How does this value indicate the relationship between the two treatments, SU011248 and IFN-a?',\n",
       " 'How does the p-value of \"<0.0001\" support the conclusion drawn from the hazard ratio analysis using the Log Rank statistical method? Explain the importance of the p-value in determining the statistical significance of the study results.',\n",
       " 'What are the three different methods of administration of Fluoropyrimidine compared in this study involving Irinotecan for the treatment of metastatic colorectal cancer?',\n",
       " 'What was the primary completion date of the randomized, multi-center Phase III trial sponsored by Pfizer that compared Irinotecan in combination with different methods of Fluoropyrimidine administration for patients with metastatic colorectal cancer?',\n",
       " 'What is the primary outcome measure for this study involving patients with colorectal cancer receiving FOLFIRI and mIFL treatments?',\n",
       " 'What are the inclusion criteria for patients to be eligible for this study on metastatic colorectal cancer, and what are the key exclusion criteria mentioned in the document?',\n",
       " 'What are the eligibility criteria for participants in this study in terms of age and sex?',\n",
       " 'What is the statistical method used to analyze the data in this study, and what was the p-value obtained from the analysis?',\n",
       " 'What was the primary outcome measured in the study evaluating Temsirolimus in Mantle Cell Lymphoma (MCL) patients, and how was it defined?',\n",
       " 'What were the eligibility criteria for participants in the open-label, randomized Phase 3 trial of Temsirolimus in relapsed, refractory subjects with Mantle Cell Lymphoma (MCL)?',\n",
       " 'What are some common chemotherapy combinations used in the treatment of the condition described in the context information? Provide examples of at least three different combinations.',\n",
       " 'What are the exclusion criteria for subjects participating in the study described in the context information? Explain why individuals who meet these criteria are not eligible to participate in the study.',\n",
       " 'What was the alternative hypothesis (Ha) for each test conducted in the study, and what was the conclusion drawn from the analysis of PFS distributions?',\n",
       " 'What statistical method was used to analyze the data in the study, and what was the hazard ratio (HR) value along with its 95% confidence interval for the comparison between group OG001 and group OG002?',\n",
       " 'What was the primary outcome measure used in the study \"Pregabalin Peripheral Neuropathic Pain Study\" conducted by Pfizer?',\n",
       " 'What were the inclusion criteria for subjects participating in the study, specifically related to their diagnosis and pain levels?',\n",
       " 'Explain the exclusion criteria related to neurologic disorders in the context of the study on pregabalin for diabetic peripheral neuropathy, post-herpetic neuralgia, and post-traumatic neuropathic pain. Why is it important to exclude patients with severe pain from conditions other than those specified in the study?',\n",
       " 'Describe the recruitment details for the study on pregabalin, including the dose levels used and the administration schedule. How were subjects randomized to either the pregabalin group or the placebo group, and what was the purpose of including a placebo group in the study design?',\n",
       " 'What was the primary outcome measure used in the study evaluating the efficacy and safety of Geodon in patients with Bipolar I Depression?',\n",
       " 'Describe the dosing regimen for the two arms in the study, including the starting doses and any flexible dosing options mentioned.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on Bipolar I Disorder, as outlined in the context information?',\n",
       " 'Describe the recruitment details for the study, including the number of centers involved and the specific dosing arms for ziprasidone assigned to subjects.',\n",
       " 'What statistical method was used in the analysis of the data presented in the document? Explain the key components of this statistical method and how it was applied to the study.',\n",
       " 'In the context of the study, what was the null hypothesis for the primary parameter being tested? How was this hypothesis related to the comparison between the ziprasidone and placebo groups in terms of the mean change from baseline to Week 6 in MADRS total score?',\n",
       " 'What was the estimated sample size needed per treatment arm in order to achieve 85% power to detect a treatment difference of 3.5 in the mean change from baseline to Week 6 in MADRS total score with a two-sided t-test at the 0.05 significance level?',\n",
       " 'What statistical method was used for the analysis in the study, and what was the p-value obtained for the comparison between ziprasidone and placebo groups in terms of the mean change from baseline to Week 6 in MADRS total score?',\n",
       " 'What is the primary outcome measure of the study comparing Irinotecan and 5 FU/FA to 5-FU/FA after resection of liver metastases for colorectal cancer?',\n",
       " 'What was the overall status of the study comparing CPT-11 in combination with a 5-FU/FA infusional regimen to the same 5-FU/FA infusional regimen alone as adjuvant treatment after resection of liver metastases for colorectal cancer?',\n",
       " 'What are the inclusion criteria for patients to be eligible for the study on colon or rectal cancer with liver metastases? Provide at least three specific criteria mentioned in the document.',\n",
       " 'Describe the two recruitment groups in the study, including the treatment regimens they received and the duration of the treatment cycles.',\n",
       " 'What was the primary objective of the study comparing irinotecan hydrochloride with cisplatin to etoposide plus cisplatin in chemotherapy-naive patients with Extensive Disease-Small Cell Lung Cancer (ED-SCLC)?',\n",
       " 'Can you explain the primary outcome measure of the study, which focused on Overall Survival (OS) for the Full Analysis Population (FAP)?',\n",
       " 'Explain the eligibility criteria for participants in the study on Small Cell Lung Cancer (SCLC) treatment. What were the inclusion and exclusion criteria specified?',\n",
       " 'Describe the recruitment details for Cohort 1 in the study, including the reason for early termination, the changes made per protocol amendment, and the subsequent analysis plan for Cohort 2.',\n",
       " 'What is the primary purpose of the IDEA study mentioned in the context information?',\n",
       " 'Describe the difference in treatment approach between the \"Early treatment\" and \"Deferred treatment\" arms in the study involving voriconazole for neutropenic patients with fever and a positive panfungal polymerase chain reaction assay.',\n",
       " 'What is the primary outcome measure of the study, and how is it defined according to the European Organization for Research and Treatment of Cancer Mycosis Study Group (EORTC/MSG) criteria?',\n",
       " 'What are the inclusion criteria for participants in this study, specifically related to their medical conditions and laboratory values?',\n",
       " 'Explain the treatment regimen for the Deferred Voriconazole Treatment group in the study, including the dosages and duration of treatment.',\n",
       " 'Discuss the statistical analysis conducted to compare the rates of invasive fungal infection (IFI) between the Immediate Voriconazole and Deferred Voriconazole treatment groups. Include details about the hypothesis tested, the statistical method used, and the interpretation of the results.',\n",
       " 'What was the primary purpose of the study evaluating the safety of sildenafil citrate in children with Pulmonary Arterial Hypertension (PAH)?',\n",
       " 'Describe the dosing regimen for the high dose and low dose treatment groups in the study evaluating the long-term safety of sildenafil citrate in children with PAH.',\n",
       " 'Explain the pre-assignment details for participants in the extension study A1481156, including the rerandomization process for those who were initially randomized to placebo in study A1481131 (NCT00159913).',\n",
       " 'Describe the recruitment details for the extension study, including the number of participants, the sites involved, and any specific information about participants who did not transition from study A1481131 (NCT00159913) to A1481156.',\n",
       " 'What is the primary purpose of the clinical research study mentioned in the context information, and what is the specific condition being studied in children aged 1 to 17 years?',\n",
       " 'Describe the arms groups and interventions used in the study evaluating sildenafil for the treatment of Pulmonary Arterial Hypertension in children.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on pulmonary arterial hypertension?',\n",
       " 'What are the exclusion criteria for subjects participating in the study on pulmonary arterial hypertension?',\n",
       " 'What are the exclusion criteria for subjects participating in the study, specifically in terms of medication use and medical conditions?',\n",
       " 'How was the recruitment conducted for the study, including the number of centers involved and the regions where the study took place?',\n",
       " 'Explain the statistical method used in the analysis of covariance for the groups OG001 and OG004. How were etiology, weight, and baseline peak VO2 utilized as covariates in the analysis?',\n",
       " 'Compare the mean differences (net) for the groups OG001 and OG004 with the confidence intervals provided. How do these results support the claim of superiority or other legacy in the study?',\n",
       " 'What was the primary purpose of the study conducted by Pfizer on children with growth retardation due to glucocorticosteroid therapy, and how long did the study last?',\n",
       " 'Describe the intervention model and primary outcome measure used in the study on the evolution of growth rate in children with growth retardation related to long-term corticotherapy and treated by Genotonorm.',\n",
       " 'What are the inclusion criteria for participants in this study on the effects of glucocorticosteroid treatment on growth in children?',\n",
       " 'How was the recruitment group \"Genotonorm\" administered in this study, and what was the maximum dose allowed per day?',\n",
       " 'What was the primary outcome measured in the study aimed at improving height with Genotonorm in children born small for gestational age and with growth retardation?',\n",
       " 'What were the eligibility criteria for participants in the study, in terms of age range for boys and girls?',\n",
       " 'What are the exclusion criteria for participants in this study regarding height measurement and pubertal signs?',\n",
       " 'Can you describe the recruitment group titled \"Genotonorm\" and the dosing regimen for participants in this study?',\n",
       " 'What were the primary objectives of the Vaspect Study regarding the use of donepezil in patients with vascular and mixed dementia?',\n",
       " 'Why was the trial terminated, and what were the reasons provided for this decision?',\n",
       " 'What was the recruitment group 0 in the study conducted in Canada, and what treatment did subjects receive in this group?',\n",
       " 'What was the rationale behind the reduction in the number of analyses specified in the protocol for the study, as mentioned in the Group IDs section?',\n",
       " 'What type of statistical analysis was used in the study, and what was the reported p-value?',\n",
       " 'Is the tested intervention considered non-inferior to the control group, based on the provided information?',\n",
       " 'What was the primary purpose of the study evaluating Bazedoxifene Acetate in osteoporosis in postmenopausal women conducted by Pfizer?',\n",
       " 'Can you explain the primary outcome measure used in the study, specifically focusing on the criteria for identifying new vertebral fractures in participants over the course of 36 months?',\n",
       " 'What are the eligibility criteria for participants in the study? Provide examples of both inclusion and exclusion criteria.',\n",
       " 'Describe the treatment regimens for the two recruitment groups in the study. What are the differences between the Bazedoxifene 20 mg (Core+SE I) and Bazedoxifene 40 mg (Core) groups in terms of dosage and duration of treatment?',\n",
       " 'What statistical method was used to calculate the p-values in the study comparing Bazedoxifene 20 mg to Raloxifene 60 mg and Bazedoxifene 40 mg?',\n",
       " 'In the comparison of Bazedoxifene 20 mg to Placebo for patients with at least 1 prevalent fracture, what was the hazard ratio and 95% confidence interval reported in the study?',\n",
       " 'What statistical method was used to calculate the hazard ratio for the comparison between Bazedoxifene 40 mg [Core] and Placebo [Core+SE I+SE II]?',\n",
       " 'In the comparison between Raloxifene 60 mg [Core] and Placebo [Core+SE I+SE II], what was the hazard ratio and its corresponding 95% confidence interval?',\n",
       " 'What statistical method was used to analyze the data in the study mentioned in the context information?',\n",
       " 'What was the hazard ratio (HR) value reported in the study, and what does this value indicate about the relationship between the variables being studied?',\n",
       " 'What is the primary outcome measure in the study evaluating the impact of pregabalin on peripheral neuropathic pain, and how is it assessed?',\n",
       " 'What are the inclusion criteria for subjects participating in the study, specifically regarding the duration and severity of peripheral neuropathic pain required for eligibility?',\n",
       " 'Explain the exclusion criteria for participants in the study. What specific diagnoses would disqualify individuals from participating in the research?',\n",
       " 'Describe the recruitment process for the study, including the treatment groups involved, the duration of the single-blind phase, and the criteria for entering the double-blind phase.',\n",
       " 'What was the primary outcome measured in the study comparing pregabalin to placebo in the treatment of nerve pain associated with HIV neuropathy?',\n",
       " 'What were the eligibility criteria for subjects to participate in the study on pregabalin versus placebo for HIV-associated neuropathic pain?',\n",
       " 'What were the exclusion criteria for subjects participating in the study on Pregabalin and Placebo? How did these criteria impact the selection of participants for the study?',\n",
       " 'Describe the recruitment process for the study, including the number of subjects screened and randomized, the duration of the study, and the dosing regimen for both the Pregabalin and Placebo groups.',\n",
       " 'What was the primary objective of the study comparing eplerenone to placebo in patients with NYHA Class II heart failure, and what was the recommendation made by the Executive Steering Committee based on the efficacy of eplerenone?',\n",
       " 'Why was further enrollment into the EMPHASIS-HF study stopped on May 26, 2010, and what was the plan for patients already enrolled in the trial following the recommendation of the Executive Steering Committee?',\n",
       " 'What is the primary outcome measure of the EMPHASIS-HF trial, and how is it defined?',\n",
       " 'What are the inclusion criteria for participants in the open-label phase of the trial, and what are the exclusion criteria?',\n",
       " 'What is the treatment regimen for participants in the Eplerenone: Double-blind Phase recruitment group?',\n",
       " 'What statistical method was used to analyze the data, and what was the p-value obtained from the analysis?',\n",
       " 'What was the primary purpose of the study evaluating bazedoxifene/conjugated estrogens combinations in postmenopausal women?',\n",
       " 'How was endometrial hyperplasia assessed in the study, and what criteria were used to determine if participants had a diagnosis of hyperplasia?',\n",
       " 'What are the inclusion criteria for participants in this study regarding age and menopausal status?',\n",
       " 'Describe the treatment regimen for participants in the \"Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg\" group, including the dosages and duration of administration.',\n",
       " 'What was the primary purpose of the Phase 3B multicenter trial conducted by Pfizer, comparing Azithromycin SR and Moxifloxacin for the treatment of Acute Exacerbation of Chronic Bronchitis (AECB)?',\n",
       " 'How was the primary outcome of the trial defined, and at what time frame was it assessed in the Clinical Per Protocol Population?',\n",
       " 'Explain the eligibility criteria for participants in the study on chronic bronchitis and acute exacerbations. What are the inclusion and exclusion criteria that were specified?',\n",
       " 'Compare and contrast the treatment regimens for the two recruitment groups in the study. Describe the administration methods and durations for Azithromycin and Moxifloxacin, highlighting any differences between the two.',\n",
       " 'What was the primary outcome measure in the study evaluating the safety and efficacy of flexibly-dosed ziprasidone in children and adolescents with bipolar I disorder?',\n",
       " 'What was the overall status of the trial evaluating the safety and efficacy of oral ziprasidone in children and adolescents with bipolar I disorder, and when was the primary completion date of the study?',\n",
       " 'Explain the eligibility criteria for participants in the study on Bipolar I disorder. What are the inclusion and exclusion criteria mentioned?',\n",
       " 'Describe the dosing regimen for the Ziprasidone group in the study. What was the starting dose, dose escalation protocol, and target dose for participants with different weight categories?',\n",
       " 'What was the primary reason for the termination of the study on the safety and efficacy of ziprasidone in adolescents with schizophrenia conducted by Pfizer?',\n",
       " 'Describe the intervention model and masking used in the clinical trial evaluating the safety and efficacy of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.',\n",
       " 'What is the primary outcome measure in this study and how is it assessed? Provide a brief description of the scale used and the scoring system.',\n",
       " 'Describe the eligibility criteria for participants in this study. What specific criteria needed to be met for inclusion, and what factors would exclude someone from participating?',\n",
       " 'What is the significance of the interim analysis at 60% enrollment in the context of the trial mentioned? How could this analysis impact the continuation of the trial?',\n",
       " 'Describe the statistical method used in the final analysis of the trial results. How is the p-value for the final analysis adjusted, and why is this adjustment necessary?',\n",
       " 'What was the primary purpose of the study mentioned in the context information, and what were the two drugs being compared in the study?',\n",
       " 'According to the eligibility criteria provided, what were the inclusion and exclusion criteria for patients participating in the study on the safety and efficacy of Lyrica in the treatment of newly diagnosed partial epilepsy?',\n",
       " 'Explain the recruitment details for the clinical trial involving Pregabalin and Lamotrigine in patients with primary generalized seizures. How were the doses of the medications adjusted during the trial?',\n",
       " 'Discuss the statistical method used in the analysis of the binary response variable for 6 consecutive months seizure freedom between the Pregabalin and Lamotrigine treatment groups. What was the non-inferiority margin set for this analysis, and how was non-inferiority determined in the study?',\n",
       " 'What is the primary purpose of the study described in the context information?',\n",
       " 'How many arms groups were involved in the study, and what were the differences between the treatments they received?',\n",
       " 'What is the primary outcome measure in this study, and how is it defined?',\n",
       " 'Describe the intervention for Arms group 1 in the study, including the dosage and duration of treatment.',\n",
       " 'How might the design of a study make it challenging to interpret treatment group comparisons in measures such as MRS, CGI-S, CGI-I, MADRS, and PANSS?',\n",
       " 'How does the presence of results impact the interpretation of timepoint by timepoint treatment group comparisons in the study mentioned in the context information?',\n",
       " 'What was the primary purpose of the study evaluating Geodon in patients with Bipolar I Depression?',\n",
       " 'How was the enrollment conducted in the study, and what were the intervention models used for the Ziprasidone and Placebo arms?',\n",
       " 'Explain the primary outcome measure in the study and how it is calculated. What is the significance of monitoring the change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score in this research?',\n",
       " 'Discuss the eligibility criteria for participants in the study. What specific criteria must individuals meet in order to be included in the research, and what conditions would make them ineligible to participate? How do these criteria ensure the validity and reliability of the study results?',\n",
       " 'What statistical method was used to compare remission and response rates between ziprasidone and placebo groups at different time points in the study?',\n",
       " 'What was the p-value for the comparison of remission and response rates between ziprasidone and placebo groups at Week 4, and was any multiple comparison adjustment made for this analysis?',\n",
       " 'What statistical method was used to compare remission and response rates between the ziprasidone and placebo groups in the study?',\n",
       " 'What was the p-value for the comparison of remission and response rates between ziprasidone and placebo groups at the endpoint of the study?',\n",
       " 'What was the primary purpose of the study on varenicline conducted by Pfizer in smokers with cardiovascular disease?',\n",
       " 'Describe the eligibility criteria for participants in the study on varenicline for smoking cessation in individuals with cardiovascular disease.',\n",
       " 'Explain the recruitment process for the study conducted on cigarette smokers with cardiovascular disease. What were the eligibility criteria for participants in terms of smoking habits and age?',\n",
       " 'Discuss the pre-assignment details of the study, including the number of participants randomized and the reasons for some participants not being treated. Additionally, explain the recruitment groups and their respective descriptions in the study.',\n",
       " 'What is the primary outcome measure of the study \"Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)\" and how is it defined?',\n",
       " 'Describe the eligibility criteria for subjects participating in the study evaluating the safety and efficacy of Varenicline Tartrate for smoking cessation in patients with mild-to-moderate COPD.',\n",
       " 'Explain the eligibility criteria for subjects participating in the study on varenicline for smoking cessation in individuals with mild to moderate COPD as outlined in the document. What specific criteria must subjects meet to be included in the study?',\n",
       " 'Discuss the recruitment groups involved in the study on varenicline versus placebo for smoking cessation in individuals with COPD. What were the treatment regimens for each group, and what was the primary endpoint of the study?',\n",
       " 'What is the primary purpose of the study comparing Voriconazole and Itraconazole in subjects with allogeneic hematopoietic stem cell transplants?',\n",
       " 'How is the success of the antifungal prophylaxis measured in this study, specifically at Day 180 after the stem cell transplant?',\n",
       " 'What are the inclusion criteria for this study on antifungal therapy in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)?',\n",
       " 'How were subjects stratified at the time of randomization in this study comparing voriconazole and itraconazole for the prevention of invasive fungal infections post-transplantation?',\n",
       " 'What statistical method was used to analyze the difference in adjusted responder rates in the study? Explain how this method was applied to the data.',\n",
       " 'What limitations and caveats were mentioned in the context information provided? How might the exclusion of data from one site impact the overall results of the study?',\n",
       " 'What was the primary objective of the study comparing the effect on carotid atherosclerosis in kidney transplant patients receiving tacrolimus-based immunosuppression versus those converted to a sirolimus-based regimen post-transplant?',\n",
       " 'Why was the study terminated, according to the detailed description provided?',\n",
       " 'What is the primary outcome measure of the study involving kidney transplant patients with atherosclerosis and kidney failure, and how is it assessed?',\n",
       " 'Describe the differences between the two arms of the intervention in the study, including the specific medications used and any conversion that occurs in one of the arms.',\n",
       " 'Explain the eligibility criteria for participants in the study. What characteristics must a participant have to be included in the study, and what factors would exclude someone from participating?',\n",
       " 'Compare and contrast the treatment regimens for the two recruitment groups in the study. What medications were administered to participants in each group, and how did the treatment plans differ in terms of drug dosages and timing?',\n",
       " 'What was the primary outcome measure in the study evaluating the efficacy and safety of ziprasidone with either lithium or divalproex in acutely manic subjects?',\n",
       " 'What was the enrollment count for the study, and what were the arms groups and interventions involved in the trial?',\n",
       " 'What are the inclusion criteria for subjects participating in the study on Bipolar I Disorder?',\n",
       " \"How was the change calculated in the study, and what was the primary outcome time frame for assessing the participants' progress?\",\n",
       " 'What statistical method was used for the analysis in the document?',\n",
       " 'What was the p-value obtained from the Mixed Models Analysis in the study?',\n",
       " 'What was the primary purpose of the study on diazepam in the management of refractory epilepsy in selected patients?',\n",
       " 'How was the administration of the placebo and diazepam solutions carried out during the double-blind period of the study?',\n",
       " 'What are the key inclusion criteria for patients participating in the study on the use of Vanquix Auto-Injector (Diazepam Injection) for acute repetitive seizures (ARS)?',\n",
       " 'Describe the primary outcome measure used in the study, including the time frame and criteria for defining an event.',\n",
       " 'In the study, what were the reasons for discontinuation prior to treatment, and which reason had the highest frequency?',\n",
       " 'Describe the recruitment groups in the study, including the medications administered, methods of administration, and any additional information provided about the treatment protocols.',\n",
       " 'What was the primary purpose of the study conducted by Pfizer on pregabalin in patients with fibromyalgia?',\n",
       " 'How was the primary outcome of the study, specifically the change from baseline in mean pain score at endpoint, measured and recorded in the trial?',\n",
       " 'What are the inclusion criteria for patients in this study on fibromyalgia treatment?',\n",
       " 'Describe the recruitment details for this study, including the regions where participants were recruited from and the treatment groups involved.',\n",
       " 'Explain the significance of the p-value of 0.2361 in the context of the statistical analysis conducted using ANCOVA. How does this p-value impact the interpretation of the results?',\n",
       " 'Discuss the implications of the confidence interval (CI) values provided for the parameter \"Least Squares (LS) mean difference\" in the context of the study. How does the CI range of -0.72 to 0.05 affect the conclusions drawn from the analysis?',\n",
       " 'What are the primary and secondary endpoints of the study comparing on-demand treatment with two prophylaxis regimens of BeneFIX in patients with severe Hemophilia B?',\n",
       " 'Describe the study design and treatment plan for subjects participating in the multicenter, open-label study comparing on-demand treatment with two prophylaxis regimens of recombinant Coagulation Factor IX (BeneFIX) in patients with severe Hemophilia B.',\n",
       " 'What are the inclusion criteria for patients to be eligible for participation in this study on hemophilia B treatment with recombinant Coagulation Factor IX (BeneFIX)?',\n",
       " 'Describe the primary outcome measure of the study and explain how it is calculated.',\n",
       " 'Explain the recruitment group \"BeneFIX OD1, Then 100 IU/kg, Then OD2, Then 50 IU/kg\" in detail, including the treatment regimen, dosage form, and duration of each phase.',\n",
       " 'Discuss the statistical analysis conducted in the study, including the p-values, statistical method (ANOVA), and the limitations and caveats mentioned. How do these findings contribute to the overall results of the study?',\n",
       " 'What is the primary purpose of the study described in the context information, and how is it being carried out?',\n",
       " 'Describe the arms groups involved in the study, including the treatments they receive and the specific conditions under which they are administered.',\n",
       " 'What is the primary outcome measure of the study, and how is it defined in terms of benzodiazepine use and testing criteria?',\n",
       " 'What are the inclusion criteria for participants in the study, and what is one specific exclusion criterion mentioned in the eligibility criteria?',\n",
       " 'Explain the treatment protocol for the recruitment group receiving Pregabalin in the study, including the dosing schedule and tapering of alprazolam.',\n",
       " 'What statistical method was used to analyze the data in this study, and what was the p-value obtained?',\n",
       " 'What was the reason for the termination of the clinical trial comparing the efficacy and safety of Sunitinib and Capecitabine in subjects with advanced breast cancer?',\n",
       " 'How did Pfizer notify clinical trial investigators and regulatory agencies about the findings that led to the discontinuation of patient enrollment in the study?',\n",
       " 'What are the inclusion criteria for participants in this study on advanced breast cancer treatment, specifically regarding prior chemotherapy regimens?',\n",
       " 'Describe the primary outcome measure in this study and explain how it is assessed in the context of evaluating treatment efficacy for breast adenocarcinoma patients.',\n",
       " 'What was the statistical method used to analyze the difference in progression-free survival (PFS) between the two treatment groups in the study?',\n",
       " 'What was the estimated hazard ratio for PFS between the sunitinib and capecitabine treatment groups, and what was the confidence interval for this estimate?',\n",
       " 'What was the primary purpose of the study described in the context information?',\n",
       " 'What was the outcome of the study in terms of the comparison between SU011248 plus paclitaxel and bevacizumab plus paclitaxel in patients with advanced breast cancer?',\n",
       " 'Explain the eligibility criteria for patients to participate in the study comparing Sunitinib + Paclitaxel and Bevacizumab + Paclitaxel in advanced breast cancer. How do these criteria ensure the selection of appropriate participants for the trial?',\n",
       " 'Discuss the statistical analysis conducted in the study, including the p-value, statistical method used, and the interpretation of the hazard ratio for the comparison between Sunitinib + Paclitaxel and Bevacizumab + Paclitaxel. How does the hazard ratio provide insight into the efficacy of the treatment regimens?',\n",
       " 'What is the primary purpose of the clinical trial described in the context information, and what are the two arms of the study comparing?',\n",
       " 'Can you explain the primary outcome measure of the study and how it is assessed?',\n",
       " 'Explain the eligibility criteria for participants in the study on high-risk renal cancer, including both the inclusion and exclusion criteria. How did these criteria ensure the selection of appropriate participants for the research?',\n",
       " 'Describe the primary outcome time frame for the study on high-risk renal cancer. What factors determined the timing of the primary analysis of Disease-Free Survival (DFS) for both the Global Cohort and the China Cohort? How did the study design account for potential variations in follow-up intervals for participants?',\n",
       " 'What is the primary completion date of the Phase III trial assessing the safety and efficacy of Plant Cell Expressed GCD in patients with Gaucher Disease?',\n",
       " 'How many treatment groups were there in the trial, and what were the dosages administered to patients in each group?',\n",
       " 'What are the inclusion criteria for patients to participate in the clinical trial for Gaucher Disease treatment with plant cell expressed recombinant glucocerebrosidase (prGCD)?',\n",
       " 'Describe the primary outcome measure of the clinical trial for Gaucher Disease treatment, including how it is calculated and the time frame for assessment.',\n",
       " 'Explain the recruitment groups and their descriptions for the study involving Taliglucerase alfa. How do these groups differ in terms of dosage and administration frequency?',\n",
       " 'Discuss the statistical methods used in the study to analyze the primary outcome of percent change in spleen volume after nine months. What was the significance level set for determining statistical significance, and what was the power of the study to detect a change of 20% or more in spleen volume?',\n",
       " 'What was the primary purpose of the study evaluating Desvenlafaxine Succinate Sustained Release in the treatment of Major Depressive Disorder?',\n",
       " 'Describe the primary outcome measure used in the study and explain its significance in assessing the efficacy of the treatment.',\n",
       " 'What are the inclusion criteria for participants in this study on Major Depressive Disorder? Provide at least three criteria mentioned in the eligibility criteria section.',\n",
       " 'How was the primary outcome, HAM-D17 total score, evaluated for the group receiving DVS SR 50 mg in the study? Explain the statistical analysis method used and the factors considered in the analysis.',\n",
       " 'In the study mentioned in the context information, what statistical method was used to evaluate the HAM-D17 total score for the different treatment groups? What factors were considered in the analysis?',\n",
       " 'For the comparison between DVS SR 100 mg and Duloxetine 60 mg, what were the mean differences in the final HAM-D17 total scores? Provide the confidence intervals for each comparison and discuss the statistical significance of the results based on the p-values provided.',\n",
       " 'What was the primary purpose of the study on ramipril conducted by Pfizer in children and adolescents with hypertension?',\n",
       " 'Describe the study design and procedures involved in the evaluation of the blood pressure lowering effects of ramipril in children and adolescents aged 6 to 16 years.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on hypertension treatment with ramipril and placebo?',\n",
       " 'What is the primary outcome measure of the study, and how is it defined in terms of blood pressure changes from baseline to 4 weeks of treatment with high-dose ramipril compared to placebo?',\n",
       " 'Explain the eligibility criteria related to cardiomyopathy, structural heart disease, and other cardiac conditions for participation in the study.',\n",
       " 'Describe the recruitment details and groups involved in the study, including the placebo run-in period and the specific recruitment groups for different treatments.',\n",
       " 'What was the primary purpose of the study titled \"Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer\" conducted by Pfizer?',\n",
       " 'How was the primary outcome, Progression-Free Survival (PFS), defined in the randomized phase 3 study of Docetaxel in combination with Sunitinib versus Docetaxel in the first-line treatment of advanced breast cancer patients?',\n",
       " 'What are the inclusion criteria for participants in this study on breast cancer treatment?',\n",
       " 'What was the primary outcome time frame for assessing the effectiveness of the treatment regimens in the study?',\n",
       " 'What was the primary purpose of the study mentioned in the context information, and what was the lead sponsor of the study?',\n",
       " 'Describe the eligibility criteria for participants in the study on the evaluation of efficacy and safety of pregabalin in the treatment of postherpetic neuralgia.',\n",
       " 'How were patients stratified in this study based on their creatinine clearance values, and how were they randomized into treatment groups?',\n",
       " 'What statistical method was used to analyze the data in this study, and what was the p-value obtained for the comparison of different treatment groups?',\n",
       " 'What was the primary objective of the study on children with Idiopathic Short Stature conducted by Pfizer, as outlined in the brief summary?',\n",
       " 'Describe the primary outcome measure used in the study, specifically focusing on the Absolute On-target Difference (AOTD) at 24 Months and how it was calculated.',\n",
       " 'Explain the eligibility criteria for participants in the study on growth hormone treatment. What were the inclusion and exclusion criteria specified for prepubertal children participating in the research?',\n",
       " 'Describe the recruitment details and study design of the research on growth hormone treatment. How were participants randomized into different arms of the study, and what were the key phases of the 4-year study conducted at multiple centers in the United States of America?',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'What adverse event is noted to be the most common in clinical studies involving Desvenlafaxine succinate (DVS SR) and is the main reason for discontinuation during the first week of therapy?',\n",
       " 'What are the inclusion criteria for participants in this study on treatment for hot flushes in postmenopausal women?',\n",
       " 'Describe the recruitment groups and their corresponding treatment regimens in the study on desvenlafaxine succinate for hot flushes in postmenopausal women.',\n",
       " 'What was the primary purpose of the study conducted by Pfizer on the effectiveness of Celecoxib in patients with painful sore throat?',\n",
       " 'How was the primary outcome, Sum of Sore Throat Pain Intensity Difference (SPID2) on Swallowing at 2 Hours Post-First Dose, measured in the study comparing Celecoxib to placebo in patients with painful pharyngitis?',\n",
       " \"What are the inclusion criteria for patients participating in the study on pharyngitis treatment with celecoxib? How does the study protocol restrict the patients' intake during the two-hour assessment period post-trial drug administration?\",\n",
       " 'Describe the recruitment groups and their respective dosing regimens for the study on celecoxib in treating pharyngitis. How was the sample size determined for the study, and what statistical method was used to analyze the primary outcome at two hours post-first dose?',\n",
       " 'What was the primary purpose of the study evaluating pregabalin for the treatment of nerve pain due to spinal cord injury?',\n",
       " 'Describe the primary outcome measure used in the study and how it was calculated.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on nerve pain after spinal cord injury? Provide specific details regarding the duration of pain, pain score, and types of spinal cord injuries included.',\n",
       " 'Describe the pre-assignment details mentioned in the context information. How was the participant who was randomized to the placebo group but actually took pregabalin handled in terms of data analysis and reporting?',\n",
       " 'What was the primary objective of the study on pregabalin in the treatment of patients with Generalized Anxiety Disorder (GAD)?',\n",
       " 'Why was further enrollment in the study stopped on January 28, 2008, according to the detailed description provided?',\n",
       " 'What are the inclusion criteria for subjects participating in the study on Generalized Anxiety Disorder (GAD) treatment optimization, as outlined in the eligibility criteria section?',\n",
       " 'How many countries were involved in the recruitment for the study on Pregabalin and Placebo treatment for GAD, and what were the specific countries mentioned in the recruitment details?',\n",
       " 'Explain the statistical method used in the study and how it was adjusted for various factors. What was the estimated mean difference in the final values between the treatment groups, and what was the corresponding 95% confidence interval?',\n",
       " 'Why was further enrollment in the study stopped, and what was the recommendation of the Data Monitoring Committee (DMC)? How was the study design impacted by the interim data analysis results, and what were the reasons for not stopping the study due to safety findings?',\n",
       " 'What was the primary purpose of the study of Embeda (Kadian NT, ALO-01) in subjects with chronic moderate to severe nonmalignant pain conducted by Pfizer?',\n",
       " 'How many subjects were enrolled in the open-label safety study of ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) capsules for up to 12 months?',\n",
       " 'Explain the exclusion criteria related to a documented history of drug abuse/dependence/misuse or narcotic analgesic abuse/dependence/misuse within five years prior to the Baseline Visit. Why is this criterion important in the selection of participants for the study?',\n",
       " \"Discuss the eligibility criteria for subjects participating in the study, specifically focusing on the history of chronic moderate to severe pain caused by a nonmalignant condition for at least 3 months prior to baseline. Why is this criterion essential for the study's objectives and outcomes?\",\n",
       " 'What was the primary outcome measured in the study comparing amlodipine 5mg and 10mg in patients with essential hypertension?',\n",
       " 'What were the eligibility criteria for inclusion in the study, specifically for untreated and treated hypertensive patients?',\n",
       " 'Explain the eligibility criteria for patients to be included in the study for the double-blind period after the screening phase. How were patients randomized into the amlodipine 10 mg group and the amlodipine 5 mg group?',\n",
       " 'Describe the recruitment details for the study, including the number of centers involved and the treatment regimens for the two recruitment groups (Amlodipine 5 mg and Amlodipine 10 mg). How was the hypothesis of group differences tested, and what was the outcome of the statistical analysis in terms of superiority between the two treatment arms?',\n",
       " 'What is the primary objective of the study on Embeda (Kadian NT, ALO-01) in subjects with pain due to osteoarthritis of the hip or knee?',\n",
       " 'What was the overall status of the study on Embeda (Kadian NT, ALO-01) and when was the primary completion date?',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'Describe the intervention for Arms group 0 in the study, including the dosage and frequency.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on osteoarthritis treatment with ALO-01 and placebo?',\n",
       " 'What was the statistical method used to analyze the data in the study, and what was the reported p-value for the comparison between ALO-01 and placebo groups?',\n",
       " 'What was the primary outcome measured in the clinical trial evaluating the effects of fesoterodine on treatment satisfaction and symptom relief in overactive bladder patients?',\n",
       " 'What were the inclusion criteria for patients participating in the study, and what were the exclusion criteria that would disqualify a patient from participating in the trial?',\n",
       " 'Explain the recruitment process for the study on OAB symptoms caused by neurological conditions. How many subjects were screened and how were eligible subjects identified for enrollment in the study?',\n",
       " 'Discuss the statistical analysis method used in the study and the significance of the p-value obtained. How was efficacy determined in the study based on the primary diary endpoints?',\n",
       " 'What was the primary endpoint that led to the termination of the study on sunitinib versus placebo for patients with advanced pancreatic islet cell tumors?',\n",
       " 'Describe the intervention protocol for patients in the sunitinib treatment arm of the study, including the starting dose, potential adjustments, and response evaluation criteria.',\n",
       " 'What is the primary outcome measure in this study and how is it calculated?',\n",
       " 'What are the eligibility criteria for participants in this study, specifically in terms of tumor progression and prior treatments?',\n",
       " 'What was the primary outcome measured in the study of sunitinib in combination with capecitabine compared with capecitabine in patients with breast cancer?',\n",
       " 'What was the enrollment count for the study and what were the two arms groups involved in the intervention?',\n",
       " 'What are the eligibility criteria for patients to participate in the study mentioned in the context information? Provide examples of both inclusion and exclusion criteria.',\n",
       " 'Describe the treatment regimens for the two recruitment groups mentioned in the document. Include details such as the drugs used, dosages, and administration schedules.',\n",
       " 'What is the primary outcome measure used in the study \"Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement\"? Describe how this outcome measure is assessed and the time frame in which it is evaluated.',\n",
       " 'What are the inclusion criteria for subjects participating in the study? Specifically, what are the requirements for subjects with osteoarthritis undergoing elective Total Knee Arthroplasty (TKA) under regional anesthesia?',\n",
       " 'What are the exclusion criteria for subjects participating in the study on the effects of pregabalin on post-operative pain management in knee arthroplasty patients?',\n",
       " 'What is the statistical method used in the analysis of the study results, and what was the p-value obtained for comparing the high dose and placebo groups in terms of pain scores?',\n",
       " 'What was the primary purpose of the clinical trial mentioned in the context information?',\n",
       " 'How was the primary outcome of the study defined and measured in relation to the efficacy of fesoterodine compared to tolterodine for overactive bladder?',\n",
       " 'What are the inclusion criteria for adult patients with overactive bladder (OAB) symptoms in this study?',\n",
       " 'How was the treatment difference between Fesoterodine and Tolterodine ER at Week 12 assessed in the study, and what statistical method was used for the analysis?',\n",
       " 'Explain the concept of Winsorized means and how they were used in estimating treatment effects in this study. Why was it necessary to censor 5% of the tails in this analysis?',\n",
       " 'Describe the statistical method used in this study to compare the treatment effects of fesoterodine, tolterodine ER, and placebo. How was the p-value calculated and what does the significance level of 0.0172 indicate in terms of the comparison between fesoterodine and tolterodine ER?',\n",
       " 'What was the primary purpose of the study evaluating the efficacy and safety of Etanercept and Methotrexate in Japanese subjects with rheumatoid arthritis?',\n",
       " 'Describe the primary outcome measure used in the study and explain how it was assessed in relation to disease progression and joint worsening.',\n",
       " 'What are the inclusion criteria for participants in this study on the treatment of rheumatoid arthritis in Japanese individuals?',\n",
       " 'What were the primary outcome time frame and statistical method used in the analysis of the study comparing the efficacy of Methotrexate and Etanercept in treating rheumatoid arthritis?',\n",
       " 'How was mTSS used consistently in the statistical analysis plan and study results?',\n",
       " 'Can you explain the significance of mTSS in the context of the study results?',\n",
       " 'What was the primary purpose of the study described in the context information provided?',\n",
       " 'How was the enrollment for the study conducted, and what was the total number of participants involved in the research?',\n",
       " 'What are the inclusion criteria for patients eligible to participate in the study on locally advanced/metastatic non-small cell lung cancer?',\n",
       " 'How was the difference in overall survival between treatment arms analyzed in the study, and what was the resulting p-value?',\n",
       " 'What was the primary purpose of the study involving FOLFIRI chemotherapy with or without sunitinib in patients with metastatic colorectal cancer?',\n",
       " 'What was the outcome of the study as determined by the independent Data Monitoring Committee (DMC) in June 2009, and how did Pfizer respond to these findings?',\n",
       " 'What is the primary outcome measure in this study on metastatic colorectal cancer patients receiving FOLFIRI treatment?',\n",
       " 'Describe the eligibility criteria for patients to participate in this study on metastatic colorectal cancer.',\n",
       " 'Explain the treatment regimen for patients in recruitment group 1, including the administration of FOLFIRI and the use of placebo during the study. How many courses of FOLFIRI were administered during each 6-week cycle?',\n",
       " 'Based on the statistical analysis provided, what was the p-value calculated for the comparison between the treatment group and the placebo group in terms of non-inferiority? What does this p-value indicate about the results of the study?',\n",
       " 'What were the primary objectives of the study comparing perceptions and satisfaction for two different delivery mechanisms for Etanercept in patients with rheumatoid arthritis?',\n",
       " 'How did the study aim to characterize patient attributes that may indicate when one device may result in greater patient satisfaction than another in the context of rheumatoid arthritis treatment?',\n",
       " 'What is the primary outcome measure of the study, and how is it assessed?',\n",
       " 'What are the inclusion criteria for participants in the study, and what are the exclusion criteria mentioned?',\n",
       " 'What were the null and alternative hypotheses tested in the study, and what was the significance level used for the non-inferiority test?',\n",
       " 'Using the information provided, calculate the 95% two-sided confidence interval for the mean difference (AI minus PFS) of subject satisfactions and determine if non-inferiority was demonstrated based on the lower limit of the confidence interval.',\n",
       " 'What is the primary outcome measure used in the study of the efficacy and safety of pregabalin compared to placebo for the treatment of post-surgical pain from hysterectomy?',\n",
       " 'What are the inclusion criteria for subjects participating in the study, specifically related to the type of surgery and expected duration of hospital stay post-surgery?',\n",
       " 'What are the exclusion criteria for subjects participating in the study on total abdominal hysterectomy? Provide specific examples of criteria that would disqualify a subject from participating.',\n",
       " \"Based on the recruitment details provided, compare and contrast the two recruitment groups (Pregabalin 150mg and Pregabalin 300mg) in terms of dosage and frequency. How does the statistical analysis of these groups support the study's objectives?\",\n",
       " 'What was the primary outcome measured in the study of Gemcitabine Plus AG-013736 versus Gemcitabine for advanced pancreatic cancer?',\n",
       " 'Why was the study prematurely discontinued, according to the detailed description provided in the context information?',\n",
       " 'What are the inclusion criteria for participants in this study on pancreatic adenocarcinoma?',\n",
       " \"How was death determined in this study, and what was the primary outcome time frame for assessing the participants' status?\",\n",
       " 'What were the two treatment arms in the study comparing temsirolimus versus sorafenib as second-line therapy in patients with advanced renal cell carcinoma who had failed first-line sunitinib?',\n",
       " 'What was the primary outcome measured in this study, and how was it defined?',\n",
       " 'What are the inclusion criteria for participants in this study on metastatic renal cell carcinoma (mRCC) receiving first-line sunitinib therapy?',\n",
       " 'What are the treatment regimens for the two recruitment groups in this study, and how long are participants expected to receive these treatments for?',\n",
       " 'What were the primary and secondary objectives of the study comparing patient satisfaction with the prefilled syringe (PFS) and the auto-injector (AI) for etanercept?',\n",
       " 'How were patient perceptions related to device attributes measured in the study, and what factors were considered in characterizing patient attributes that may indicate greater satisfaction with one device over another?',\n",
       " 'What is the primary outcome measure evaluated in this study for the treatment of psoriasis with Enbrel and Etanercept?',\n",
       " 'What are the inclusion criteria for participants in this study on the treatment of moderate to severe plaque psoriasis with Enbrel and Etanercept?',\n",
       " 'What are the two recruitment groups mentioned in the context information, and what is the difference in the administration method of Etanercept between these two groups?',\n",
       " 'Based on the group IDs provided, what statistical method was used to analyze the data, and what was the outcome in terms of non-inferiority testing?',\n",
       " 'What was the primary purpose of the study on Adjunctive Ziprasidone in the Treatment of Bipolar I Depression conducted by Pfizer?',\n",
       " 'Describe the intervention model and masking used in the study evaluating the efficacy and safety of flexible doses of oral Ziprasidone as add-on therapy with lithium, valproate, or lamotrigine in Bipolar I Depression.',\n",
       " 'What is the primary outcome measure in this study and how is it assessed?',\n",
       " 'What are the inclusion criteria for participants in this study, specifically regarding their diagnosis and medication history?',\n",
       " 'Explain the significance of the p-value provided in the context information. How does it relate to the null hypothesis and the conclusion drawn from the study?',\n",
       " 'Describe the statistical method used in the analysis of the data presented. What are the key components of this method and how do they contribute to the interpretation of the results?',\n",
       " 'What was the primary objective of the study on the efficacy and safety of IV diclofenac (DIV075V) for pain after elective orthopedic surgery?',\n",
       " 'How was the primary outcome, Sum of the Pain Intensity Differences (SPID) Over 24 Hours, measured in the study comparing diclofenac to placebo or Ketorolac tromethamine for post-operative pain relief?',\n",
       " 'What are the eligibility criteria for participants to be included in the study on pain reduction following orthopedic surgery?',\n",
       " 'Describe the dosages and administration schedules of DIC075V and ketorolac tromethamine for participants in the study.',\n",
       " 'What was the primary completion date of the study on the efficacy and safety of pregabalin (Lyrica) as monotherapy in patients with partial seizures?',\n",
       " 'Why was the study on pregabalin (Lyrica) as monotherapy in patients with partial seizures terminated, according to the detailed description provided in the context information?',\n",
       " 'What is the primary outcome measure of the study involving the use of Pregabalin in participants with epilepsy? Describe the criteria for participants to discontinue the study based on this outcome measure.',\n",
       " 'What are the inclusion criteria for participants in the study on Pregabalin for epilepsy treatment? Provide details on the eligibility requirements related to the diagnosis of epilepsy, seizure history, and current anti-epileptic drug treatment.',\n",
       " 'Explain the statistical method used in the analysis of the data provided in the context information. How was the p-value calculated and what does it indicate about the results?',\n",
       " 'Discuss the limitations and caveats mentioned in the context information regarding the study. How did the External Data Monitoring Committee (DMC) impact the study and what was the basis for the primary analysis reported?',\n",
       " 'What is the primary purpose of the study comparing anidulafungin and voriconazole in combination to voriconazole alone for the treatment of Invasive Aspergillosis?',\n",
       " 'Describe the intervention plan for the Arms group receiving Voriconazole and Anidulafungin in the study.',\n",
       " 'What are the inclusion criteria for participants in this study on the treatment of invasive aspergillosis with voriconazole and anidulafungin?',\n",
       " 'Describe the treatment regimen for participants in the Voriconazole/Anidulafungin group during the second week of the study.',\n",
       " 'Explain the statistical method used to analyze the data on all-cause mortality on Day 42 (Week 6) within each stratum. How was the treatment difference calculated and what was the significance level used for determining statistical significance?',\n",
       " 'Discuss the significance of the p-value of 0.0434 in the context of the study results. How does this p-value relate to the non-inferiority type and the tested hypothesis?',\n",
       " 'What was the primary outcome measured in the Fesoterodine Flexible Dose Study, and how was it calculated?',\n",
       " 'What were the inclusion criteria for patients to participate in the study evaluating the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder?',\n",
       " 'Explain the exclusion criteria for participants in the study on fesoterodine treatment for overactive bladder (OAB) symptoms. How do these criteria impact the selection of participants for the study?',\n",
       " 'Describe the recruitment process for participants in the study comparing fesoterodine and placebo for OAB symptoms. How were participants assigned to the placebo and fesoterodine groups, and what were the treatment protocols for each group?',\n",
       " 'What was the primary outcome measured in the study comparing pregabalin and levetiracetam in patients with partial seizures? Provide a brief description of how this outcome was determined.',\n",
       " 'According to the eligibility criteria, what are the requirements for subjects to be included in the study comparing pregabalin and levetiracetam as adjunctive therapy for reducing seizure frequency in patients with partial seizures?',\n",
       " 'What are the eligibility criteria for subjects to participate in the study on epilepsy treatment, specifically in terms of their diagnosis, treatment history, and current medication regimen?',\n",
       " 'Describe the treatment regimens for the two recruitment groups in the study, including the dosages and administration schedules for pregabalin and levetiracetam during the titration phase, maintenance phase, and optional continuation phase.',\n",
       " 'What is the parameter type being analyzed in the given context information?',\n",
       " 'What limitation was mentioned regarding the results for the BPRS in the study?',\n",
       " 'What was the primary purpose of the study evaluating prophylaxis treatment with B-domain deleted recombinant Factor VIII in children with Hemophilia A?',\n",
       " 'How was the Mean Annualized Bleed Rate (ABR) by Treatment calculated for the On Demand Cohort in the study?',\n",
       " 'What are the inclusion criteria for male subjects aged less than 6 years with moderately severe to severe hemophilia A in this study?',\n",
       " 'Describe the treatment regimen followed by participants in the Moroctocog Alfa (AF-CC) OD Cohort during Period 1 and Period 2 of the study.',\n",
       " 'Explain the treatment regimen followed by participants in Recruitment group 1 for routine prophylaxis therapy in this study. What was the dosage of moroctocog alfa (AF-CC) administered during Period 1 and Period 2?',\n",
       " 'In Recruitment group 1, a statistical analysis was conducted to compare the efficacy of on demand therapy versus routine prophylaxis therapy at 25 IU/kg. Describe the statistical method used for this analysis and interpret the reported p-value and confidence interval in the context of the study results.',\n",
       " 'What was the primary outcome measured in the study \"Fesoterodine \"add-on\" Male Overactive Bladder Study\" and how was it assessed?',\n",
       " 'What were the eligibility criteria for male participants in the study, specifically regarding age, medication, and symptoms of overactive bladder?',\n",
       " 'What are the exclusion criteria for this study involving fesoterodine treatment, and why are they important in determining eligibility for participation?',\n",
       " 'Describe the recruitment groups in this study, including the treatment regimens and adjustments made at the Week 4 visit. How do these groups differ in terms of medication administration and dosage adjustments?',\n",
       " 'What was the primary outcome measured in the \"Celebrex In Acute Gouty Arthritis Study\" and how was it assessed?',\n",
       " 'Describe the treatment regimens for the two arms in the study, including the dosage and duration of the medications used.',\n",
       " 'What are the inclusion criteria for participants in this study on acute gouty arthritis?',\n",
       " 'How was the primary analysis conducted in this study, and what factors were considered in the analysis?',\n",
       " 'What is the statistical method used in the study, and what type of parameter values were analyzed for each group comparison?',\n",
       " 'What limitations and caveats should be considered when interpreting the study results, particularly in relation to the data collection for the Patients Global Evaluation of study medication?',\n",
       " 'What is the primary purpose of the study \"Surgical Pain After Inguinal Hernia Repair (SPAIHR)\"?',\n",
       " 'What is the primary outcome measure used in the study, and how is it assessed?',\n",
       " 'What are the exclusion criteria for subjects participating in the study on surgery and pain control medication?',\n",
       " 'Describe the recruitment details for male subjects enrolled in the study on Pregabalin for pain management before and after surgery.',\n",
       " 'What statistical method was used to analyze the data in the given context information? Explain why this method was chosen for the analysis.',\n",
       " 'In the context information, it is mentioned that centers with fewer than 8 treated subjects were combined into pooled centers. How might this pooling of centers impact the interpretation of the study results, particularly in relation to the p-values reported?',\n",
       " 'What was the primary outcome measure in the study evaluating the efficacy and safety of pregabalin for pain associated with diabetic peripheral neuropathy?',\n",
       " 'What were the inclusion criteria for patients participating in the study, and what was one of the exclusion criteria mentioned in the context information provided?',\n",
       " 'Explain the pre-assignment details of the study, including how subjects were classified and randomly assigned to treatment groups based on creatinine clearance values.',\n",
       " 'Discuss the statistical analysis conducted in the study, including the significance level, p-values, and statistical method used. How were the treatment groups and creatinine clearance strata factored into the analysis?',\n",
       " \"What was the reason for the termination of the study comparing Inotuzumab Ozogamicin in combination with Rituximab versus defined investigator's choice in follicular non-Hodgkin's lymphoma?\",\n",
       " 'Describe the treatment arms in the study, including the interventions and dosing schedules for each arm.',\n",
       " 'What is the dosing regimen for R-FND in this clinical trial, including the specific drugs and their administration schedules?',\n",
       " 'What are the eligibility criteria for participants in this study, including requirements related to the type of lymphoma, prior treatment history, and laboratory values?',\n",
       " 'Explain the treatment regimens received by participants in Recruitment Group 0 (FG000) and Recruitment Group 1 (FG001) in the study. How do these regimens differ in terms of the drugs administered and the duration of each cycle?',\n",
       " 'What statistical method was used to analyze the data in this study, and what was the p-value obtained? Additionally, discuss the limitations and caveats of the study as mentioned in the context information.',\n",
       " 'What is the primary endpoint of the study comparing Bosutinib to Imatinib in subjects with newly diagnosed chronic phase Philadelphia Chromosome Positive CML?',\n",
       " 'Describe the intervention for Arms group 0 in the study, including dosage, administration, and duration of treatment.',\n",
       " 'Explain the criteria for achieving a complete cytogenetic response (CCyR) in patients with chronic phase Ph+ CML, as outlined in the context information. How is CCyR determined in terms of Ph+ metaphases and Bcr-Abl fusion product percentages?',\n",
       " 'Compare and contrast the eligibility criteria for inclusion and exclusion in the clinical trial for patients with chronic phase Ph+ CML. What are the key differences between the two sets of criteria, and why are they important in selecting participants for the study?',\n",
       " 'What was the reason for the termination of the study on CP-751,871 in combination with paclitaxel and carboplatin for patients with non-small cell lung cancer?',\n",
       " 'Describe the treatment arms in the study, including the interventions received by patients in each arm and the purpose of each arm in the trial.',\n",
       " 'What is the primary outcome measure in the study described in the context information? Provide a brief description of how this outcome is assessed and the time frame for assessment.',\n",
       " 'What are the eligibility criteria for patients to participate in the clinical trial involving Figitumumab, Paclitaxel, and Carboplatin? Provide examples of both inclusion and exclusion criteria mentioned in the document.',\n",
       " 'Explain the standard platinum-based doublet chemotherapy regimen used in the study, including the specific drugs administered and the treatment schedule.',\n",
       " 'What were the key findings of the study regarding the efficacy of CP-751,871 in the treatment of advanced non-adenocarcinoma non-small cell lung cancer (NSCLC)? What led to the early termination of the study?',\n",
       " 'What was the primary outcome measured in the clinical trial evaluating the efficacy and safety of fesoterodine in comparison to tolterodine extended release in patients with overactive bladder?',\n",
       " 'What were the inclusion criteria for adult subjects to participate in the 12-week, randomized, double-blind, placebo-controlled trial comparing fesoterodine to tolterodine extended release for overactive bladder?',\n",
       " 'What are the exclusion criteria for subjects participating in the study of fesoterodine, and why are these criteria important to consider?',\n",
       " 'Describe the recruitment details for participants with urgency incontinence Overactive Bladder (OAB) symptoms in the study. What were the different treatment groups and their respective descriptions?',\n",
       " 'Explain the statistical method used in the analysis of the treatment difference between fesoterodine and tolterodine ER at Week 12. How was the p-value adjusted in this analysis?',\n",
       " 'Why was the comparison between fesoterodine and tolterodine ER only performed if statistical significance favoring fesoterodine was achieved in the comparison with placebo? How was the overall alpha level maintained in this analysis?',\n",
       " 'What was the primary outcome measure in the study on neuromuscular changes in small for gestational age children during somatropin therapy, and how was it assessed?',\n",
       " 'Describe the intervention model and allocation method used in the study conducted by Pfizer on the effect of somatropin treatment in short children born small for gestational age.',\n",
       " 'Explain the eligibility criteria for participants in the study, including the specific age range, birth length/weight-SDS requirements, and growth velocity SDS criteria. Why were participants with prior GH treatment excluded from the study?',\n",
       " 'Compare and contrast the treatment regimens for the two recruitment groups (Somatropin and Control Arm) in terms of dosage, administration, and duration. How did the study design account for potential confounding variables such as baseline values and study duration in the analysis of the results?',\n",
       " 'What was the primary purpose of the study titled \"Genotropin Treatment In Very Young Children Born Small For Gestational Age\"?',\n",
       " 'What were the eligibility criteria for inclusion in the study, specifically regarding the age range, ethnicity, and birth characteristics of the subjects?',\n",
       " 'What are the exclusion criteria for participants in this study on small for gestational age (SGA) children, and why are these criteria important for the research?',\n",
       " 'Describe the recruitment process for the randomized controlled trial involving Genotropin and the untreated control group. How many participants were screened, and how many were ultimately randomized for the study?',\n",
       " 'What were the primary and secondary objectives of the study comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa in advanced renal cell carcinoma subjects?',\n",
       " 'Can you explain the primary outcome measure of the study, Progression-Free Survival (PFS), as defined in the context information provided?',\n",
       " 'Explain the eligibility criteria for participants in the study on advanced renal cell carcinoma (RCC) treatment. What were the key inclusion and exclusion criteria mentioned?',\n",
       " 'Describe the treatment regimens for the two recruitment groups in the study. What were the specific drugs administered and how often were they given to participants?',\n",
       " 'What was the primary purpose of the study titled \"Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder\" conducted by Pfizer?',\n",
       " 'Describe the eligibility criteria for participants in the study evaluating the safety and efficacy of Varenicline Tartrate for smoking cessation in subjects with schizophrenia and schizoaffective disorder.',\n",
       " 'Explain the eligibility criteria for participants in the study based on the provided context information. What are the specific criteria that must be met for individuals to be considered eligible to participate in the study?',\n",
       " 'Compare and contrast the treatment plans for the two recruitment groups (Varenicline and Placebo) in the study. What are the specific dosages and schedules for each group, and how do they differ in terms of administration?',\n",
       " 'What were the primary objectives of the study comparing celecoxib and tramadol in patients with chronic low back pain?',\n",
       " 'Describe the criteria used to determine a successful responder in the study based on the Numerical Rating Scale-Pain (NRS-Pain) at Week 6.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on chronic low back pain treatment?',\n",
       " 'Describe the recruitment groups and their respective treatment descriptions in the study comparing celecoxib and tramadol HCL for chronic low back pain.',\n",
       " 'What was the primary outcome measure in the study evaluating the efficacy and safety of bapineuzumab in patients with mild to moderate Alzheimer Disease?',\n",
       " 'What was the overall status of the study evaluating the efficacy and safety of bapineuzumab in Alzheimer Disease patients, and when was the primary completion date?',\n",
       " \"Explain the eligibility criteria for participants in the study of bapineuzumab for Alzheimer's Disease. What were the inclusion and exclusion criteria, and why were women of childbearing potential excluded from the study?\",\n",
       " 'Describe the primary outcome measure and the analysis method used in the study of bapineuzumab. How was the ADAS-Cog score calculated, and what did a negative change from baseline indicate in terms of cognitive impairment?',\n",
       " 'How was the Hochberg approach utilized in the analysis of the two dose levels (0.5 mg/kg and 1.0 mg/kg) of bapineuzumab in the study?',\n",
       " 'What were the limitations and caveats mentioned in the context information that may have impacted the interpretation of the study results?',\n",
       " 'What was the primary reason for the termination of the study on CP-751,871 in combination with erlotinib for patients with advanced non-small cell lung cancer of non-adenocarcinoma histology?',\n",
       " 'Describe the treatment plan for patients in Arm A of the study, which involved the combination of CP 751,871 and erlotinib.',\n",
       " 'What is the primary outcome measure in the study described in the context information? Provide a brief description of this outcome measure and the time frame for its assessment.',\n",
       " 'Describe the eligibility criteria for participants in the study. What are the inclusion criteria related to the type of non-small cell lung cancer, and what are some of the exclusion criteria mentioned?',\n",
       " 'What statistical method was used to analyze the data in the study mentioned in the context information?',\n",
       " 'What was the reported p-value for the study, and what significance level was used to determine statistical significance?',\n",
       " 'What is the primary outcome measure used in the study evaluating the safety and efficacy of Bapineuzumab in Alzheimer Disease patients?',\n",
       " 'Describe the study design, including the allocation, intervention model, masking, and enrollment count, of the trial evaluating Bapineuzumab in patients with mild to moderate Alzheimer Disease.',\n",
       " 'Explain the scoring system and items included in the ADAS-Cog/11 scale used in the study. How is cognitive impairment measured using this scale, and what does a negative change from baseline indicate?',\n",
       " 'Describe the eligibility criteria for participants in the study, including both inclusion and exclusion criteria. How were participants selected for enrollment, and what were the key requirements for their involvement in the research?',\n",
       " 'What was the primary purpose of the study comparing sunitinib in combination with prednisone versus placebo and prednisone in patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy?',\n",
       " 'How was the primary outcome, Overall Survival (OS), defined in this study, and what was the time frame for assessing this outcome?',\n",
       " 'What are the eligibility criteria for patients to participate in the clinical trial for progressive, metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy?',\n",
       " 'What were the key findings regarding the comparison between the treatment groups in terms of non-inferiority, as indicated by the p-value and hazard ratio in the clinical trial?',\n",
       " 'What is the primary outcome measured in the study on axitinib (AG-013736) as second-line therapy for metastatic renal cell cancer?',\n",
       " 'What was the overall status of the study on axitinib (AG-013736) as second-line therapy for metastatic renal cell cancer, and when was the completion date?',\n",
       " 'What are the eligibility criteria for patients to participate in the study on renal cell cancer treatment, specifically in terms of their cancer subtype, prior treatments, and timing of major surgeries or radiation?',\n",
       " 'Based on the group IDs provided, what was the statistical method used to compare progression-free survival (PFS) between the two treatment arms, and what was the hazard ratio (HR) value calculated for the comparison?',\n",
       " 'What was the primary purpose of the study evaluating Desvenlafaxine Succinate (DVS) Sustained Release for the treatment of Vasomotor Symptoms in menopausal women?',\n",
       " 'Describe the intervention plan for Arms group 0 in the study assessing the safety and efficacy of DVS SR for the treatment of Vasomotor Symptoms associated with menopause.',\n",
       " 'What were the inclusion criteria for participants in this study on the treatment of hot flushes in postmenopausal women?',\n",
       " 'How was the comparison between Desvenlafaxine Succinate Sustained Release (DVS SR) 100 mg and placebo conducted in terms of statistical analysis, and what was the result of this comparison?',\n",
       " 'What was the primary reason for the termination of the study comparing sunitinib malate versus sorafenib in patients with advanced hepatocellular carcinoma?',\n",
       " 'Describe the treatment plan for patients in Arm A (sunitinib arm) of the study, including dosing and criteria for discontinuation of treatment.',\n",
       " 'What are the eligibility criteria for participants to be included in this study on hepatocellular carcinoma treatment?',\n",
       " 'What dosing interruptions and/or reductions are allowed for the sorafenib intervention in this study?',\n",
       " 'What was the primary purpose of the study conducted by Pfizer in pediatric subjects with glaucoma?',\n",
       " 'Describe the primary outcome measure used in the Phase 3 study evaluating the efficacy and safety of latanoprost and timolol in pediatric subjects with glaucoma.',\n",
       " 'Explain the eligibility criteria for participants in the study on glaucoma treatment, including both the inclusion and exclusion criteria. How did these criteria help ensure the validity of the study results?',\n",
       " 'Describe the recruitment details provided in the context information. How did the randomization process contribute to the study design, and why was it important to stratify by age, diagnosis, and intraocular pressure of the study eye at baseline?',\n",
       " 'What was the primary purpose of the study titled \"Tanezumab in Osteoarthritis of the Knee\" conducted by Pfizer?',\n",
       " 'How was the efficacy of Tanezumab in patients with osteoarthritis of the knee measured in the study, according to the primary outcome described in the document?',\n",
       " 'Explain the eligibility criteria for participants in the study evaluating the effectiveness of tanezumab for osteoarthritis knee pain. What are the key inclusion and exclusion criteria that potential participants must meet?',\n",
       " 'Describe the primary outcome measure used in the study and how it is calculated. What is the significance of the WOMAC pain subscale score in assessing the efficacy of tanezumab for knee pain relief?',\n",
       " 'Explain the statistical method used in the study as described in the context information. How does ANCOVA help in analyzing the data in this particular research scenario?',\n",
       " 'Compare the results of the LS Mean Difference parameter between the two groups (OG000 and OG003) as presented in the context information. How do the confidence intervals and p-values contribute to the interpretation of the findings in terms of treatment effectiveness?',\n",
       " 'What was the primary purpose of the study on tanezumab in osteoarthritis of the hip conducted by Pfizer?',\n",
       " 'Describe the primary outcome measure used in the study, including its specific assessment and the timeframe for evaluation.',\n",
       " 'Explain the eligibility criteria for participants in the study on osteoarthritis of the hip, including the specific requirements related to pain levels, medication use, and willingness to undergo certain treatments.',\n",
       " 'Describe the primary outcome measures and time frame for assessment in the study comparing the effects of placebo and tanezumab on pain levels in individuals with osteoarthritis of the hip.',\n",
       " 'Explain the statistical method used in the analysis of the data presented in the context information. How does ANCOVA help in comparing the LS Mean Difference between different groups?',\n",
       " 'Discuss the significance of the LS Mean Difference value of -1.69 and -1.75, along with their corresponding confidence intervals, in the context of the study results. How do these values support the conclusion of superiority or other legacy non-inferiority in the study?',\n",
       " 'What was the primary purpose of the study titled \"Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis\" conducted by Pfizer?',\n",
       " 'Describe the primary outcome measure used in the study to evaluate the efficacy of celecoxib versus diclofenac SR in Chinese patients with Ankylosing Spondylitis.',\n",
       " 'Explain the eligibility criteria for participants in the study comparing Celecoxib 200 mg to Diclofenac SR 75 mg for the treatment of Ankylosing Spondylitis. What were the key inclusion and exclusion criteria?',\n",
       " 'Discuss the statistical analysis method used in the study and the results obtained. What was the p-value for the comparison between Celecoxib and Diclofenac, and how was non-inferiority determined in this analysis?',\n",
       " 'What was the primary outcome measure in the study on Sitaxsentan for subjects with pulmonary arterial hypertension? Provide a brief description of how this outcome measure was assessed.',\n",
       " 'What were the inclusion criteria for participants in the study on Sitaxsentan efficacy and safety in subjects with pulmonary arterial hypertension? Specifically, what were the diagnostic criteria for pulmonary arterial hypertension and the symptom classification required for inclusion in the study?',\n",
       " 'What are the exclusion criteria for this study involving patients with WHO functional class III symptoms? Why is previous exposure to an endothelin receptor antagonist (ETRA) such as sitaxsentan, bosentan, or ambrisentan considered an exclusion criterion?',\n",
       " 'Describe the recruitment groups for this study. What are the titles and descriptions of the two recruitment groups, and what is the purpose of each group in the study?',\n",
       " 'What is the primary objective of the study titled \"A Phase 3, Multi-Center, Randomized, Double-Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001 (NCT00795639)\"?',\n",
       " 'Why was the study on combination therapy (Sitaxsentan+Sildenafil) versus monotherapy (Sitaxsentan alone) terminated, according to the information provided?',\n",
       " 'What is the primary outcome measure of the study described in the context information? Provide a detailed explanation of how this outcome is defined and measured.',\n",
       " 'Describe the eligibility criteria for participants in the study. What are the specific inclusion and exclusion criteria mentioned in the document?',\n",
       " 'Explain the recruitment groups involved in the study, including the medications administered and dosages for each group. What was the purpose of comparing these specific groups in the study?',\n",
       " 'Discuss the statistical analysis conducted in the study, including the p-value, statistical method used, and the interpretation of the results. What limitations and caveats were mentioned in the context information that may impact the study findings?',\n",
       " 'What was the primary purpose of the study evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the treatment of Major Depressive Disorder?',\n",
       " 'Describe the primary outcome measure used in the study and explain its significance in assessing the efficacy of the treatment.',\n",
       " 'Explain the eligibility criteria for participants in the study, including the required scores on the Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) and the Clinical Global Impressions Scale-Severity (CGI-S). How were participants with a significant risk of suicide excluded from the study?',\n",
       " 'Describe the pre-assignment details of the study, including the number of potential participants screened, the number enrolled, and the treatment received during the screening period prior to randomization. How did this pre-assignment phase contribute to the overall study design?',\n",
       " 'What was the primary purpose of the study conducted by Pfizer on pregabalin in patients with idiopathic Restless Legs Syndrome (RLS)?',\n",
       " 'Describe the primary outcome measure used in the study to assess the severity of Restless Legs Syndrome symptoms in the participants.',\n",
       " 'What are the inclusion criteria for participants in this study on idiopathic Restless Leg Syndrome (RLS)?',\n",
       " 'Describe the treatment regimen for the recruitment group receiving Pregabalin 300 mg in the study.',\n",
       " 'What is the primary purpose of the study evaluating the effects of Bazedoxifene/Conjugated Estrogens on endometrial safety and postmenopausal osteoporosis?',\n",
       " 'Describe the intervention for Arms group 1 in the study, including the dosage and frequency of administration.',\n",
       " 'Explain the primary outcome of the study regarding endometrial hyperplasia assessment at Month 12. What were the two definitions used to determine the presence of hyperplasia, and how were the results summarized?',\n",
       " 'Describe the eligibility criteria for participants in the study. What were the inclusion criteria related to age, menopausal status, and uterine health? Additionally, what were some of the exclusion criteria mentioned, such as the use of certain medications and medical history restrictions?',\n",
       " 'What was the primary purpose of the study mentioned in the context information, and why was it terminated?',\n",
       " 'Can you explain the significance of the US FDA clinical hold on tanezumab osteoarthritis clinical studies and how it impacted the study mentioned in the document?',\n",
       " 'What is the primary outcome measure in this study on osteoarthritis and arthritis treatment, and how is it assessed?',\n",
       " 'What are the inclusion criteria for patients participating in this study on tanezumab and NSAID treatment for osteoarthritis of the knee or hip?',\n",
       " 'What are the exclusion criteria for participants in this study on osteoarthritis pain management? Provide at least three criteria mentioned in the context information.',\n",
       " 'Describe the treatment plan for participants in the recruitment group receiving tanezumab 10 mg with naproxen exposure. Include details about the dosages and administration schedule mentioned in the document.',\n",
       " 'What statistical method was used for the analysis in the study described in the context information?',\n",
       " 'Compare the results of the LS Mean Difference between group OG001 and group OG004 with the results of the LS Mean Difference between group OG000 and group OG002. What can be inferred from these comparisons?',\n",
       " 'In the analysis based on the ANCOVA model with treatment, baseline value, and index joint as covariates, what was the LS Mean Difference for the comparison between groups OG008 and OG009? Provide the confidence interval values as well.',\n",
       " 'What statistical method was used in the analysis comparing groups OG001 and OG003? Describe the non-inferiority type and provide the p-value for this comparison.',\n",
       " 'Explain the statistical method used in the analysis described in the context information. How does this method help in comparing the treatment groups?',\n",
       " 'Compare the results of the LS Mean Difference parameter for the treatment groups OG005 and OG009 with the corresponding confidence intervals. What conclusions can be drawn from this comparison in terms of non-inferiority or superiority?',\n",
       " 'What is the statistical method used in the study, and what was the p-value obtained from the analysis?',\n",
       " 'What is the confidence interval (CI) for the LS Mean Difference in the study, and what does the CI range suggest about the results in relation to the null hypothesis?',\n",
       " 'What is the primary purpose of the Phase 3 study comparing two doses of CP-690,550 vs. placebo for the treatment of Rheumatoid Arthritis?',\n",
       " 'Describe the primary outcome measure used in the study, specifically focusing on the criteria for achieving an American College of Rheumatology 20% (ACR20) response at Month 3.',\n",
       " 'What are the inclusion criteria for patients participating in the study on RA treatment with CP-690,550?',\n",
       " 'How were the different doses of CP-690,550 compared to placebo in terms of efficacy, and what statistical method was used for the analysis?',\n",
       " 'Explain the significance of the p-value \"<0.0001\" in the context of the statistical analysis conducted using the normal approximation method. How does this value impact the interpretation of the results?',\n",
       " 'Calculate the percent difference between the two groups mentioned in the context information, and determine if the confidence interval of 95% (with a two-sided approach) supports the conclusion drawn from the analysis. Justify your answer with reference to the lower and upper limits of the confidence interval.',\n",
       " 'What was the primary purpose of the study titled \"Tanezumab In Osteoarthritis Of The Knee (2)\" conducted by Pfizer?',\n",
       " 'How was the efficacy and safety of tanezumab compared with naproxen and placebo tested in patients with osteoarthritis in the study with National Clinical Identification NCT ID NCT00830063?',\n",
       " 'Explain the eligibility criteria for participants in the study, including both inclusion and exclusion criteria. How did these criteria help ensure the validity of the study results?',\n",
       " 'Describe the recruitment groups in the study, including the treatments received by participants in each group. How were the outcomes compared between these groups, and what statistical methods were used for analysis?',\n",
       " 'Explain how the 95% confidence interval was calculated for the LS mean difference in the first group, and what the lower and upper limits of the interval represent in this context.',\n",
       " 'Compare the p-values obtained from the ANCOVA analysis for the two groups mentioned in the document. Discuss the implications of these p-values in relation to the non-inferiority type specified for each group.',\n",
       " 'What was the primary purpose of the study titled \"Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia\" conducted by Pfizer?',\n",
       " 'How was the primary outcome of the study measured, and what specific scale was used to assess daily pain scores in patients with fibromyalgia?',\n",
       " 'Explain the eligibility criteria for participants in the study comparing placebo and pregabalin for fibromyalgia treatment. What were the inclusion and exclusion criteria that participants had to meet in order to be eligible for the study?',\n",
       " 'Discuss the recruitment details for the study comparing placebo and pregabalin for fibromyalgia treatment. How were participants assigned to either the Placebo group or the Pregabalin group, and what was the administration schedule for each treatment group?',\n",
       " 'What was the primary objective of the study conducted by Pfizer regarding two different Tick-Borne Encephalitis (TBE) vaccines in children aged 1-11 years?',\n",
       " 'Can you explain the vaccination schedule and interventions followed in the study, including the types of vaccines administered and the timing of each dose for the participants?',\n",
       " 'What are the inclusion criteria for male and female children to participate in the study regarding TBE vaccination?',\n",
       " 'What are the exclusion criteria for subjects to be excluded from participation in the study on TBE vaccination?',\n",
       " 'What were the two recruitment groups in the study, and what vaccines did participants receive in each group according to the conventional immunization schedule?',\n",
       " 'How was the non-inferiority of seropositive response rate tested in the study, and what was the p-value obtained from the statistical method used?',\n",
       " 'What was the primary purpose of the Phase 3 study of CP-690,550 in patients with active rheumatoid arthritis on background methotrexate conducted by Pfizer?',\n",
       " 'Describe the primary outcome measure used in the study to assess the efficacy of CP-690,550 in patients with rheumatoid arthritis.',\n",
       " 'What are the inclusion and exclusion criteria for participants in this study on rheumatoid arthritis treatment?',\n",
       " 'How was the statistical significance of the different doses of CP-690,550 compared to placebo determined in this study, and what were the results of the comparison?',\n",
       " 'What is the primary purpose of the Phase 3 study comparing CP 690,550, Humira, and placebo in patients with Rheumatoid Arthritis?',\n",
       " 'Can you explain the significance of including an active comparator, adalimumab, in the study design?',\n",
       " 'What are the inclusion criteria for patients participating in the study on rheumatoid arthritis treatment with CP-690,550?',\n",
       " 'Describe the primary outcome measure used in the study and explain how it is assessed in participants with rheumatoid arthritis.',\n",
       " 'What are the eligibility criteria for patients to participate in the study, specifically in relation to their history of infection, previous TNFi treatment, and contraindications for adalimumab therapy?',\n",
       " 'Can you explain the recruitment groups and their corresponding treatments in the study, including the dosages of CP-690,550 and adalimumab, as well as the administration schedule up to Month 12?',\n",
       " 'Explain the statistical method used in the analysis and how it relates to the calculation of the percent difference with a 95% confidence interval.',\n",
       " 'Discuss the significance of the p-value being less than 0.0001 in the context of the study and how it impacts the interpretation of the results.',\n",
       " 'What is the primary objective of the Phase 3 study involving CP-690,550 in patients with active rheumatoid arthritis?',\n",
       " 'Can you explain the significance of the completion date and verification date in the context of the study conducted by Pfizer on CP-690,550 for the treatment of rheumatoid arthritis?',\n",
       " 'What are the inclusion criteria for patients to participate in the clinical trial for Rheumatoid Arthritis involving CP-690,550?',\n",
       " 'Describe the primary outcome measure used in the study, including the specific criteria for achieving an ACR20 response at Month 6.',\n",
       " 'What are the two recruitment groups in the study, and what are the respective doses of CP-690,550 being administered to participants in each group?',\n",
       " 'What statistical method was used to analyze the data in this study, and what was the p-value obtained for the comparison between the two doses of CP-690,550?',\n",
       " 'What was the primary outcome measure in the study testing the efficacy and safety of tanezumab in patients with osteoarthritis of the hip or knee?',\n",
       " 'What was the overall status of the clinical study involving tanezumab in osteoarthritis patients conducted by Pfizer?',\n",
       " 'What is the total score range for the WOMAC pain subscale score in this study, and what does a higher score indicate?',\n",
       " 'What were the eligibility criteria for participants in this study, and what were some of the exclusion criteria mentioned?',\n",
       " 'Explain the statistical method used in the analysis described in the context information. How does ANCOVA help in comparing the treatment groups while controlling for covariates and random effects?',\n",
       " 'Compare the results of the LS Mean Difference between group OG001 and OG003 with a p-value of 0.009 to the results between group OG002 and OG003 with a p-value of 0.175. Discuss the implications of these findings in terms of treatment effectiveness and statistical significance.',\n",
       " 'What was the primary outcome measure in the study on tanezumab and nerve function in arthritis patients, and how was it assessed?',\n",
       " 'Why was the study on tanezumab terminated, and what were the implications of the US FDA clinical hold on the clinical trials involving tanezumab for osteoarthritis patients?',\n",
       " 'Explain the eligibility criteria for participants in the study of Tanezumab for osteoarthritis pain relief. What are some of the key inclusion and exclusion criteria that potential participants must meet or avoid?',\n",
       " 'Describe the primary outcome measures and time frame for the study on Tanezumab. How are the values of attributes scored and what do positive and negative scores indicate in terms of response to treatment?',\n",
       " 'What statistical method was used in the analysis of the data presented in the context information? What was the p-value obtained from this analysis?',\n",
       " 'What limitations and caveats were mentioned in the context information regarding the study? How did these limitations impact the study results?',\n",
       " 'What was the primary purpose of the study mentioned in the context information, and why was it terminated?',\n",
       " 'Can you explain the significance of the US FDA clinical hold on tanezumab osteoarthritis clinical studies and how it impacted the study mentioned in the document?',\n",
       " 'What is the primary outcome measure in this study on osteoarthritis treatment with tanezumab and diclofenac? Describe the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score and how it is assessed at Week 16.',\n",
       " 'What are the inclusion criteria for patients to participate in this study on osteoarthritis treatment with tanezumab and diclofenac? Explain the requirements related to the diagnosis of osteoarthritis, current medication regimen, pain and function levels, and use of non-study pain medications.',\n",
       " 'What are the exclusion criteria for participants in the study on osteoarthritis of the knee or hip, specifically related to medical history and conditions that may affect the assessment of pain associated with OA?',\n",
       " 'Describe the recruitment details for participants in the study, including the medication regimen they were required to follow prior to randomization.',\n",
       " 'What statistical method was used to analyze the data in the study mentioned in the context information?',\n",
       " 'What limitation affected the study mentioned in the context information, leading to the premature termination of further study drug dosing?',\n",
       " 'What was the primary purpose of the study evaluating on-demand treatment with Xyntha in Chinese subjects with hemophilia A?',\n",
       " 'Describe the primary outcome measure used in the study, specifically focusing on the Investigator Hemostatic Efficacy Assessment 8 Hours Post Infusion.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on Xyntha for hemophilia A treatment?',\n",
       " 'How were participants recruited for the study on Xyntha in China, and what was the treatment regimen they received during the active phase of the study?',\n",
       " 'What was the primary outcome measured in the study on the effects of Pregabalin on sleep maintenance in subjects with fibromyalgia?',\n",
       " 'What was the enrollment count for the study, and what were the arms groups involved in the intervention?',\n",
       " 'What are the inclusion criteria for subjects participating in the study on fibromyalgia and insomnia disorder?',\n",
       " 'How were the secondary outcome measures analyzed in the study, and what was the rationale behind this approach according to the limitations and caveats mentioned in the context information?',\n",
       " 'What is the primary purpose of the study described in the context information, and what is the study design used to evaluate the efficacy and safety of desvenlafaxine succinate sustained release in adults with Major Depressive Disorder?',\n",
       " 'Can you explain the treatment protocol for subjects participating in the study, including the duration of the open-label period, the criteria for withdrawal from the study, and the randomization process for subjects who demonstrate a stable response to treatment?',\n",
       " 'What is the primary outcome measure of the study and how is it defined? Provide details on the time frame for assessing this outcome.',\n",
       " 'Describe the eligibility criteria for participants in the study, including both inclusion and exclusion criteria. How many participants were enrolled in the Desvenlafaxine succinate sustained release open-label response phase?',\n",
       " 'In the study described, what was the treatment regimen for subjects in the \"DVS SR 50 mg (Open-label Phase)\" group during the 20-week open-label phase?',\n",
       " 'What statistical method was used to analyze the data in the study, and what was the significance level for declaring statistical significance?',\n",
       " 'What was the primary objective of the study on Quillivant XR oral suspension in pediatric patients with ADHD?',\n",
       " 'Describe the primary outcome measure used in the study and explain how it assessed the manifestations of ADHD in the participants.',\n",
       " 'What were the inclusion criteria for participants in this study on ADHD medication?',\n",
       " 'Describe the pre-assignment details of the study design, including the phases involved and any dose adjustments mentioned.',\n",
       " 'Explain the treatment plan for participants in recruitment group 1, including the dosing schedule and duration of each intervention period.',\n",
       " 'How were treatment comparisons for observed scores analyzed in the study, and what was the key finding in terms of the efficacy of NWP06 compared to placebo?',\n",
       " 'What is the primary purpose of the Phase 3 trial involving the investigational drug PF-02341066 in patients with advanced non-small cell lung cancer?',\n",
       " 'How many arms were involved in the study comparing PF-02341066 versus pemetrexed or docetaxel, and what were the intervention names for each arm?',\n",
       " 'What is the primary outcome measure in this clinical trial, and how is it defined and calculated?',\n",
       " 'What are the inclusion criteria for patients to be eligible for participation in this study, specifically regarding their diagnosis and prior treatment history?',\n",
       " 'What was the statistical significance level for the analysis conducted using the Log Rank method, and why was it set at a one-sided alpha of 0.025?',\n",
       " 'What limitations and caveats were mentioned in the study regarding the analysis of ALK fusion variants and protein expression, and why were these analyses not conducted?',\n",
       " \"What is the primary purpose of the study mentioned in the context information? Provide a brief explanation of the study's focus and objectives.\",\n",
       " 'Describe the primary outcome measure used in the study. What criteria need to be met for a participant to achieve the American College of Rheumatology 20% (ACR20) response at Month 3?',\n",
       " 'What were the inclusion criteria for participants in the study comparing CP-690,550 with placebo for the treatment of rheumatoid arthritis?',\n",
       " 'Describe the statistical method used to analyze the superiority of CP-690,550 10 mg and 5 mg compared to placebo in the study.',\n",
       " 'What was the primary outcome measured in the study on MDV3100 in patients with castration-resistant prostate cancer who had previously been treated with docetaxel-based chemotherapy?',\n",
       " 'What were the eligibility criteria for patients to participate in the phase 3 study comparing the clinical benefit of MDV3100 versus placebo in castration-resistant prostate cancer patients?',\n",
       " 'What are the eligibility criteria for participants to be included in the study of Enzalutamide versus Placebo in patients with certain cancer types?',\n",
       " 'What were the primary objectives of the study comparing Enzalutamide versus Placebo, and what were the key findings in terms of statistical significance and clinical outcomes?',\n",
       " 'What was the primary purpose of the study on tanezumab in patients with osteoarthritis of the knee or hip conducted by Pfizer?',\n",
       " 'Why was the study on tanezumab terminated in December 2010, according to the detailed description provided in the context information?',\n",
       " 'Explain the eligibility criteria for participants in the study based on the information provided. How did these criteria impact the selection of participants for the research?',\n",
       " 'Describe the primary outcome time frame for the study and discuss how the change in the primary time-point from Week 16 to Week 8 affected the analysis of the results.',\n",
       " 'What was the primary purpose of the study described in the context information provided?',\n",
       " 'Can you explain the primary outcome measure, Wake After Sleep Onset (WASO), as described in the study?',\n",
       " 'What are the inclusion criteria for participants in this study on restless legs syndrome?',\n",
       " 'Describe the intervention schedule for participants in the \"Placebo Then Pramipexole 0.5 mg Then Pregabalin 300 mg\" recruitment group.',\n",
       " 'Explain the significance of the PBO wash-out period of 7 days between each period in the study. How does this impact the validity of the results obtained?',\n",
       " 'Compare and contrast the statistical methods used in the analysis of Group IDs OG000 vs. OG002 and Group IDs OG000 vs. OG001. How do the results and confidence intervals differ between these comparisons?',\n",
       " 'What was the primary purpose of the study involving bapineuzumab in Alzheimer Disease patients, as described in the context information?',\n",
       " 'How was safety measured in the study, and what was the primary outcome related to safety that was assessed in the participants?',\n",
       " 'What were the eligibility criteria for participants in the extension study 3133K1-3002 of the bapineuzumab program?',\n",
       " 'Why were efficacy results obtained after Week 78 not presented in the study results of the bapineuzumab program extension study?',\n",
       " \"What was the primary purpose of the study described in the context information, and how long was each subject's participation expected to last?\",\n",
       " 'How was safety measured in the study, and what specific outcome was the primary focus in terms of adverse events reported by participants?',\n",
       " \"What are the inclusion criteria for subjects participating in this study's extension phase, as outlined in the context information?\",\n",
       " 'Describe the recruitment details of the study, including the number of centers involved, the countries where the study was conducted, and the reason for its early termination by the sponsor.',\n",
       " 'What is the primary purpose of the study evaluating the antibody response of the 13-valent pneumococcal conjugate vaccine 24 months after the toddler dose?',\n",
       " 'How many arms were involved in the study, and what intervention was administered in Arm group 0?',\n",
       " 'What are the inclusion criteria for participants in the study evaluating the Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration one month after receiving a single dose of the 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine?',\n",
       " 'Describe the recruitment groups and their corresponding descriptions in the study involving the administration of a single dose of the 13-valent pneumococcal conjugate (13vPnC) vaccine two years after completing a full schedule of pneumococcal conjugate vaccine doses.',\n",
       " 'Explain the significance of calculating the GMC ratio and the confidence interval for the GMC ratio in the context of comparing different pneumococcal vaccines for serotypes 4 and 6B. How does the GMC ratio help in assessing the effectiveness of the vaccines?',\n",
       " 'Compare and contrast the results of the GMC ratio calculations for serotypes 4 and 6B between groups OG000 and OG002. Discuss the implications of these findings in terms of vaccine efficacy and potential differences in immune response.',\n",
       " 'Explain the process of calculating the confidence interval (CI) for the geometric mean concentration (GMC) ratio in the context of the study mentioned in the document. Provide an example using one of the serotypes mentioned.',\n",
       " 'Discuss the significance of testing for non-inferiority in the context of the study described in the document. How does the determination of non-inferiority impact the interpretation of the results for vaccine efficacy?',\n",
       " 'Explain the significance of the GMC ratio in the context of the given information. How is it calculated and why is it important in comparing different measures?',\n",
       " 'Compare and contrast the non-inferiority testing results for Serotype 14 and Serotype 18C based on the GMC ratios provided in the document. Discuss the implications of the confidence intervals for each serotype.',\n",
       " 'Explain the significance of the GMC ratio in the context of the study mentioned in the document. How was the GMC ratio calculated for the different group comparisons?',\n",
       " 'Compare and contrast the results of the GMC ratio for Serotype 19F and Serotype 23F based on the confidence intervals provided in the document. Discuss any implications of these findings in the context of the study.',\n",
       " 'Explain the significance of the GMC ratio in the context of the given information. How is it calculated and what does it indicate about the measures being compared?',\n",
       " 'Compare and contrast the non-inferiority testing results for Serotype 23F and Serotype 1 based on the GMC ratio and confidence intervals provided in the document. What conclusions can be drawn from these results in terms of vaccine effectiveness?',\n",
       " 'Explain how the confidence interval for the geometric mean concentration (GMC) ratio was calculated for Serotype 3 in the given context information.',\n",
       " 'Compare the GMC ratios for Serotype 5 between different groups as described in the context information. What can be inferred from the confidence intervals provided for these comparisons?',\n",
       " 'What is the GMC ratio for Serotype 6A when comparing the measures of 13vPnC/13vPnC/13vPnC to 7vPnC/7vPnC/13vPnC? Provide the confidence interval values for this comparison.',\n",
       " 'How does the GMC ratio for Serotype 7F differ when comparing the measures of 13vPnC/13vPnC/13vPnC to 7vPnC/7vPnC/13vPnC compared to 7vPnC/13vPnC/13vPnC? Include the confidence interval values in your explanation.',\n",
       " 'Explain the significance of the GMC ratio in the context of the study mentioned in the document. How was the confidence interval (CI) for the GMC ratio calculated for different serotypes?',\n",
       " 'Discuss the non-inferiority type mentioned in the document and how it relates to the GMC ratio values for different group comparisons. How does the back transformation of CI based on the Student t distribution play a role in determining non-inferiority in this study?',\n",
       " 'What was the primary outcome measure in the study evaluating the efficacy of a novel ibuprofen formulation on fever in patients with an uncomplicated acute infection?',\n",
       " 'What were the inclusion criteria for subjects participating in the study, and what were the exclusion criteria that would disqualify individuals from participating?',\n",
       " 'Explain the eligibility criteria for participation in the study based on the provided context information. How does pregnancy, breast-feeding, serious medical or psychiatric disorders, and age factor into the eligibility requirements?',\n",
       " 'Discuss the recruitment groups and their respective descriptions in the study. What were the differences between the Placebo group and the Ibuprofen Sodium group in terms of dosage and treatment? Additionally, explain the statistical analysis method used to compare the two groups and the limitations mentioned in the study results.',\n",
       " 'What is the primary purpose of the study comparing the effectiveness and safety of CP-690,550 to methotrexate in patients with rheumatoid arthritis who have not previously received methotrexate?',\n",
       " 'Describe the primary outcome measure used in this study and explain its significance in evaluating the effectiveness of the experimental drug CP-690,550 compared to methotrexate.',\n",
       " 'What are the inclusion criteria for participants in this study on Rheumatoid Arthritis (RA) treatment with methotrexate? How are these criteria defined in terms of joint pain, joint swelling, and inflammatory markers?',\n",
       " 'Describe the treatment regimens for the two recruitment groups in the study, including the dosage and frequency of administration for CP-690,550 and methotrexate.',\n",
       " 'What was the primary purpose of the study mentioned in the context information, and why was it terminated?',\n",
       " 'Describe the primary outcome measure of the study and how it was assessed in participants with HIV neuropathy.',\n",
       " 'What are the inclusion criteria for participants in this study on HIV-associated Distal Symmetrical Polyneuropathy (DSP) with subjective sensory symptom of pain?',\n",
       " 'Describe the treatment regimen for participants in the Pregabalin group during the 16-week study period.',\n",
       " 'What statistical method was used in the study to analyze the data?',\n",
       " 'Why was the study terminated on April 2, 2012, according to the limitations and caveats provided?',\n",
       " 'What was the primary purpose of the study titled \"A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY\" conducted by Pfizer?',\n",
       " \"How was the primary outcome of the study measured, and what scale was used to assess the participants' diabetic peripheral neuropathy pain levels during the double-blind phase?\",\n",
       " 'Explain the eligibility criteria for patients to participate in the study on painful diabetic peripheral neuropathy. What are the inclusion and exclusion criteria mentioned in the document?',\n",
       " 'Describe the recruitment process for participants in the study on pregabalin treatment for diabetic peripheral neuropathy. What were the specific requirements for participants to be eligible for the double-blind treatment phase?',\n",
       " 'What was the primary purpose of the study titled \"Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation\" conducted by Pfizer?',\n",
       " 'How was the primary outcome of the study measured, and what specific parameter was used to assess the change from baseline in annual growth rate in the participants treated with Genotonorm?',\n",
       " 'Explain the eligibility criteria for participants in the study on growth hormone treatment. What are the inclusion and exclusion criteria specified for the subjects?',\n",
       " 'Discuss the recruitment groups and treatment descriptions in the study. What were the differences between the Genotonorm 0.7 and Genotonorm 1.4 continuous treatment groups, and how were they administered to the subjects?',\n",
       " 'What was the primary outcome measure used in the study evaluating a novel ibuprofen formulation in the treatment of episodic tension-type headache?',\n",
       " 'Describe the arms groups and interventions used in the study comparing the novel ibuprofen formulation to standard ibuprofen and placebo in the treatment of episodic tension-type headache.',\n",
       " 'What are the inclusion criteria for participants in this study on episodic tension-type headaches?',\n",
       " 'Based on the recruitment details provided, what are the differences between the placebo and ibuprofen sodium treatment groups in terms of dosage and composition?',\n",
       " 'What was the primary purpose of the study evaluating a novel ibuprofen formulation in the treatment of post-surgical dental pain?',\n",
       " 'Describe the primary outcome measure used in the study and explain how it was calculated.',\n",
       " 'Explain the eligibility criteria for participants in the study on post-operative pain relief following surgical extraction of third molars. What are the inclusion and exclusion criteria specified in the document?',\n",
       " 'The study compared the efficacy of ibuprofen sodium versus a placebo in managing post-operative pain. Based on the provided information, describe the recruitment groups, including the description of the placebo and ibuprofen sodium treatments. What statistical method was used to analyze the results, and what was the p-value obtained for the comparison between the two treatments?',\n",
       " 'What was the primary purpose of the study comparing 0.3 mg Pegaptanib Sodium to sham injections in subjects with diabetic macular edema?',\n",
       " 'Describe the issue that was reported during the study regarding the maintenance of treatment masking, as mentioned in the detailed description section.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on diabetic macular edema treatment with pegaptanib sodium?',\n",
       " 'What statistical method was used to analyze the data comparing the efficacy of pegaptanib sodium and sham injection in the treatment of macular edema, and what was the resulting p-value?',\n",
       " 'What was the primary objective of the study evaluating Azithromycin Plus Chloroquine and Sulfadoxine Plus Pyrimethamine combinations for intermittent preventive treatment of Falciparum Malaria in pregnant women in Africa?',\n",
       " 'Why was the study terminated after an interim analysis of efficacy data by an External Data Monitoring Committee, and what was the notification date to the investigators regarding this termination?',\n",
       " 'What are the eligibility criteria for pregnant women to participate in the study mentioned in the context information? Provide examples of both inclusion and exclusion criteria.',\n",
       " 'Describe the treatment regimen for participants in the \"Azithromycin + Chloroquine\" recruitment group as outlined in the recruitment details. How many treatments are administered and at what intervals?',\n",
       " 'What was the treatment regimen for participants in recruitment group 1, \"Sulfadoxine + Pyrimethamine\"? How many treatments were administered and at what intervals?',\n",
       " 'Why was the program terminated by Pfizer, according to the limitations and caveats mentioned in the document?',\n",
       " 'What was the primary purpose of the study comparing the new Genotropin Mark VII pen to the current Genotropin pen in pediatric and adult subjects?',\n",
       " 'Describe the arms groups and intervention plans for the participants in the study assessing the convenience and preference of the newly developed Genotropin Mark VII pen.',\n",
       " 'Explain the primary outcome of the study regarding the comparison between the Genotropin Pen and the new Genotropin Mark VII Injection Pen. What question was asked to participants to assess this outcome, and what were the response options provided to them?',\n",
       " 'Describe the eligibility criteria for participants in the study. What were the inclusion criteria for subjects, and what were the exclusion criteria? Additionally, why were subjects with Prader-Willi syndrome or chronic renal insufficiency excluded from the study?',\n",
       " 'What is the primary outcome measured in the clinical trial comparing the efficacy of crizotinib versus standard chemotherapy in patients with ALK positive lung cancer?',\n",
       " 'What was the overall status of the study as of the verification date in September 2017?',\n",
       " 'What are the eligibility criteria for patients to participate in the study comparing Crizotinib and chemotherapy for locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer with ALK gene locus involvement?',\n",
       " 'Describe the treatment regimens for the two recruitment groups in the study, including the dosages and administration schedules for Crizotinib and chemotherapy.',\n",
       " 'Explain the administration protocol for the combination treatment of pemetrexed and either cisplatin or carboplatin as described in the context information. What are the specific doses and timing of each drug infusion?',\n",
       " 'Based on the statistical analysis provided in the context information, discuss the significance of the p-value obtained from the 1-sided log rank test in comparing progression-free survival (PFS) between the two treatment arms. What does the hazard ratio of 0.454 indicate in terms of treatment efficacy?',\n",
       " 'What were the primary objectives of the study evaluating the effects and safety of treatment, treatment withdrawal, and re-treatment with CP-690,550 in subjects with moderate to severe chronic plaque psoriasis?',\n",
       " 'Can you explain the significance of comparing the efficacy responses of CP-690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of treatment and subsequent withdrawal of active treatment in the study conducted by Pfizer?',\n",
       " 'Explain the primary outcome measure in the study, which focuses on the Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period. How is the PASI score calculated and what does it indicate about the severity of psoriasis in participants?',\n",
       " 'Describe the treatment arms in the study for participants with Psoriasis. What are the differences between the two arms in terms of the duration and type of treatment received, as well as the intervention model and masking used in the study?',\n",
       " 'What are the inclusion criteria for participants in this study on plaque-type psoriasis, as outlined in the eligibility criteria section?',\n",
       " 'How were participants in the study divided into different recruitment groups based on the dosage of CP-690,550 they received during Period A (Initial Treatment)?',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'How is overall survival defined in the study, and what factors determine when overall survival data is censored for analysis?',\n",
       " 'What are the inclusion criteria for patients participating in the randomized, double-blind treatment period of the study? Provide at least three criteria mentioned in the document.',\n",
       " 'Explain the significance of the hazard ratio value of 0.706 in the study results, as described in the group IDs section of the context information. What does a hazard ratio of less than 1 favoring enzalutamide indicate in comparison to placebo?',\n",
       " 'Explain the significance of the p-value being less than 0.0001 in the context of the statistical analysis method used (Log Rank). How does this p-value impact the interpretation of the results?',\n",
       " 'Discuss the importance of considering limitations and caveats in a research study. In this specific case, why is it important to acknowledge any potential limitations or caveats despite the results being statistically significant?',\n",
       " 'What was the primary purpose of the study evaluating a novel ibuprofen formulation in the treatment of post-surgical dental pain?',\n",
       " 'Describe the primary outcome measure used in the study and explain how it was calculated.',\n",
       " 'What are the inclusion criteria for participants in the study on post-operative pain relief following surgical extraction of third molars?',\n",
       " 'Describe the recruitment groups and their respective descriptions in the study on the effectiveness of ibuprofen sodium for post-operative pain relief.',\n",
       " 'Explain the statistical method used in the analysis of the treatment difference between Acetaminophen and Placebo. How was the p-value calculated and what does it indicate about the results?',\n",
       " 'Describe the approach taken to control Type I error at a 5% significance level in the comparison of co-primary endpoints sequentially for IBU Na vs PBO, IBU Na vs APAP, and APAP vs PBO for SPRID 0-6 and time to meaningful relief. How was the significance of subsequent comparisons determined based on the results of preceding steps?',\n",
       " 'What is the primary objective of the study involving inotuzumab ozogamicin plus rituximab for relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not candidates for intensive high-dose chemotherapy?',\n",
       " \"Can you explain the significance of the study's termination status and its implications on the evaluation of the efficacy of the treatment combination?\",\n",
       " 'What is the primary outcome measure of the study described in the context information? Provide a brief explanation of how this outcome is defined and measured.',\n",
       " 'Describe the treatment arms in the study, including the interventions used in each arm and the number of cycles administered. How do the two arms differ in terms of treatment options for participants with Non-Hodgkin lymphoma?',\n",
       " 'Explain the two treatment options given to participants in the study, including the dosages and administration schedules for each option.',\n",
       " 'Discuss the statistical analysis conducted in the study, including the primary null hypothesis, the statistical method used, and the interpretation of the results based on the hazard ratio and confidence interval provided.',\n",
       " 'What was the primary outcome measured in the study \"Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens\"? Provide a brief description of how this outcome was assessed and the time frame for measurement.',\n",
       " 'What were the inclusion and exclusion criteria for participants in the study on the long-term efficacy of exemestane compared to megestrol acetate in the treatment of postmenopausal women with advanced breast cancer? Specifically, what was the key requirement for inclusion, and who was excluded from the study?',\n",
       " 'What are the eligibility criteria for participants in this study in terms of sex and age?',\n",
       " 'What were the recruitment groups and their respective descriptions in this study?',\n",
       " 'What is the primary completion date of the study comparing Etanercept against a placebo for Etanercept on a background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the treatment of early Spondyloarthritis patients who do not have X-ray structural changes?',\n",
       " 'What is the enrollment count for the study, and what is the intervention model used in the trial comparing Etanercept against a placebo for Etanercept on a background NSAID in the treatment of adult subjects with non radiographic axial Spondyloarthritis?',\n",
       " 'What is the primary outcome measure of the study and how is it defined?',\n",
       " 'What are the inclusion criteria for participants in the study?',\n",
       " 'Explain the null and alternative hypotheses in the context of the study comparing the efficacy of etanercept to placebo in achieving an ASAS 40 response after 12 weeks of treatment. What was the primary endpoint of the study and how was it tested?',\n",
       " 'Describe the statistical method used to analyze the Week 12 data in the study. What was the p-value obtained from the analysis, and how was statistical significance determined? Additionally, provide the 95% confidence interval for the mean difference between etanercept and placebo in achieving an ASAS 40 response.',\n",
       " 'What is the primary purpose of the study \"Once-A-Day Pregabalin For Partial Seizures\" conducted by Pfizer?',\n",
       " 'How was the efficacy of two different dosages of pregabalin CR dosed once daily compared to placebo in the study, and what was the primary outcome measure used to assess this efficacy?',\n",
       " 'What were the inclusion criteria for participants in the study on epilepsy with partial onset seizures?',\n",
       " 'Describe the recruitment group titled \"Pregabalin 330 mg\" and the dosing regimen followed during the study.',\n",
       " 'Explain the statistical method used in the study to calculate the p-value and the significance of the p-value obtained in the context of the ANCOVA model.',\n",
       " 'Discuss the fixed terms included in the ANCOVA model and their relevance in determining the treatment effect on the participants.',\n",
       " 'What was the primary outcome measured in the study on the multiple dose dental pain study of ibuprofen extended release, and how was it calculated?',\n",
       " 'Describe the intervention for Arms group 0 in the study, including the dosage and timing of administration for the ibuprofen 600 mg extended release caplets.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on post-operative pain management following surgical removal of third molars?',\n",
       " 'Based on the group IDs provided, what was the primary outcome measure used to assess the efficacy of the placebo and ibuprofen treatments, and what was the statistical significance of the results?',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'Describe the primary outcome measure used in the study and how it is defined.',\n",
       " 'What are the inclusion criteria for patients participating in the study on pain management after healing from herpes zoster skin rash?',\n",
       " 'How was the recruitment conducted for the study on pregabalin controlled release and placebo in patients with persistent pain after herpes zoster skin rash?',\n",
       " 'What is the primary objective of the study mentioned in the context information?',\n",
       " 'Can you identify the key dates associated with the completion and verification of the study on AN2690 topical solution for onychomycosis of the toenail?',\n",
       " 'What is the primary outcome measure of the study on onychomycosis of toenails, and how is it defined?',\n",
       " 'Describe the intervention arms in the study, including the type of treatment and duration of application for each arm.',\n",
       " 'What were the eligibility criteria for participants in the study on distal subungual onychomycosis, and why were these criteria important for the research?',\n",
       " 'Describe the pre-assignment details of the study, including the treatment options and application instructions for participants. How did the study design aim to evaluate the effectiveness of the AN2690 Topical Solution, 5% compared to the Solution Vehicle?',\n",
       " 'What is the primary purpose of the study mentioned in the context information, and what is the primary outcome measure used to evaluate the efficacy of the treatment?',\n",
       " 'According to the eligibility criteria outlined in the document, what are the inclusion and exclusion criteria for patients participating in the study on the controlled release formulation of pregabalin for fibromyalgia treatment?',\n",
       " 'Describe the eligibility criteria for participants in the study, including any exclusion criteria and the minimum age requirement. How were participants selected for the double blind phase of the study?',\n",
       " 'Explain the dosing regimen for participants in the pregabalin (Single Blind Phase) group during the study. What was the consequence for participants who were unable to tolerate the optimized dose of study medication?',\n",
       " 'What is the main objective of the study mentioned in the context information, and what is the duration of the study?',\n",
       " 'Identify the lead sponsor of the study, the overall status of the study, and the primary completion date.',\n",
       " 'What is the primary outcome measure of the study on Psoriasis treatment with CP-690,550 at Week 16?',\n",
       " 'How is the Physician Global Assessment (PGA) of Psoriasis scored in this study, and what criteria define a positive response in terms of PGA score categories?',\n",
       " 'What is the primary outcome time frame for the study mentioned in the context information?',\n",
       " 'What are the eligibility criteria for participants in the study, specifically in terms of age, duration of diagnosis, and severity of psoriasis?',\n",
       " 'What statistical method was used for the analysis in the study described in the context information? Explain why this method was chosen and how it contributes to the validity of the results.',\n",
       " 'In the study, one of the comparisons had an odds ratio of 12.45 with a 95% confidence interval ranging from 9.01 to 31.88. Discuss the implications of this finding in terms of the effectiveness of the treatment being studied.',\n",
       " 'What is the primary objective of the study mentioned in the context information?',\n",
       " 'Can you identify the key dates associated with the completion and submission of the study mentioned in the context information?',\n",
       " 'What is the primary purpose of the study mentioned in the context information?',\n",
       " 'Can you explain the intervention model and masking used in the study?',\n",
       " 'What were the eligibility criteria for participants in the study on AN2690 Topical Solution for distal subungual onychomycosis?',\n",
       " 'How was the recruitment conducted for the study, including details on the treatment groups and the timeline of subject enrollment and completion?',\n",
       " 'What is the primary objective of the study mentioned in the context information?',\n",
       " 'Can you explain the overall status and timeline of the study conducted by Pfizer for patients with moderate to severe chronic plaque psoriasis?',\n",
       " 'What is the primary outcome measure of this study on Psoriasis treatment with CP-690,550?',\n",
       " 'How is the Physician Global Assessment (PGA) of Psoriasis scored in this study, and what criteria define a positive response in terms of PGA score?',\n",
       " 'What are the inclusion criteria for participants in this study on plaque psoriasis treatment?',\n",
       " 'How were the primary outcome measures reported in this study, and what was the significance of the statistical analysis method used?',\n",
       " 'What statistical method was used for the analysis in the study, and what significance level was set for testing each hypothesis against placebo?',\n",
       " 'For the comparison between two groups (OG000 and OG001), what was the p-value obtained, and what type of non-inferiority was tested in this case?',\n",
       " 'What was the primary purpose of the study titled \"Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy\" conducted by Pfizer?',\n",
       " 'How was the enrollment for the study structured in terms of the intervention groups, and what were the specific interventions administered to each group?',\n",
       " 'What is the primary outcome measure used in this study, and how is it assessed?',\n",
       " 'Describe the eligibility criteria for participants in this study, including both the inclusion and exclusion criteria.',\n",
       " 'What was the primary purpose of the study comparing on-demand treatment to a prophylaxis regimen of BeneFIX in subjects with moderately severe to severe Hemophilia B?',\n",
       " 'How was the annualized bleed rate (ABR) calculated in the study, and what was the primary outcome related to this calculation?',\n",
       " 'Explain the eligibility criteria for subjects to participate in the study, focusing on the requirements related to exposure days to factor IX products and the number of bleeding episodes, particularly joint bleeds, in the 12-month period before the Screening visit.',\n",
       " 'Describe the timeline of participation in the study, including the different periods involved (Screening, Period 1, Period 2, follow-up safety period), and the duration of each period. Additionally, discuss the recruitment details, including the number of enrolled participants, study centers, and countries involved in the research.',\n",
       " 'What is the primary objective of the Archer 1009 study comparing PF-00299804 to erlotinib in patients with advanced non-small cell lung cancer?',\n",
       " 'Can you explain the significance of the co-primary populations defined in the protocol for analyzing the primary objective of Progression Free Survival in the Archer 1009 study?',\n",
       " 'What is the primary outcome measure in the study comparing PF-00299804 and Erlotinib for the treatment of Non-Small Cell Lung Cancer?',\n",
       " 'What are the inclusion criteria for patients to be eligible for enrollment in the study, as outlined in the context information provided?',\n",
       " 'Explain the recruitment process for this study, including the number of participants, treatment arms, and the criteria for eligibility and randomization.',\n",
       " 'Discuss the statistical analysis conducted in this study, including the p-value, statistical method used, and the interpretation of the hazard ratio (HR) and confidence interval (CI) for the comparison between the Dacomitinib arm and Erlotinib arm.',\n",
       " 'What was the primary purpose of the \"Ibuprofen Sodium Tension Headache Study\" conducted by Pfizer?',\n",
       " 'Describe the primary outcome measure used in the study to compare the effectiveness of a novel ibuprofen formulation to placebo and standard ibuprofen in treating tension-type headache.',\n",
       " 'What are the inclusion criteria for participants in this study on episodic tension-type headache treatment?',\n",
       " 'Based on the group IDs provided, what was the statistical method used to analyze the treatment difference between Ibuprofen sodium and Ibuprofen (Motrin IB) for time to meaningful relief, and what was the p-value obtained from the analysis?',\n",
       " 'What is the primary purpose of the study mentioned in the context information? Provide a brief explanation of the study design and the intervention being tested.',\n",
       " \"Describe the primary outcome measure used in the study and explain how it is assessed. What is the significance of measuring the change from baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score?\",\n",
       " 'Explain the eligibility criteria for participants in the study on major depressive disorder (MDD) treatment. What were the inclusion and exclusion criteria specified for individuals aged 7 to 18 years with a primary diagnosis of MDD?',\n",
       " 'Discuss the primary outcome time frame and the statistical method used in the study comparing the efficacy of Placebo and DVS SR Low Dose in treating major depressive disorder. What was the p-value obtained from the analysis, and what does it indicate about the difference between the two treatment groups?',\n",
       " 'What is the primary outcome measure used in the study evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release versus placebo in children and adolescent outpatients with Major Depressive Disorder (MDD)? Describe how this outcome measure is assessed and interpreted.',\n",
       " 'Discuss the study design and methodology employed in the multicenter, randomized, double-blind, placebo-controlled study conducted to evaluate the efficacy, safety, and tolerability of Desvenlafaxine Succinate Sustained Release (DVS SR) in the treatment of children and adolescent outpatients with MDD. Include details about the arms groups, interventions, masking, and enrollment criteria.',\n",
       " 'Explain the eligibility criteria for participants in the study on major depressive disorder (MDD) treatment. What are the inclusion and exclusion criteria that were specified?',\n",
       " 'Discuss the recruitment groups involved in the study comparing Fluoxetine versus Placebo for the treatment of MDD. What were the treatment regimens for each group, and what were the key findings in terms of the adjusted mean difference between the two groups?',\n",
       " 'What was the primary purpose of the study on pregabalin in patients with fibromyalgia conducted by Pfizer?',\n",
       " 'How was the primary outcome of the study measured, and what was the specific endpoint assessed in relation to pain scores during the double-blind treatment period at Week 14?',\n",
       " 'What are the inclusion criteria for patients participating in the study on fibromyalgia treatment with pregabalin and placebo?',\n",
       " 'How was the recruitment process conducted for the study, and what were the details of the two recruitment groups (Pregabalin and Placebo)?',\n",
       " 'What statistical method was used in the analysis of the data, and what type of parameter was calculated? Provide the specific values for the parameter and its confidence interval.',\n",
       " 'Based on the provided information, what was the p-value obtained from the analysis, and what does this value indicate about the significance of the results?',\n",
       " 'What is the primary purpose of study A0081041 conducted by Pfizer in children ages 4-16 years with partial onset seizures?',\n",
       " 'How many arms groups were involved in the study, and what were the interventions administered in each group?',\n",
       " 'Explain the primary outcome measure of the study and how it is calculated. What is the significance of log-transforming the 28-day seizure rate for all partial onset seizures during the baseline phase?',\n",
       " 'Discuss the eligibility criteria for subjects to participate in the study. What are the inclusion and exclusion criteria that potential participants must meet or avoid in order to be enrolled in the trial?',\n",
       " 'What are the two recruitment groups in the study, and what doses of pregabalin were administered to participants in each group based on their weight and age?',\n",
       " 'What eligibility criteria were set for participants in the study, in terms of age, sex, and health status?',\n",
       " 'What was the primary purpose of the Phase 3b multicenter study of Pregabalin in fibromyalgia subjects with comorbid depression?',\n",
       " 'Describe the intervention for Arms group 0 in the study, including the dosage and duration of treatment with Pregabalin.',\n",
       " 'How are the endpoint mean pain scores for Period 1 and Period 2 defined in the study, and when are they measured?',\n",
       " 'Describe the recruitment process for participants in the double-blind, crossover study, including the treatment sequences and the number of participants recruited from different countries and study centers.',\n",
       " \"How was Satterthwaite's approximation used in the statistical analysis of the data?\",\n",
       " 'What was the significance level (p-value) obtained from the Mixed Models Analysis, and how does it impact the interpretation of the results?',\n",
       " 'What is the primary purpose of the clinical study mentioned in the context information?',\n",
       " 'Can you explain the significance of using DA-9501 (Dexmedetomidine) in patients undergoing surgery with epidural or spinal anesthesia without intubation under monitored sedation care?',\n",
       " 'What is the primary purpose of the study described in the context information?',\n",
       " 'What are the inclusion criteria for patients participating in the study mentioned in the context information?',\n",
       " 'What are some of the exclusion criteria for patients participating in the study, particularly in relation to their medical history and current health status?',\n",
       " 'Can you explain the different recruitment groups and their corresponding descriptions in the study, focusing on the dosages and administration details of the drugs being tested?',\n",
       " 'What type of statistical test was used in the study, and how was it applied (e.g. stratified by a specific variable)?',\n",
       " 'What was the reported p-value in the study, and what does a p-value of less than 0.001 indicate in terms of statistical significance?',\n",
       " 'What is the primary completion date of the study on Venlafaxine ER for Major Depressive Disorder (MDD)?',\n",
       " 'Describe the design of the study on Venlafaxine ER, including the treatment phases and follow-up visit evaluation.',\n",
       " 'What is the primary outcome measure of this study, and how is it assessed?',\n",
       " 'Describe the eligibility criteria for participants in this study.',\n",
       " 'Explain the exclusion criteria related to Axis II personality disorders and mental retardation according to DSM-IV diagnostic criteria. Why are subjects with these conditions excluded from the study?',\n",
       " 'Describe the pre-assignment details for subjects participating in the study, including the screening process, randomization, and treatment options. How were subjects confirmed to meet the entry criteria before being randomized to different treatment groups?',\n",
       " 'Explain the statistical method used in the analysis of the data provided in the context information. How does this method help in comparing the mean differences between the different treatment groups?',\n",
       " 'Discuss the significance of the p-value of 0.031 in the context of the study. How does this p-value indicate the strength of the relationship between the treatment groups and the outcome variables?',\n",
       " 'What is the primary purpose of the study described in the context information?',\n",
       " 'How was the average Diabetic Peripheral Neuropathy (DPN) pain measured in the study, and what was the time frame for data collection?',\n",
       " 'Explain the eligibility criteria for participants in the study on pregabalin treatment for diabetic neuropathy pain. What were the inclusion and exclusion criteria that participants had to meet in order to be eligible for the study?',\n",
       " 'Describe the recruitment details for the study, including the number of participants screened, randomized, and withdrawn before randomization. In which countries were the 47 centers located, and what were the key treatment periods and procedures for the participants in the study?',\n",
       " 'What was the primary purpose of the study titled \"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis\" conducted by Pfizer?',\n",
       " 'How was remission defined in the study, and what specific criteria were used to determine if a participant was in remission at Week 52?',\n",
       " 'Explain the components of the Mayo score and how they are used to measure disease activity in ulcerative colitis patients.',\n",
       " 'Describe the eligibility criteria for participants in the study, including both inclusion and exclusion criteria.',\n",
       " 'What statistical method was used to analyze the data in the study mentioned in the context information?',\n",
       " 'What was the difference in percentage between the groups being compared, and what was the confidence interval for this difference?',\n",
       " 'What is the primary outcome measure of the study evaluating the efficacy and safety of tofacitinib in patients with moderate to severe ulcerative colitis?',\n",
       " 'What is the overall status of the study evaluating the use of CP-690,550 in patients with ulcerative colitis, and when was the primary completion date of the study?',\n",
       " 'What are the inclusion criteria for subjects participating in the study on UC treatment with tofacitinib? How do these criteria ensure that the study participants have moderately to severely active UC?',\n",
       " 'How was the efficacy of tofacitinib at different dosages (10 mg BID and 15 mg BID) evaluated in the study? Provide details on the statistical method used and the significance of the p-value obtained.',\n",
       " 'What is the primary outcome measure of the study evaluating the efficacy and safety of tofacitinib in patients with moderate to severe ulcerative colitis?',\n",
       " 'What is the overall status of the study evaluating the efficacy and safety of tofacitinib in patients with moderate to severe ulcerative colitis conducted by Pfizer?',\n",
       " 'Explain the eligibility criteria for participants in the study on tofacitinib for ulcerative colitis. What are the inclusion and exclusion criteria that were specified for enrollment in the study?',\n",
       " 'Describe the primary outcome measure and time frame used in the study on tofacitinib for ulcerative colitis. What was the total score range for disease severity, and how were the scores calculated to assess the severity of the disease?',\n",
       " 'What is the primary purpose of the study comparing the effects of Intravenous Epoetin Hospira and Epoetin Alfa in patients with chronic renal failure requiring hemodialysis?',\n",
       " 'Describe the arms groups in the study, including the interventions and labels associated with each group.',\n",
       " 'Explain the eligibility criteria for patients with chronic renal failure and renal anemia to participate in the study, focusing on the requirements related to stable Epogen treatment, hemoglobin levels, dialysis regimen, and iron stores.',\n",
       " 'Discuss the exclusion criteria for patients with chronic renal failure and renal anemia to participate in the study, highlighting specific medical conditions, treatments, and health parameters that would disqualify a patient from being included in the research.',\n",
       " 'Explain the eligibility criteria for participants in the study comparing Epoetin Hospira and Epogen for the treatment of chronic renal failure.',\n",
       " 'Discuss the recruitment details for participants with chronic renal failure who were receiving Epoetin maintenance therapy prior to enrollment in the study.',\n",
       " 'What is the LS Mean Difference reported in the context information provided?',\n",
       " 'What is the confidence interval (CI) for the LS Mean Difference, and what does it suggest about the statistical significance of the results?',\n",
       " 'What is the primary purpose of the study described in the context information, and what is the brief title of the study?',\n",
       " 'How many arms groups were involved in the study, and what were the interventions provided in each arm group?',\n",
       " 'What are the inclusion criteria for hemodialysis patients with chronic renal failure and renal anemia to participate in the study, specifically regarding Epogen dosing, hemoglobin levels, dialysis stability, and iron stores?',\n",
       " 'Identify three exclusion criteria for patients to be considered ineligible for participation in the study, including specific medical conditions, treatments, and laboratory values.',\n",
       " 'What are some of the exclusion criteria for participation in the study involving Epoetin Hospira and Epogen?',\n",
       " 'Can you explain the recruitment details for participants with chronic renal failure who were receiving Epoetin maintenance therapy prior to enrollment in the study?',\n",
       " 'What was the dosing regimen for participants during the maintenance period of the study, and how long were they followed up after the last dose of study treatment?',\n",
       " 'Based on the group IDs provided, what was the non-inferiority margin considered relevant to demonstrate the equivalence of the two products, and what was the LS mean difference with its corresponding 95% confidence interval?',\n",
       " 'What was the primary purpose of the study conducted by Pfizer on the efficacy and safety of Pregabalin in treating patients with painful Diabetic Peripheral Neuropathy (DPN) who also experience pain on walking?',\n",
       " 'How was the primary outcome of the study, which focused on the average Diabetic Peripheral Neuropathy (DPN) pain based on a Numeric Rating Scale (NRS) over the last 7 days of each treatment period, assessed and recorded by the participants?',\n",
       " 'How was the endpoint mean pain score defined in the study, and what criteria were used to categorize pain severity?',\n",
       " 'Can you explain the recruitment process for participants in the study, including the number of participants screened, randomized, and the countries where the study was conducted?',\n",
       " 'What statistical method was used in the analysis of the data provided in the context information?',\n",
       " 'What was the calculated p-value for the analysis, and does it suggest a statistically significant difference between the groups being compared?',\n",
       " 'What is the primary objective of the study mentioned in the context information, and how is it being evaluated in children aged 6 to 17 years with bladder overactivity caused by a neurological condition?',\n",
       " 'Describe the arms groups and interventions used in the study to evaluate the safety and efficacy of fesoterodine in subjects with symptoms of detrusor overactivity associated with a neurological condition.',\n",
       " 'What is the primary outcome measure of the study at Week 12 in the Active Comparator Phase/Efficacy Phase?',\n",
       " 'What are the inclusion criteria for subjects participating in the study, specifically related to age and medical conditions?',\n",
       " 'Explain the statistical method used in the study to calculate the p-value for change from Baseline at Week 12. How does this method account for baseline factors such as maximum cystometric bladder capacity and weight?',\n",
       " 'Compare the results for the difference in Least square (LS) Mean between group OG000 and OG002 with the results for the difference in LS Mean between group OG001 and OG002. How do these findings contribute to the overall interpretation of the study results?',\n",
       " \"What is the primary completion date of the study comparing inotuzumab ozogamicin to investigator's choice of chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia?\",\n",
       " 'Who is the lead sponsor of the study and what is their organization class?',\n",
       " 'What is the primary outcome measure of the study for participants with Acute Lymphoblastic Leukemia?',\n",
       " 'Describe the intervention for Arm A in the study, including the dose, administration schedule, and total number of cycles.',\n",
       " 'What were the eligibility criteria for participants in this study? Provide examples of both inclusion and exclusion criteria.',\n",
       " 'Describe the treatment regimens for participants in the two recruitment groups, \"Inotuzumab Ozogamicin\" and \"Defined Investigator\\'s Choice of Chemotherapy.\" What were the differences in dosing and administration between the two groups?',\n",
       " 'What was the primary objective of the study involving the investigational drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in patients with moderate to severe chronic low back pain?',\n",
       " 'Describe the primary outcome measure used in the study, including how it was calculated and what it represents in terms of pain assessment.',\n",
       " 'Explain the eligibility criteria for participants in the study on the efficacy and safety of ALO-02 Extended-Release Capsules for chronic low back pain. What were the inclusion and exclusion criteria that participants had to meet in order to be eligible for the study?',\n",
       " 'Describe the recruitment process and treatment protocol for participants in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Study on ALO-02 Extended-Release Capsules. What were the different recruitment groups, and what was the treatment regimen for participants in each group during the study?',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'How many participants were enrolled in the study comparing Ceftazidime-Avibactam with Doripenem for treating complicated urinary tract infections in hospitalized adults?',\n",
       " 'Explain the difference in treatment interventions between Arms group 0 and Arms group 1 in the study, including the specific drugs used and their administration methods.',\n",
       " 'Describe the primary outcome measure of the study, focusing on the patient-reported symptomatic response at Day 5 and the criteria for determining non-inferiority.',\n",
       " 'Explain the eligibility criteria for patients participating in the study, including the age range, requirements for female patients, and criteria for urine culture results.',\n",
       " 'Describe the recruitment details provided in the document, including the treatment groups involved, the number of randomized patients in each protocol, and the combined total number of patients in the study.',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'How many participants were enrolled in the study comparing Ceftazidime-Avibactam with Doripenem for treating complicated urinary tract infections, including acute pyelonephritis?',\n",
       " 'Explain the difference in the intervention descriptions for Arms group 0 (Ceftazidime - Avibactam) and Arms group 1 (Doripenem) in the context of IV treatment for the study.',\n",
       " 'Describe the primary outcome measure for the study, focusing on the patient-reported symptomatic response at Day 5 and the criteria for concluding noninferiority.',\n",
       " 'Explain the inclusion criteria for patients participating in the study, focusing on the age range, sterilization requirements for female patients, and the presence of pyuria and positive urine culture.',\n",
       " 'Discuss the recruitment details provided in the context information, including the treatment groups (CAZ-AVI and doripenem), the number of randomized patients in each protocol, and the combined total of patients in the study.',\n",
       " 'What is the primary objective of the Phase III study comparing Crizotinib to chemotherapy regimens in East Asian non-small cell lung cancer patients with ALK gene alterations?',\n",
       " 'Can you provide the start date, primary completion date, and completion date of the clinical trial comparing Crizotinib to chemotherapy in previously untreated ALK positive East Asian non-small cell lung cancer patients?',\n",
       " 'What is the primary outcome measure of the study described in the context information? Provide a detailed explanation of how this outcome is defined and calculated.',\n",
       " 'What are the inclusion criteria for patients participating in the study? Specifically, what are the requirements related to the diagnosis of lung cancer and the presence of a specific genetic alteration?',\n",
       " 'What are the eligibility criteria for patients to participate in the study, specifically in terms of prior treatments, cardiac health, and medical conditions?',\n",
       " 'Describe the treatment regimens for participants in the Crizotinib arm and the Chemotherapy arm of the study, including dosages, administration methods, and maximum treatment durations.',\n",
       " 'Explain the administration protocol for pemetrexed, cisplatin, and carboplatin in the study described in the context information. What was the maximum duration of chemotherapy treatment allowed in this study?',\n",
       " 'What was the hypothesis being tested in the study, and what was the significance level required to detect a hazard ratio of 0.64 with 80% power? Additionally, based on the results provided, what can be concluded about the efficacy of crizotinib compared to chemotherapy in terms of hazard rate reduction?',\n",
       " 'What was the primary outcome measure used in the study on NWP09 in children with ADHD, and how was it assessed?',\n",
       " 'Describe the study design and methodology used in the evaluation of the safety and efficacy of the chewable formulation of extended-release methylphenidate in pediatric patients with ADHD.',\n",
       " 'Explain the eligibility criteria for children participating in the study on ADHD treatment with NWP09. What are the inclusion and exclusion criteria specified for the participants?',\n",
       " 'Discuss the recruitment details for the study, including the total number of participants enrolled, the randomization process, and the description of the two recruitment groups (Placebo and NWP09).',\n",
       " 'What is the primary outcome measure in the study on pregabalin for post-traumatic peripheral neuropathic pain, and how is it assessed?',\n",
       " 'Describe the eligibility criteria for subjects participating in the study on pregabalin for post-traumatic peripheral neuropathic pain.',\n",
       " 'Explain the exclusion criteria for subjects participating in the study on pregabalin treatment for post-traumatic neuropathic pain. How do these criteria ensure the validity and reliability of the study results?',\n",
       " 'Describe the recruitment details for the study on pregabalin treatment for post-traumatic neuropathic pain. How were participants randomized and what data was collected during the screening and taper periods?',\n",
       " 'What is the primary purpose of the study mentioned in the context information, and what is the brief title of the study?',\n",
       " 'Describe the arms groups involved in the study, including the intervention types, labels, and descriptions for each group.',\n",
       " 'What are the inclusion criteria for neonates in this study on persistent pulmonary hypertension of the newborn (PPHN)?',\n",
       " 'Describe the treatment protocol for participants in Part A of the study, including the dosage and administration of sildenafil and placebo.',\n",
       " 'Explain the statistical method used in the study mentioned in the context information. How does ANCOVA help in analyzing the data?',\n",
       " 'Discuss the significance of the p-value provided in the group IDs section. How does a p-value of 0.9850 impact the interpretation of the study results?',\n",
       " 'What is the primary objective of the study comparing Ceftazidime Avibactam plus Metronidazole to Meropenem for treating complicated intra-abdominal infections in hospitalized adults?',\n",
       " 'Can you identify the key dates associated with the completion and verification of the study, as well as the submission and update dates related to the research findings?',\n",
       " 'What is the primary purpose of the study described in the context information?',\n",
       " 'How is the primary outcome of the study defined and measured?',\n",
       " 'What are the inclusion criteria for patients participating in the study on intra-abdominal infections associated with peritonitis?',\n",
       " 'What was the primary objective of the study comparing Ceftazidime-Avibactam Plus Metronidazole to Meropenem in patients with intra-abdominal infections, and how was non-inferiority determined?',\n",
       " 'Explain the statistical method used in this study to calculate the risk difference (RD) between CAZ AVI and Meropenem clinical cure rates. How was the confidence interval (CI) calculated, and what does the CI range indicate about the results?',\n",
       " 'Based on the given information, what can be inferred about the comparison between CAZ AVI and Meropenem in terms of clinical cure rates? Provide a brief explanation of the parameter value, confidence interval, and statistical significance indicated by the p-value.',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'Describe the treatment regimen for the experimental group in the study, including the dosage and administration schedule of the drugs involved.',\n",
       " 'What is the primary outcome of the study as described in the context information? Provide a detailed explanation of how this outcome is measured and calculated.',\n",
       " 'What are the inclusion criteria for patients eligible to participate in the study based on the eligibility criteria provided? Explain why each criterion is important for selecting participants in this clinical trial.',\n",
       " 'Explain the treatment regimens for the two recruitment groups in the study on Palbociclib Plus Letrozole versus Placebo Plus Letrozole.',\n",
       " 'What statistical method was used to analyze the data in this study, and what was the reported p-value indicating the difference between the two treatment groups?',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'How many arms groups were involved in the study, and what were the intervention names for each group?',\n",
       " 'What is the primary outcome measure of the study, and how is it calculated?',\n",
       " 'What are the inclusion criteria for participants in the study, and why is it important for them to have a minimum number of Primary Generalized Tonic Clonic (PGTC) seizures during the baseline phase?',\n",
       " 'Explain the dosing regimens of Pregabalin for participants aged less than 17 years in the two recruitment groups mentioned in the document.',\n",
       " 'What statistical method was used to analyze the data in the Group IDs section, and what was the p-value obtained from the analysis?',\n",
       " 'What type of statistical analysis was used in the study, and what was the p-value obtained from the analysis?',\n",
       " 'What was the LS mean difference between the two groups being compared, and what was the confidence interval (CI) for this difference?',\n",
       " 'What is the primary completion date of the study comparing the efficacy of MEK162 versus Dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma?',\n",
       " 'How many patients were enrolled in the study, and what were the two arms they were randomized into for treatment?',\n",
       " 'What is the primary outcome measure in this clinical trial, and how is it defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1?',\n",
       " 'What are some of the key eligibility criteria for patients to be included in this clinical trial evaluating the use of MEK162 and dacarbazine for locally advanced, unresectable, or metastatic cutaneous melanoma?',\n",
       " 'What were the eligibility criteria for participants in the study on advanced unresectable or metastatic Neuroblastoma RAS viral oncogene homolog (NRAS) mutation-positive melanoma?',\n",
       " 'Describe the treatment regimens received by participants in the study, including the dosage and duration of binimetinib (MEK162) and dacarbazine, as well as the follow-up protocol after discontinuation of study treatment.',\n",
       " 'What is the primary completion date of the study \"ARCHER 1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC\"?',\n",
       " 'How many patients were randomized in a 1:1 ratio between dacomitinib (PF-00299804) and gefitinib in the study?',\n",
       " 'What is the primary outcome measure in this clinical trial involving patients with advanced NSCLC and EGFR-activating mutations? Describe the criteria used to determine disease progression based on this outcome measure.',\n",
       " 'What are the eligibility criteria for patients to be included in this study? Provide details on the specific requirements related to histology, EGFR mutations, prior treatment history, and overall health status.',\n",
       " 'Explain the pre-assignment details of the study, including the number of participants randomized, the treatment arms they were assigned to, and the outcomes observed after the last data cutoff date.',\n",
       " 'Discuss the recruitment details for the two treatment groups (Dacomitinib and Gefitinib) in terms of the dosage, administration, and duration of treatment specified for each group.',\n",
       " 'What was the primary objective of the study on topical Ibuprofen for delayed onset muscle soreness, and how was it conducted?',\n",
       " 'Describe the primary outcome measure used in the study and explain how it was assessed in participants.',\n",
       " 'Explain how the change from baseline in the time-weighted sum of muscle soreness with movement (MSM) over 0-24 hours is calculated in the study. What does a higher score indicate in this calculation?',\n",
       " 'Discuss the eligibility criteria for participants in the study, including both inclusion and exclusion criteria. Why is it important for participants to refrain from certain treatments during the study period?',\n",
       " 'What is the statistical method used in the study mentioned in the context information?',\n",
       " 'What is the LS Mean Difference value reported in the study, and what is the confidence interval for this parameter?',\n",
       " 'What is the primary purpose of the study comparing Ceftazidime-Avibactam versus Meropenem in hospitalized adults with nosocomial pneumonia, including ventilator-associated pneumonia?',\n",
       " 'How many participants were enrolled in the study, and what were the intervention arms used for the treatment of nosocomial pneumonia and ventilator-associated pneumonia?',\n",
       " 'What are the inclusion criteria for patients participating in the study, specifically regarding age, pregnancy status, onset of symptoms, and systemic signs?',\n",
       " 'Can you explain the primary outcome of the study in terms of what constitutes a clinical cure at the test-of-cure visit and the timeframe for this assessment?',\n",
       " 'What is the treatment regimen for recruitment group 0 (FG000) in the study, and how does it differ from the treatment regimen for recruitment group 1 (FG001)?',\n",
       " 'Based on the statistical analysis provided in the document, what was the calculated risk difference (RD) between the clinical cure rates of patients receiving CAZ-AVI and Meropenem, and was the non-inferiority margin met for the primary efficacy analysis?',\n",
       " 'What is the primary objective of the study evaluating the efficacy and safety of CP-690,550 in Asian subjects with moderate to severe plaque psoriasis?',\n",
       " 'What was the overall status of the study, and when were the primary completion date and completion date for the research on CP-690,550 in Asian subjects with moderate to severe chronic plaque psoriasis?',\n",
       " 'What is the primary outcome measure of this study on the treatment of psoriasis with Tofacitinib (CP-690,550)?',\n",
       " 'What are the inclusion criteria for participants in this study on the use of Tofacitinib for psoriasis treatment?',\n",
       " 'What are the eligibility criteria for subjects participating in the study on tofacitinib for the treatment of psoriasis?',\n",
       " 'Describe the recruitment groups and the dosages of tofacitinib administered to participants in each group up to Week 52 of the study.',\n",
       " 'What is the primary completion date of the study investigating the effectiveness and safety of tofacitinib in treating psoriatic arthritis, and what was the overall status of the study at that time?',\n",
       " 'Can you explain the purpose of using adalimumab as a comparator in the study on tofacitinib for psoriatic arthritis, and what was the lead sponsor of this research?',\n",
       " 'What is the primary outcome measure of the study, and when is it assessed?',\n",
       " 'What are the inclusion criteria for participants in the study regarding their diagnosis and previous treatment with disease-modifying anti-rheumatic drugs (DMARDs)?',\n",
       " 'What are the eligibility criteria for participants to be included in the study, specifically in terms of joint symptoms and skin lesions?',\n",
       " 'Describe the treatment regimen for participants in the \"Tofacitinib, 10 mg, Twice Daily\" recruitment group, including the dosages of tofacitinib and frequency of subcutaneous placebo administration.',\n",
       " 'What is the primary purpose of the study described in the context information?',\n",
       " 'Describe the primary outcome measure used in the study and how it is calculated.',\n",
       " 'Explain the eligibility criteria for participants in the study. What specific criteria needed to be met for inclusion, and what criteria would result in exclusion from the study?',\n",
       " 'Compare and contrast the two recruitment groups in terms of the treatment received by participants. What were the differences in the dosage and administration of tofacitinib between the two groups?',\n",
       " 'What is the primary outcome measure used in the study to assess driving performance in normal volunteer subjects after taking gabapentin, diphenhydramine, and triazolam compared to placebo?',\n",
       " 'What was the enrollment count for this clinical trial examining the next-day residual effects of gabapentin, diphenhydramine, and triazolam on simulated driving performance in normal volunteers?',\n",
       " 'What were the inclusion criteria for participants in the study on the effects of diphenhydramine citrate, gabapentin, triazolam, and placebo on driving performance?',\n",
       " 'Can you explain the pre-assignment details that were conducted before randomization in the study, and why they were important for the research outcomes?',\n",
       " ...]"
      ]
     },
     "execution_count": 87,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "queries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Question: What is the primary purpose of the study described in the context information?\n",
      "Relevant Context: \"National Clinical Identification NCT ID\": \"NCT00036270\",\n",
      "\"Organization study identification\": \"971-ONC-0028-081\",\n",
      "\"EudraCT number\": \"A5991026\",\n",
      "\"Organization\": \"Pfizer\",\n",
      "\"Organization class\": \"INDUSTRY\",\n",
      "\"Brief title\": \"Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane\",\n",
      "\"Official title\": \"Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen For 2.5- 3 Years Followed By Exemestane (Aromasin) For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients\",\n",
      "\"Overall status\": \"COMPLETED\",\n",
      "\"Start date\": \"2001-08\",\n",
      "\"Primary completion date\": \"2008-10\",\n",
      "\"Completion date\": \"2011-02\",\n",
      "\"Verification date\": \"2015-10\",\n",
      "\"Study first submitted date\": \"2002-05-08\",\n",
      "\"Results first submitted date\": \"2009-10-30\",\n",
      "\"Last update submitted date\": \"2015-10-06\",\n",
      "\"Last update posted date\": \"2015-10-28\",\n",
      "\"Lead sponsor\": \"Pfizer\",\n",
      "\"Lead sp...\n"
     ]
    }
   ],
   "source": [
    "sample_id, sample_query = list(qa_dataset.queries.items())[0]\n",
    "\n",
    "# get the relevant document IDs for the sample question\n",
    "relevant_doc_ids = qa_dataset.relevant_docs[sample_id]\n",
    "\n",
    "# get the text content of the relevant documents\n",
    "relevant_contexts = [qa_dataset.corpus[doc_id] for doc_id in relevant_doc_ids]\n",
    "\n",
    "# print the question and relevant contexts\n",
    "print(f\"Question: {sample_query}\")\n",
    "for context in relevant_contexts:\n",
    "    print(f\"Relevant Context: {context[:1000]}...\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "retriever = vector_index.as_retriever(similarity_top_k=2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "retrieved_nodes = retriever.retrieve(\"What are the key inclusion criteria for patients to be eligible for this study on sunitinib treatment for malignant GIST?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "**Node ID:** 9d50f0d2-9388-4879-b58d-13b60c18900f<br>**Similarity:** 0.7527507095974909<br>**Text:** \",\n",
       "\"Primary outcome time frame\": \"Day 28 of each 6-week cycle : duration of double-blind treatment phase\",\n",
       "\"Eligibility criteria\": \"Key Inclusion Criteria:\n",
       "* Histologically-proven diagnosis of malignant GIST not amenable to surgery, radiation or combined modality treatment with curative intent\n",
       "* Failed Gleevec treatment or intolerant to Gleevec therapy\n",
       "Key Exclusion Criteria:\n",
       "* Treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or investigational agent since the last dose of Gleevec\",\n",
       "\"Eligibility of healthy volunteer\": \"False\",\n",
       "\"Eligibility sex\": \"ALL\",\n",
       "\"Eligibility minimum age\": \"18 Years\",\n",
       "\"Eligibility standard age\": \"['ADULT', 'OLDER_ADULT']\",\n",
       "\"Pre-assignment details\": \"361 subjects randomized to double-blind treatment in 2:1 ratio (sunitinib vs. Placebo).\n",
       "255 subjects continued on or crossed over to Open-label treatment.\",\n",
       "\"Recruitment details\": \"Enrollment began (medical clinic) in December 2003. Study was unblinded on 27 January 2005 (end of Double-blind treatment). Subjects experiencing disease progression could crossover to Open-label treatment. Open-label data collection ended May 2008.\",\n",
       "\"Recruitment group 0 id\": \"FG000\",\n",
       "\"Recruitment group 0 title\": \"Sunitinib Double-Blind Treatment\",\n",
       "\"Recruitment group 0 description\": \"Starting dose: 50 mg orally once daily as a single agent for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks. (Schedule 4/2). Subjects received best supportive care in addition to the study treatment.\",\n",
       "\"Recruitment group 1 id\": \"FG001\",\n",
       "\"Recruitment group 1 title\": \"Placebo Double-Blind Treatment\",\n",
       "\"Recruitment group 1 description\": \"Starting daily dose of 1 capsule, size- and color-matched to the sunitinib 50-mg capsule for 4 consecutive weeks followed by a 2-week off-treatment period to form a complete cycle of 6 weeks (Schedule 4/2). Subjects received best supportive care in addition to the study treatment. Subjects were provided the opportunity to receive open-label sunitinib at the time of confirmed disease progression or study unblinding.\",\n",
       "\"Group IDs\": \"[{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'The study was designed to test the null hypothesis that the median TTP from placebo treatment is 4 months versus the alternative hypothesis that the median TTP from sunitinib treatment is at least 6 months with an overall 2-sided significance level of 0.05 and power of 90%.', 'testedNonInferiority': False, 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'pValue': '<0.001', 'pValueComment': \"The nominal levels of significance for the interim and final analyses were determined at the time of the analyses using the Lan-DeMets procedure with an O'Brien-Fleming stopping rule.\", 'statisticalMethod': 'Log Rank', 'statisticalComment': 'two-sided unstratified log-rank test', 'paramType': 'Hazard Ratio (HR)', 'paramValue': '0.329', 'ciPctValue': '95', 'ciLowerLimit': '0.233', 'ciUpperLimit': '0.466'}]\",\n",
       "\"p-value\": \"<0.001\",\n",
       "\"Statistical Method\": \"Log Rank\",\n",
       "\"Limitations and caveats\": \"Duration of Tumor Response could not be reliably estimated at the time of analysis.\",\n",
       "\"Has results\": \"True\"<br>"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/markdown": [
       "**Node ID:** 399f4cda-c7df-4fcd-90cb-532515e7b62f<br>**Similarity:** 0.744039125087418<br>**Text:** \"National Clinical Identification NCT ID\": \"NCT00075218\",\n",
       "\"Organization study identification\": \"A6181004\",\n",
       "\"EudraCT number\": \"\",\n",
       "\"Organization\": \"Pfizer\",\n",
       "\"Organization class\": \"INDUSTRY\",\n",
       "\"Brief title\": \"A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)\",\n",
       "\"Official title\": \"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor\",\n",
       "\"Overall status\": \"COMPLETED\",\n",
       "\"Start date\": \"2003-12\",\n",
       "\"Primary completion date\": \"2008-05\",\n",
       "\"Completion date\": \"2008-05\",\n",
       "\"Verification date\": \"2009-08\",\n",
       "\"Study first submitted date\": \"2004-01-06\",\n",
       "\"Results first submitted date\": \"2009-05-06\",\n",
       "\"Last update submitted date\": \"2009-08-31\",\n",
       "\"Last update posted date\": \"2009-09-28\",\n",
       "\"Lead sponsor\": \"Pfizer\",\n",
       "\"Lead sponsor class\": \"INDUSTRY\",\n",
       "\"Brief summary\": \"A study to assess the safety and efficacy of SU11248 in patients with gastrointestinal stromal tumor (GIST) whose disease has failed imatinib therapy or who were intolerant to imatinib treatment.\",\n",
       "\"Detailed description\": \"oof, this data not available\",\n",
       "\"Condition\": \"['Gastrointestinal Stromal Tumor']\",\n",
       "\"Conditions keywords\": \"oof, this data not available\",\n",
       "\"Study type\": \"INTERVENTIONAL\",\n",
       "\"Phases\": \"['PHASE3']\",\n",
       "\"Allocation\": \"RANDOMIZED\",\n",
       "\"Intervention model\": \"CROSSOVER\",\n",
       "\"Primary purpose\": \"TREATMENT\",\n",
       "\"Masking\": \"DOUBLE\",\n",
       "\"Who is masked\": \"['PARTICIPANT', 'INVESTIGATOR']\",\n",
       "\"Enrollment count\": \"361\",\n",
       "\"Enrollment type\": \"ACTUAL\",\n",
       "\"Arms group 0 label\": \"B\",\n",
       "\"Arms group 0 type\": \"PLACEBO_COMPARATOR\",\n",
       "\"Arms group 0 description\": \"\",\n",
       "\"Arms group 0 intervention names\": \"['Drug: Placebo']\",\n",
       "\"Arms group 1 label\": \"A\",\n",
       "\"Arms group 1 type\": \"ACTIVE_COMPARATOR\",\n",
       "\"Arms group 1 description\": \"\",\n",
       "\"Arms group 1 intervention names\": \"['Drug: SU011248']\",\n",
       "\"Arms group 0 intervention type\": \"DRUG\",\n",
       "\"Arms group 0 intervention name\": \"Placebo\",\n",
       "\"Arms group 0 intervention description\": \"50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.\",\n",
       "\"Arms group 0 intervention labels\": \"['B']\",\n",
       "\"Arms group 1 intervention type\": \"DRUG\",\n",
       "\"Arms group 1 intervention name\": \"SU011248\",\n",
       "\"Arms group 1 intervention description\": \"50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.\",\n",
       "\"Arms group 1 intervention labels\": \"['A']\",\n",
       "\"Primary outcome\": \"Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase\",\n",
       "\"Primary outcome description\": \"Time from randomization to first documentation of objective tumor progression based on the assessment of an independent, third-party imaging laboratory using RECIST (Response Evaluation Criteria in Solid Tumors).<br>"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from llama_index.core.response.notebook_utils import display_source_node\n",
    "\n",
    "for node in retrieved_nodes:\n",
    "    display_source_node(node, source_length=10000)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Doing Retreival Evalution"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [],
   "source": [
    "from llama_index.core.evaluation import RetrieverEvaluator\n",
    "import pandas as pd\n",
    "retriever_evaluator = RetrieverEvaluator.from_metric_names(\n",
    "    [\"mrr\", \"hit_rate\"], retriever=retriever\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "eval_results = await retriever_evaluator.aevaluate_dataset(qa_dataset)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "def display_results(name, eval_results):\n",
    "    \"\"\"Display results from evaluate.\"\"\"\n",
    "\n",
    "    metric_dicts = []\n",
    "    for eval_result in eval_results:\n",
    "        metric_dict = eval_result.metric_vals_dict\n",
    "        metric_dicts.append(metric_dict)\n",
    "\n",
    "    full_df = pd.DataFrame(metric_dicts)\n",
    "\n",
    "    hit_rate = full_df[\"hit_rate\"].mean()\n",
    "    mrr = full_df[\"mrr\"].mean()\n",
    "\n",
    "    metric_df = pd.DataFrame(\n",
    "        {\"Retriever Name\": [name], \"Hit Rate\": [hit_rate], \"MRR\": [mrr]}\n",
    "    )\n",
    "\n",
    "    return metric_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Retriever Name</th>\n",
       "      <th>Hit Rate</th>\n",
       "      <th>MRR</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>OpenAI Embedding Retriever</td>\n",
       "      <td>0.385714</td>\n",
       "      <td>0.328929</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "               Retriever Name  Hit Rate       MRR\n",
       "0  OpenAI Embedding Retriever  0.385714  0.328929"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "display_results(\"OpenAI Embedding Retriever\", eval_results)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Retreieval Evaluation Results\n",
    "\n",
    "* Hit Rate:\n",
    "The hit rate measures the fraction of queries for which at least one relevant document is retrieved within the top-k results. A higher hit rate indicates that the retrieval system is able to surface relevant information for more queries. However, the hit rate alone doesn't tell you how highly ranked the relevant documents are within the top-k.\n",
    "\n",
    "* Mean Reciprocal Rank (MRR):\n",
    "MRR takes into account the ranking of the relevant documents. It calculates the reciprocal of the rank of the first relevant document for each query, and then takes the mean across all queries. A higher MRR score (closer to 1) indicates that the relevant documents are ranked higher, on average.\n",
    "MRR is a useful metric because it not only considers whether relevant documents are retrieved but also how highly they are ranked. In many applications, users are more likely to pay attention to the top few results, so having the relevant documents highly ranked is important."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query: Discuss the eligibility criteria for inclusion and exclusion of patients in the study comparing exemestane and tamoxifen therapy for adjuvant treatment of breast cancer. Why were patients with ER and PR negative primary tumors or unknown ER/PR status excluded from the study?\n",
      "Metrics: {'mrr': 0.0, 'hit_rate': 0.0}\n",
      "\n"
     ]
    }
   ],
   "source": [
    "sample_id, sample_query = list(qa_dataset.queries.items())[3]\n",
    "sample_expected = qa_dataset.relevant_docs[sample_id]\n",
    "\n",
    "eval_result = retriever_evaluator.evaluate(sample_query, sample_expected)\n",
    "print(eval_result)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Doing a Response Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['What is the primary purpose of the study described in the context information?',\n",
       " 'How many arms groups were involved in the study, and what were the interventions for each group?',\n",
       " 'Explain the primary outcome of the study comparing adjuvant treatment with exemestane versus tamoxifen therapy in postmenopausal, receptor positive, node negative or node positive breast cancer patients. What is the time frame for assessing this outcome?',\n",
       " 'Discuss the eligibility criteria for inclusion and exclusion of patients in the study comparing exemestane and tamoxifen therapy for adjuvant treatment of breast cancer. Why were patients with ER and PR negative primary tumors or unknown ER/PR status excluded from the study?',\n",
       " 'What was the primary purpose of the randomized trial conducted by Pfizer in postmenopausal women with early breast cancer who had already received adjuvant tamoxifen for 2-3 years?',\n",
       " 'Describe the primary outcome measured in the study, including how Disease-Free Survival (DFS) was defined and what events were considered as relapse.',\n",
       " 'What were the inclusion criteria for postmenopausal women participating in the study, and how long were they required to have been continuously treated with tamoxifen before being eligible for enrollment?',\n",
       " 'What was the statistical method used to analyze the data in the study, and what was the p-value obtained for the comparison between the two recruitment groups?',\n",
       " 'What was the primary objective of the study evaluating Interferon and CCI-779 in advanced renal cell carcinoma, and what was the primary efficacy endpoint of the study?',\n",
       " 'Describe the treatment arms in the study, including the interventions used, the number of participants in each arm, and the primary outcome measured in the study.',\n",
       " 'What are the inclusion criteria for participants in this study on advanced RCC who have not received prior systemic therapy for their disease?',\n",
       " 'What is the statistical method used to analyze the data in this study, and what was the p-value obtained for the comparison between the temsirolimus and Interferon Alfa treatment groups?',\n",
       " 'What was the primary purpose of the study mentioned in the context information?',\n",
       " 'How was the primary outcome of the study defined and assessed according to the details provided?',\n",
       " 'What are the key inclusion criteria for patients to be eligible for this study on sunitinib treatment for malignant GIST?',\n",
       " 'Describe the recruitment details and timeline of the study, including the start and end dates of the double-blind treatment phase and the option for subjects to crossover to open-label treatment.',\n",
       " 'What is the primary purpose of the study described in the context information?',\n",
       " 'Describe the intervention for Arms group 1 in the study, including the dosage and treatment schedule.',\n",
       " 'What were the eligibility criteria for patients to participate in the study on renal cell carcinoma treatment, including specific requirements related to histology, disease status, and performance status?',\n",
       " 'Describe the treatment regimens for the two recruitment groups in the study, including dosages, administration methods, and cycle durations.',\n",
       " 'Explain the significance of the hazard ratio value of 0.5136 in the context of the study results. How does this value indicate the relationship between the two treatments, SU011248 and IFN-a?',\n",
       " 'How does the p-value of \"<0.0001\" support the conclusion drawn from the hazard ratio analysis using the Log Rank statistical method? Explain the importance of the p-value in determining the statistical significance of the study results.',\n",
       " 'What are the three different methods of administration of Fluoropyrimidine compared in this study involving Irinotecan for the treatment of metastatic colorectal cancer?',\n",
       " 'What was the primary completion date of the randomized, multi-center Phase III trial sponsored by Pfizer that compared Irinotecan in combination with different methods of Fluoropyrimidine administration for patients with metastatic colorectal cancer?',\n",
       " 'What is the primary outcome measure for this study involving patients with colorectal cancer receiving FOLFIRI and mIFL treatments?',\n",
       " 'What are the inclusion criteria for patients to be eligible for this study on metastatic colorectal cancer, and what are the key exclusion criteria mentioned in the document?',\n",
       " 'What are the eligibility criteria for participants in this study in terms of age and sex?',\n",
       " 'What is the statistical method used to analyze the data in this study, and what was the p-value obtained from the analysis?',\n",
       " 'What was the primary outcome measured in the study evaluating Temsirolimus in Mantle Cell Lymphoma (MCL) patients, and how was it defined?',\n",
       " 'What were the eligibility criteria for participants in the open-label, randomized Phase 3 trial of Temsirolimus in relapsed, refractory subjects with Mantle Cell Lymphoma (MCL)?',\n",
       " 'What are some common chemotherapy combinations used in the treatment of the condition described in the context information? Provide examples of at least three different combinations.',\n",
       " 'What are the exclusion criteria for subjects participating in the study described in the context information? Explain why individuals who meet these criteria are not eligible to participate in the study.',\n",
       " 'What was the alternative hypothesis (Ha) for each test conducted in the study, and what was the conclusion drawn from the analysis of PFS distributions?',\n",
       " 'What statistical method was used to analyze the data in the study, and what was the hazard ratio (HR) value along with its 95% confidence interval for the comparison between group OG001 and group OG002?',\n",
       " 'What was the primary outcome measure used in the study \"Pregabalin Peripheral Neuropathic Pain Study\" conducted by Pfizer?',\n",
       " 'What were the inclusion criteria for subjects participating in the study, specifically related to their diagnosis and pain levels?',\n",
       " 'Explain the exclusion criteria related to neurologic disorders in the context of the study on pregabalin for diabetic peripheral neuropathy, post-herpetic neuralgia, and post-traumatic neuropathic pain. Why is it important to exclude patients with severe pain from conditions other than those specified in the study?',\n",
       " 'Describe the recruitment details for the study on pregabalin, including the dose levels used and the administration schedule. How were subjects randomized to either the pregabalin group or the placebo group, and what was the purpose of including a placebo group in the study design?',\n",
       " 'What was the primary outcome measure used in the study evaluating the efficacy and safety of Geodon in patients with Bipolar I Depression?',\n",
       " 'Describe the dosing regimen for the two arms in the study, including the starting doses and any flexible dosing options mentioned.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on Bipolar I Disorder, as outlined in the context information?',\n",
       " 'Describe the recruitment details for the study, including the number of centers involved and the specific dosing arms for ziprasidone assigned to subjects.',\n",
       " 'What statistical method was used in the analysis of the data presented in the document? Explain the key components of this statistical method and how it was applied to the study.',\n",
       " 'In the context of the study, what was the null hypothesis for the primary parameter being tested? How was this hypothesis related to the comparison between the ziprasidone and placebo groups in terms of the mean change from baseline to Week 6 in MADRS total score?',\n",
       " 'What was the estimated sample size needed per treatment arm in order to achieve 85% power to detect a treatment difference of 3.5 in the mean change from baseline to Week 6 in MADRS total score with a two-sided t-test at the 0.05 significance level?',\n",
       " 'What statistical method was used for the analysis in the study, and what was the p-value obtained for the comparison between ziprasidone and placebo groups in terms of the mean change from baseline to Week 6 in MADRS total score?',\n",
       " 'What is the primary outcome measure of the study comparing Irinotecan and 5 FU/FA to 5-FU/FA after resection of liver metastases for colorectal cancer?',\n",
       " 'What was the overall status of the study comparing CPT-11 in combination with a 5-FU/FA infusional regimen to the same 5-FU/FA infusional regimen alone as adjuvant treatment after resection of liver metastases for colorectal cancer?',\n",
       " 'What are the inclusion criteria for patients to be eligible for the study on colon or rectal cancer with liver metastases? Provide at least three specific criteria mentioned in the document.',\n",
       " 'Describe the two recruitment groups in the study, including the treatment regimens they received and the duration of the treatment cycles.',\n",
       " 'What was the primary objective of the study comparing irinotecan hydrochloride with cisplatin to etoposide plus cisplatin in chemotherapy-naive patients with Extensive Disease-Small Cell Lung Cancer (ED-SCLC)?',\n",
       " 'Can you explain the primary outcome measure of the study, which focused on Overall Survival (OS) for the Full Analysis Population (FAP)?',\n",
       " 'Explain the eligibility criteria for participants in the study on Small Cell Lung Cancer (SCLC) treatment. What were the inclusion and exclusion criteria specified?',\n",
       " 'Describe the recruitment details for Cohort 1 in the study, including the reason for early termination, the changes made per protocol amendment, and the subsequent analysis plan for Cohort 2.',\n",
       " 'What is the primary purpose of the IDEA study mentioned in the context information?',\n",
       " 'Describe the difference in treatment approach between the \"Early treatment\" and \"Deferred treatment\" arms in the study involving voriconazole for neutropenic patients with fever and a positive panfungal polymerase chain reaction assay.',\n",
       " 'What is the primary outcome measure of the study, and how is it defined according to the European Organization for Research and Treatment of Cancer Mycosis Study Group (EORTC/MSG) criteria?',\n",
       " 'What are the inclusion criteria for participants in this study, specifically related to their medical conditions and laboratory values?',\n",
       " 'Explain the treatment regimen for the Deferred Voriconazole Treatment group in the study, including the dosages and duration of treatment.',\n",
       " 'Discuss the statistical analysis conducted to compare the rates of invasive fungal infection (IFI) between the Immediate Voriconazole and Deferred Voriconazole treatment groups. Include details about the hypothesis tested, the statistical method used, and the interpretation of the results.',\n",
       " 'What was the primary purpose of the study evaluating the safety of sildenafil citrate in children with Pulmonary Arterial Hypertension (PAH)?',\n",
       " 'Describe the dosing regimen for the high dose and low dose treatment groups in the study evaluating the long-term safety of sildenafil citrate in children with PAH.',\n",
       " 'Explain the pre-assignment details for participants in the extension study A1481156, including the rerandomization process for those who were initially randomized to placebo in study A1481131 (NCT00159913).',\n",
       " 'Describe the recruitment details for the extension study, including the number of participants, the sites involved, and any specific information about participants who did not transition from study A1481131 (NCT00159913) to A1481156.',\n",
       " 'What is the primary purpose of the clinical research study mentioned in the context information, and what is the specific condition being studied in children aged 1 to 17 years?',\n",
       " 'Describe the arms groups and interventions used in the study evaluating sildenafil for the treatment of Pulmonary Arterial Hypertension in children.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on pulmonary arterial hypertension?',\n",
       " 'What are the exclusion criteria for subjects participating in the study on pulmonary arterial hypertension?',\n",
       " 'What are the exclusion criteria for subjects participating in the study, specifically in terms of medication use and medical conditions?',\n",
       " 'How was the recruitment conducted for the study, including the number of centers involved and the regions where the study took place?',\n",
       " 'Explain the statistical method used in the analysis of covariance for the groups OG001 and OG004. How were etiology, weight, and baseline peak VO2 utilized as covariates in the analysis?',\n",
       " 'Compare the mean differences (net) for the groups OG001 and OG004 with the confidence intervals provided. How do these results support the claim of superiority or other legacy in the study?',\n",
       " 'What was the primary purpose of the study conducted by Pfizer on children with growth retardation due to glucocorticosteroid therapy, and how long did the study last?',\n",
       " 'Describe the intervention model and primary outcome measure used in the study on the evolution of growth rate in children with growth retardation related to long-term corticotherapy and treated by Genotonorm.',\n",
       " 'What are the inclusion criteria for participants in this study on the effects of glucocorticosteroid treatment on growth in children?',\n",
       " 'How was the recruitment group \"Genotonorm\" administered in this study, and what was the maximum dose allowed per day?',\n",
       " 'What was the primary outcome measured in the study aimed at improving height with Genotonorm in children born small for gestational age and with growth retardation?',\n",
       " 'What were the eligibility criteria for participants in the study, in terms of age range for boys and girls?',\n",
       " 'What are the exclusion criteria for participants in this study regarding height measurement and pubertal signs?',\n",
       " 'Can you describe the recruitment group titled \"Genotonorm\" and the dosing regimen for participants in this study?',\n",
       " 'What were the primary objectives of the Vaspect Study regarding the use of donepezil in patients with vascular and mixed dementia?',\n",
       " 'Why was the trial terminated, and what were the reasons provided for this decision?',\n",
       " 'What was the recruitment group 0 in the study conducted in Canada, and what treatment did subjects receive in this group?',\n",
       " 'What was the rationale behind the reduction in the number of analyses specified in the protocol for the study, as mentioned in the Group IDs section?',\n",
       " 'What type of statistical analysis was used in the study, and what was the reported p-value?',\n",
       " 'Is the tested intervention considered non-inferior to the control group, based on the provided information?',\n",
       " 'What was the primary purpose of the study evaluating Bazedoxifene Acetate in osteoporosis in postmenopausal women conducted by Pfizer?',\n",
       " 'Can you explain the primary outcome measure used in the study, specifically focusing on the criteria for identifying new vertebral fractures in participants over the course of 36 months?',\n",
       " 'What are the eligibility criteria for participants in the study? Provide examples of both inclusion and exclusion criteria.',\n",
       " 'Describe the treatment regimens for the two recruitment groups in the study. What are the differences between the Bazedoxifene 20 mg (Core+SE I) and Bazedoxifene 40 mg (Core) groups in terms of dosage and duration of treatment?',\n",
       " 'What statistical method was used to calculate the p-values in the study comparing Bazedoxifene 20 mg to Raloxifene 60 mg and Bazedoxifene 40 mg?',\n",
       " 'In the comparison of Bazedoxifene 20 mg to Placebo for patients with at least 1 prevalent fracture, what was the hazard ratio and 95% confidence interval reported in the study?',\n",
       " 'What statistical method was used to calculate the hazard ratio for the comparison between Bazedoxifene 40 mg [Core] and Placebo [Core+SE I+SE II]?',\n",
       " 'In the comparison between Raloxifene 60 mg [Core] and Placebo [Core+SE I+SE II], what was the hazard ratio and its corresponding 95% confidence interval?',\n",
       " 'What statistical method was used to analyze the data in the study mentioned in the context information?',\n",
       " 'What was the hazard ratio (HR) value reported in the study, and what does this value indicate about the relationship between the variables being studied?',\n",
       " 'What is the primary outcome measure in the study evaluating the impact of pregabalin on peripheral neuropathic pain, and how is it assessed?',\n",
       " 'What are the inclusion criteria for subjects participating in the study, specifically regarding the duration and severity of peripheral neuropathic pain required for eligibility?',\n",
       " 'Explain the exclusion criteria for participants in the study. What specific diagnoses would disqualify individuals from participating in the research?',\n",
       " 'Describe the recruitment process for the study, including the treatment groups involved, the duration of the single-blind phase, and the criteria for entering the double-blind phase.',\n",
       " 'What was the primary outcome measured in the study comparing pregabalin to placebo in the treatment of nerve pain associated with HIV neuropathy?',\n",
       " 'What were the eligibility criteria for subjects to participate in the study on pregabalin versus placebo for HIV-associated neuropathic pain?',\n",
       " 'What were the exclusion criteria for subjects participating in the study on Pregabalin and Placebo? How did these criteria impact the selection of participants for the study?',\n",
       " 'Describe the recruitment process for the study, including the number of subjects screened and randomized, the duration of the study, and the dosing regimen for both the Pregabalin and Placebo groups.',\n",
       " 'What was the primary objective of the study comparing eplerenone to placebo in patients with NYHA Class II heart failure, and what was the recommendation made by the Executive Steering Committee based on the efficacy of eplerenone?',\n",
       " 'Why was further enrollment into the EMPHASIS-HF study stopped on May 26, 2010, and what was the plan for patients already enrolled in the trial following the recommendation of the Executive Steering Committee?',\n",
       " 'What is the primary outcome measure of the EMPHASIS-HF trial, and how is it defined?',\n",
       " 'What are the inclusion criteria for participants in the open-label phase of the trial, and what are the exclusion criteria?',\n",
       " 'What is the treatment regimen for participants in the Eplerenone: Double-blind Phase recruitment group?',\n",
       " 'What statistical method was used to analyze the data, and what was the p-value obtained from the analysis?',\n",
       " 'What was the primary purpose of the study evaluating bazedoxifene/conjugated estrogens combinations in postmenopausal women?',\n",
       " 'How was endometrial hyperplasia assessed in the study, and what criteria were used to determine if participants had a diagnosis of hyperplasia?',\n",
       " 'What are the inclusion criteria for participants in this study regarding age and menopausal status?',\n",
       " 'Describe the treatment regimen for participants in the \"Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg\" group, including the dosages and duration of administration.',\n",
       " 'What was the primary purpose of the Phase 3B multicenter trial conducted by Pfizer, comparing Azithromycin SR and Moxifloxacin for the treatment of Acute Exacerbation of Chronic Bronchitis (AECB)?',\n",
       " 'How was the primary outcome of the trial defined, and at what time frame was it assessed in the Clinical Per Protocol Population?',\n",
       " 'Explain the eligibility criteria for participants in the study on chronic bronchitis and acute exacerbations. What are the inclusion and exclusion criteria that were specified?',\n",
       " 'Compare and contrast the treatment regimens for the two recruitment groups in the study. Describe the administration methods and durations for Azithromycin and Moxifloxacin, highlighting any differences between the two.',\n",
       " 'What was the primary outcome measure in the study evaluating the safety and efficacy of flexibly-dosed ziprasidone in children and adolescents with bipolar I disorder?',\n",
       " 'What was the overall status of the trial evaluating the safety and efficacy of oral ziprasidone in children and adolescents with bipolar I disorder, and when was the primary completion date of the study?',\n",
       " 'Explain the eligibility criteria for participants in the study on Bipolar I disorder. What are the inclusion and exclusion criteria mentioned?',\n",
       " 'Describe the dosing regimen for the Ziprasidone group in the study. What was the starting dose, dose escalation protocol, and target dose for participants with different weight categories?',\n",
       " 'What was the primary reason for the termination of the study on the safety and efficacy of ziprasidone in adolescents with schizophrenia conducted by Pfizer?',\n",
       " 'Describe the intervention model and masking used in the clinical trial evaluating the safety and efficacy of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.',\n",
       " 'What is the primary outcome measure in this study and how is it assessed? Provide a brief description of the scale used and the scoring system.',\n",
       " 'Describe the eligibility criteria for participants in this study. What specific criteria needed to be met for inclusion, and what factors would exclude someone from participating?',\n",
       " 'What is the significance of the interim analysis at 60% enrollment in the context of the trial mentioned? How could this analysis impact the continuation of the trial?',\n",
       " 'Describe the statistical method used in the final analysis of the trial results. How is the p-value for the final analysis adjusted, and why is this adjustment necessary?',\n",
       " 'What was the primary purpose of the study mentioned in the context information, and what were the two drugs being compared in the study?',\n",
       " 'According to the eligibility criteria provided, what were the inclusion and exclusion criteria for patients participating in the study on the safety and efficacy of Lyrica in the treatment of newly diagnosed partial epilepsy?',\n",
       " 'Explain the recruitment details for the clinical trial involving Pregabalin and Lamotrigine in patients with primary generalized seizures. How were the doses of the medications adjusted during the trial?',\n",
       " 'Discuss the statistical method used in the analysis of the binary response variable for 6 consecutive months seizure freedom between the Pregabalin and Lamotrigine treatment groups. What was the non-inferiority margin set for this analysis, and how was non-inferiority determined in the study?',\n",
       " 'What is the primary purpose of the study described in the context information?',\n",
       " 'How many arms groups were involved in the study, and what were the differences between the treatments they received?',\n",
       " 'What is the primary outcome measure in this study, and how is it defined?',\n",
       " 'Describe the intervention for Arms group 1 in the study, including the dosage and duration of treatment.',\n",
       " 'How might the design of a study make it challenging to interpret treatment group comparisons in measures such as MRS, CGI-S, CGI-I, MADRS, and PANSS?',\n",
       " 'How does the presence of results impact the interpretation of timepoint by timepoint treatment group comparisons in the study mentioned in the context information?',\n",
       " 'What was the primary purpose of the study evaluating Geodon in patients with Bipolar I Depression?',\n",
       " 'How was the enrollment conducted in the study, and what were the intervention models used for the Ziprasidone and Placebo arms?',\n",
       " 'Explain the primary outcome measure in the study and how it is calculated. What is the significance of monitoring the change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score in this research?',\n",
       " 'Discuss the eligibility criteria for participants in the study. What specific criteria must individuals meet in order to be included in the research, and what conditions would make them ineligible to participate? How do these criteria ensure the validity and reliability of the study results?',\n",
       " 'What statistical method was used to compare remission and response rates between ziprasidone and placebo groups at different time points in the study?',\n",
       " 'What was the p-value for the comparison of remission and response rates between ziprasidone and placebo groups at Week 4, and was any multiple comparison adjustment made for this analysis?',\n",
       " 'What statistical method was used to compare remission and response rates between the ziprasidone and placebo groups in the study?',\n",
       " 'What was the p-value for the comparison of remission and response rates between ziprasidone and placebo groups at the endpoint of the study?',\n",
       " 'What was the primary purpose of the study on varenicline conducted by Pfizer in smokers with cardiovascular disease?',\n",
       " 'Describe the eligibility criteria for participants in the study on varenicline for smoking cessation in individuals with cardiovascular disease.',\n",
       " 'Explain the recruitment process for the study conducted on cigarette smokers with cardiovascular disease. What were the eligibility criteria for participants in terms of smoking habits and age?',\n",
       " 'Discuss the pre-assignment details of the study, including the number of participants randomized and the reasons for some participants not being treated. Additionally, explain the recruitment groups and their respective descriptions in the study.',\n",
       " 'What is the primary outcome measure of the study \"Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)\" and how is it defined?',\n",
       " 'Describe the eligibility criteria for subjects participating in the study evaluating the safety and efficacy of Varenicline Tartrate for smoking cessation in patients with mild-to-moderate COPD.',\n",
       " 'Explain the eligibility criteria for subjects participating in the study on varenicline for smoking cessation in individuals with mild to moderate COPD as outlined in the document. What specific criteria must subjects meet to be included in the study?',\n",
       " 'Discuss the recruitment groups involved in the study on varenicline versus placebo for smoking cessation in individuals with COPD. What were the treatment regimens for each group, and what was the primary endpoint of the study?',\n",
       " 'What is the primary purpose of the study comparing Voriconazole and Itraconazole in subjects with allogeneic hematopoietic stem cell transplants?',\n",
       " 'How is the success of the antifungal prophylaxis measured in this study, specifically at Day 180 after the stem cell transplant?',\n",
       " 'What are the inclusion criteria for this study on antifungal therapy in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)?',\n",
       " 'How were subjects stratified at the time of randomization in this study comparing voriconazole and itraconazole for the prevention of invasive fungal infections post-transplantation?',\n",
       " 'What statistical method was used to analyze the difference in adjusted responder rates in the study? Explain how this method was applied to the data.',\n",
       " 'What limitations and caveats were mentioned in the context information provided? How might the exclusion of data from one site impact the overall results of the study?',\n",
       " 'What was the primary objective of the study comparing the effect on carotid atherosclerosis in kidney transplant patients receiving tacrolimus-based immunosuppression versus those converted to a sirolimus-based regimen post-transplant?',\n",
       " 'Why was the study terminated, according to the detailed description provided?',\n",
       " 'What is the primary outcome measure of the study involving kidney transplant patients with atherosclerosis and kidney failure, and how is it assessed?',\n",
       " 'Describe the differences between the two arms of the intervention in the study, including the specific medications used and any conversion that occurs in one of the arms.',\n",
       " 'Explain the eligibility criteria for participants in the study. What characteristics must a participant have to be included in the study, and what factors would exclude someone from participating?',\n",
       " 'Compare and contrast the treatment regimens for the two recruitment groups in the study. What medications were administered to participants in each group, and how did the treatment plans differ in terms of drug dosages and timing?',\n",
       " 'What was the primary outcome measure in the study evaluating the efficacy and safety of ziprasidone with either lithium or divalproex in acutely manic subjects?',\n",
       " 'What was the enrollment count for the study, and what were the arms groups and interventions involved in the trial?',\n",
       " 'What are the inclusion criteria for subjects participating in the study on Bipolar I Disorder?',\n",
       " \"How was the change calculated in the study, and what was the primary outcome time frame for assessing the participants' progress?\",\n",
       " 'What statistical method was used for the analysis in the document?',\n",
       " 'What was the p-value obtained from the Mixed Models Analysis in the study?',\n",
       " 'What was the primary purpose of the study on diazepam in the management of refractory epilepsy in selected patients?',\n",
       " 'How was the administration of the placebo and diazepam solutions carried out during the double-blind period of the study?',\n",
       " 'What are the key inclusion criteria for patients participating in the study on the use of Vanquix Auto-Injector (Diazepam Injection) for acute repetitive seizures (ARS)?',\n",
       " 'Describe the primary outcome measure used in the study, including the time frame and criteria for defining an event.',\n",
       " 'In the study, what were the reasons for discontinuation prior to treatment, and which reason had the highest frequency?',\n",
       " 'Describe the recruitment groups in the study, including the medications administered, methods of administration, and any additional information provided about the treatment protocols.',\n",
       " 'What was the primary purpose of the study conducted by Pfizer on pregabalin in patients with fibromyalgia?',\n",
       " 'How was the primary outcome of the study, specifically the change from baseline in mean pain score at endpoint, measured and recorded in the trial?',\n",
       " 'What are the inclusion criteria for patients in this study on fibromyalgia treatment?',\n",
       " 'Describe the recruitment details for this study, including the regions where participants were recruited from and the treatment groups involved.',\n",
       " 'Explain the significance of the p-value of 0.2361 in the context of the statistical analysis conducted using ANCOVA. How does this p-value impact the interpretation of the results?',\n",
       " 'Discuss the implications of the confidence interval (CI) values provided for the parameter \"Least Squares (LS) mean difference\" in the context of the study. How does the CI range of -0.72 to 0.05 affect the conclusions drawn from the analysis?',\n",
       " 'What are the primary and secondary endpoints of the study comparing on-demand treatment with two prophylaxis regimens of BeneFIX in patients with severe Hemophilia B?',\n",
       " 'Describe the study design and treatment plan for subjects participating in the multicenter, open-label study comparing on-demand treatment with two prophylaxis regimens of recombinant Coagulation Factor IX (BeneFIX) in patients with severe Hemophilia B.',\n",
       " 'What are the inclusion criteria for patients to be eligible for participation in this study on hemophilia B treatment with recombinant Coagulation Factor IX (BeneFIX)?',\n",
       " 'Describe the primary outcome measure of the study and explain how it is calculated.',\n",
       " 'Explain the recruitment group \"BeneFIX OD1, Then 100 IU/kg, Then OD2, Then 50 IU/kg\" in detail, including the treatment regimen, dosage form, and duration of each phase.',\n",
       " 'Discuss the statistical analysis conducted in the study, including the p-values, statistical method (ANOVA), and the limitations and caveats mentioned. How do these findings contribute to the overall results of the study?',\n",
       " 'What is the primary purpose of the study described in the context information, and how is it being carried out?',\n",
       " 'Describe the arms groups involved in the study, including the treatments they receive and the specific conditions under which they are administered.',\n",
       " 'What is the primary outcome measure of the study, and how is it defined in terms of benzodiazepine use and testing criteria?',\n",
       " 'What are the inclusion criteria for participants in the study, and what is one specific exclusion criterion mentioned in the eligibility criteria?',\n",
       " 'Explain the treatment protocol for the recruitment group receiving Pregabalin in the study, including the dosing schedule and tapering of alprazolam.',\n",
       " 'What statistical method was used to analyze the data in this study, and what was the p-value obtained?',\n",
       " 'What was the reason for the termination of the clinical trial comparing the efficacy and safety of Sunitinib and Capecitabine in subjects with advanced breast cancer?',\n",
       " 'How did Pfizer notify clinical trial investigators and regulatory agencies about the findings that led to the discontinuation of patient enrollment in the study?',\n",
       " 'What are the inclusion criteria for participants in this study on advanced breast cancer treatment, specifically regarding prior chemotherapy regimens?',\n",
       " 'Describe the primary outcome measure in this study and explain how it is assessed in the context of evaluating treatment efficacy for breast adenocarcinoma patients.',\n",
       " 'What was the statistical method used to analyze the difference in progression-free survival (PFS) between the two treatment groups in the study?',\n",
       " 'What was the estimated hazard ratio for PFS between the sunitinib and capecitabine treatment groups, and what was the confidence interval for this estimate?',\n",
       " 'What was the primary purpose of the study described in the context information?',\n",
       " 'What was the outcome of the study in terms of the comparison between SU011248 plus paclitaxel and bevacizumab plus paclitaxel in patients with advanced breast cancer?',\n",
       " 'Explain the eligibility criteria for patients to participate in the study comparing Sunitinib + Paclitaxel and Bevacizumab + Paclitaxel in advanced breast cancer. How do these criteria ensure the selection of appropriate participants for the trial?',\n",
       " 'Discuss the statistical analysis conducted in the study, including the p-value, statistical method used, and the interpretation of the hazard ratio for the comparison between Sunitinib + Paclitaxel and Bevacizumab + Paclitaxel. How does the hazard ratio provide insight into the efficacy of the treatment regimens?',\n",
       " 'What is the primary purpose of the clinical trial described in the context information, and what are the two arms of the study comparing?',\n",
       " 'Can you explain the primary outcome measure of the study and how it is assessed?',\n",
       " 'Explain the eligibility criteria for participants in the study on high-risk renal cancer, including both the inclusion and exclusion criteria. How did these criteria ensure the selection of appropriate participants for the research?',\n",
       " 'Describe the primary outcome time frame for the study on high-risk renal cancer. What factors determined the timing of the primary analysis of Disease-Free Survival (DFS) for both the Global Cohort and the China Cohort? How did the study design account for potential variations in follow-up intervals for participants?',\n",
       " 'What is the primary completion date of the Phase III trial assessing the safety and efficacy of Plant Cell Expressed GCD in patients with Gaucher Disease?',\n",
       " 'How many treatment groups were there in the trial, and what were the dosages administered to patients in each group?',\n",
       " 'What are the inclusion criteria for patients to participate in the clinical trial for Gaucher Disease treatment with plant cell expressed recombinant glucocerebrosidase (prGCD)?',\n",
       " 'Describe the primary outcome measure of the clinical trial for Gaucher Disease treatment, including how it is calculated and the time frame for assessment.',\n",
       " 'Explain the recruitment groups and their descriptions for the study involving Taliglucerase alfa. How do these groups differ in terms of dosage and administration frequency?',\n",
       " 'Discuss the statistical methods used in the study to analyze the primary outcome of percent change in spleen volume after nine months. What was the significance level set for determining statistical significance, and what was the power of the study to detect a change of 20% or more in spleen volume?',\n",
       " 'What was the primary purpose of the study evaluating Desvenlafaxine Succinate Sustained Release in the treatment of Major Depressive Disorder?',\n",
       " 'Describe the primary outcome measure used in the study and explain its significance in assessing the efficacy of the treatment.',\n",
       " 'What are the inclusion criteria for participants in this study on Major Depressive Disorder? Provide at least three criteria mentioned in the eligibility criteria section.',\n",
       " 'How was the primary outcome, HAM-D17 total score, evaluated for the group receiving DVS SR 50 mg in the study? Explain the statistical analysis method used and the factors considered in the analysis.',\n",
       " 'In the study mentioned in the context information, what statistical method was used to evaluate the HAM-D17 total score for the different treatment groups? What factors were considered in the analysis?',\n",
       " 'For the comparison between DVS SR 100 mg and Duloxetine 60 mg, what were the mean differences in the final HAM-D17 total scores? Provide the confidence intervals for each comparison and discuss the statistical significance of the results based on the p-values provided.',\n",
       " 'What was the primary purpose of the study on ramipril conducted by Pfizer in children and adolescents with hypertension?',\n",
       " 'Describe the study design and procedures involved in the evaluation of the blood pressure lowering effects of ramipril in children and adolescents aged 6 to 16 years.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on hypertension treatment with ramipril and placebo?',\n",
       " 'What is the primary outcome measure of the study, and how is it defined in terms of blood pressure changes from baseline to 4 weeks of treatment with high-dose ramipril compared to placebo?',\n",
       " 'Explain the eligibility criteria related to cardiomyopathy, structural heart disease, and other cardiac conditions for participation in the study.',\n",
       " 'Describe the recruitment details and groups involved in the study, including the placebo run-in period and the specific recruitment groups for different treatments.',\n",
       " 'What was the primary purpose of the study titled \"Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer\" conducted by Pfizer?',\n",
       " 'How was the primary outcome, Progression-Free Survival (PFS), defined in the randomized phase 3 study of Docetaxel in combination with Sunitinib versus Docetaxel in the first-line treatment of advanced breast cancer patients?',\n",
       " 'What are the inclusion criteria for participants in this study on breast cancer treatment?',\n",
       " 'What was the primary outcome time frame for assessing the effectiveness of the treatment regimens in the study?',\n",
       " 'What was the primary purpose of the study mentioned in the context information, and what was the lead sponsor of the study?',\n",
       " 'Describe the eligibility criteria for participants in the study on the evaluation of efficacy and safety of pregabalin in the treatment of postherpetic neuralgia.',\n",
       " 'How were patients stratified in this study based on their creatinine clearance values, and how were they randomized into treatment groups?',\n",
       " 'What statistical method was used to analyze the data in this study, and what was the p-value obtained for the comparison of different treatment groups?',\n",
       " 'What was the primary objective of the study on children with Idiopathic Short Stature conducted by Pfizer, as outlined in the brief summary?',\n",
       " 'Describe the primary outcome measure used in the study, specifically focusing on the Absolute On-target Difference (AOTD) at 24 Months and how it was calculated.',\n",
       " 'Explain the eligibility criteria for participants in the study on growth hormone treatment. What were the inclusion and exclusion criteria specified for prepubertal children participating in the research?',\n",
       " 'Describe the recruitment details and study design of the research on growth hormone treatment. How were participants randomized into different arms of the study, and what were the key phases of the 4-year study conducted at multiple centers in the United States of America?',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'What adverse event is noted to be the most common in clinical studies involving Desvenlafaxine succinate (DVS SR) and is the main reason for discontinuation during the first week of therapy?',\n",
       " 'What are the inclusion criteria for participants in this study on treatment for hot flushes in postmenopausal women?',\n",
       " 'Describe the recruitment groups and their corresponding treatment regimens in the study on desvenlafaxine succinate for hot flushes in postmenopausal women.',\n",
       " 'What was the primary purpose of the study conducted by Pfizer on the effectiveness of Celecoxib in patients with painful sore throat?',\n",
       " 'How was the primary outcome, Sum of Sore Throat Pain Intensity Difference (SPID2) on Swallowing at 2 Hours Post-First Dose, measured in the study comparing Celecoxib to placebo in patients with painful pharyngitis?',\n",
       " \"What are the inclusion criteria for patients participating in the study on pharyngitis treatment with celecoxib? How does the study protocol restrict the patients' intake during the two-hour assessment period post-trial drug administration?\",\n",
       " 'Describe the recruitment groups and their respective dosing regimens for the study on celecoxib in treating pharyngitis. How was the sample size determined for the study, and what statistical method was used to analyze the primary outcome at two hours post-first dose?',\n",
       " 'What was the primary purpose of the study evaluating pregabalin for the treatment of nerve pain due to spinal cord injury?',\n",
       " 'Describe the primary outcome measure used in the study and how it was calculated.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on nerve pain after spinal cord injury? Provide specific details regarding the duration of pain, pain score, and types of spinal cord injuries included.',\n",
       " 'Describe the pre-assignment details mentioned in the context information. How was the participant who was randomized to the placebo group but actually took pregabalin handled in terms of data analysis and reporting?',\n",
       " 'What was the primary objective of the study on pregabalin in the treatment of patients with Generalized Anxiety Disorder (GAD)?',\n",
       " 'Why was further enrollment in the study stopped on January 28, 2008, according to the detailed description provided?',\n",
       " 'What are the inclusion criteria for subjects participating in the study on Generalized Anxiety Disorder (GAD) treatment optimization, as outlined in the eligibility criteria section?',\n",
       " 'How many countries were involved in the recruitment for the study on Pregabalin and Placebo treatment for GAD, and what were the specific countries mentioned in the recruitment details?',\n",
       " 'Explain the statistical method used in the study and how it was adjusted for various factors. What was the estimated mean difference in the final values between the treatment groups, and what was the corresponding 95% confidence interval?',\n",
       " 'Why was further enrollment in the study stopped, and what was the recommendation of the Data Monitoring Committee (DMC)? How was the study design impacted by the interim data analysis results, and what were the reasons for not stopping the study due to safety findings?',\n",
       " 'What was the primary purpose of the study of Embeda (Kadian NT, ALO-01) in subjects with chronic moderate to severe nonmalignant pain conducted by Pfizer?',\n",
       " 'How many subjects were enrolled in the open-label safety study of ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) capsules for up to 12 months?',\n",
       " 'Explain the exclusion criteria related to a documented history of drug abuse/dependence/misuse or narcotic analgesic abuse/dependence/misuse within five years prior to the Baseline Visit. Why is this criterion important in the selection of participants for the study?',\n",
       " \"Discuss the eligibility criteria for subjects participating in the study, specifically focusing on the history of chronic moderate to severe pain caused by a nonmalignant condition for at least 3 months prior to baseline. Why is this criterion essential for the study's objectives and outcomes?\",\n",
       " 'What was the primary outcome measured in the study comparing amlodipine 5mg and 10mg in patients with essential hypertension?',\n",
       " 'What were the eligibility criteria for inclusion in the study, specifically for untreated and treated hypertensive patients?',\n",
       " 'Explain the eligibility criteria for patients to be included in the study for the double-blind period after the screening phase. How were patients randomized into the amlodipine 10 mg group and the amlodipine 5 mg group?',\n",
       " 'Describe the recruitment details for the study, including the number of centers involved and the treatment regimens for the two recruitment groups (Amlodipine 5 mg and Amlodipine 10 mg). How was the hypothesis of group differences tested, and what was the outcome of the statistical analysis in terms of superiority between the two treatment arms?',\n",
       " 'What is the primary objective of the study on Embeda (Kadian NT, ALO-01) in subjects with pain due to osteoarthritis of the hip or knee?',\n",
       " 'What was the overall status of the study on Embeda (Kadian NT, ALO-01) and when was the primary completion date?',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'Describe the intervention for Arms group 0 in the study, including the dosage and frequency.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on osteoarthritis treatment with ALO-01 and placebo?',\n",
       " 'What was the statistical method used to analyze the data in the study, and what was the reported p-value for the comparison between ALO-01 and placebo groups?',\n",
       " 'What was the primary outcome measured in the clinical trial evaluating the effects of fesoterodine on treatment satisfaction and symptom relief in overactive bladder patients?',\n",
       " 'What were the inclusion criteria for patients participating in the study, and what were the exclusion criteria that would disqualify a patient from participating in the trial?',\n",
       " 'Explain the recruitment process for the study on OAB symptoms caused by neurological conditions. How many subjects were screened and how were eligible subjects identified for enrollment in the study?',\n",
       " 'Discuss the statistical analysis method used in the study and the significance of the p-value obtained. How was efficacy determined in the study based on the primary diary endpoints?',\n",
       " 'What was the primary endpoint that led to the termination of the study on sunitinib versus placebo for patients with advanced pancreatic islet cell tumors?',\n",
       " 'Describe the intervention protocol for patients in the sunitinib treatment arm of the study, including the starting dose, potential adjustments, and response evaluation criteria.',\n",
       " 'What is the primary outcome measure in this study and how is it calculated?',\n",
       " 'What are the eligibility criteria for participants in this study, specifically in terms of tumor progression and prior treatments?',\n",
       " 'What was the primary outcome measured in the study of sunitinib in combination with capecitabine compared with capecitabine in patients with breast cancer?',\n",
       " 'What was the enrollment count for the study and what were the two arms groups involved in the intervention?',\n",
       " 'What are the eligibility criteria for patients to participate in the study mentioned in the context information? Provide examples of both inclusion and exclusion criteria.',\n",
       " 'Describe the treatment regimens for the two recruitment groups mentioned in the document. Include details such as the drugs used, dosages, and administration schedules.',\n",
       " 'What is the primary outcome measure used in the study \"Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement\"? Describe how this outcome measure is assessed and the time frame in which it is evaluated.',\n",
       " 'What are the inclusion criteria for subjects participating in the study? Specifically, what are the requirements for subjects with osteoarthritis undergoing elective Total Knee Arthroplasty (TKA) under regional anesthesia?',\n",
       " 'What are the exclusion criteria for subjects participating in the study on the effects of pregabalin on post-operative pain management in knee arthroplasty patients?',\n",
       " 'What is the statistical method used in the analysis of the study results, and what was the p-value obtained for comparing the high dose and placebo groups in terms of pain scores?',\n",
       " 'What was the primary purpose of the clinical trial mentioned in the context information?',\n",
       " 'How was the primary outcome of the study defined and measured in relation to the efficacy of fesoterodine compared to tolterodine for overactive bladder?',\n",
       " 'What are the inclusion criteria for adult patients with overactive bladder (OAB) symptoms in this study?',\n",
       " 'How was the treatment difference between Fesoterodine and Tolterodine ER at Week 12 assessed in the study, and what statistical method was used for the analysis?',\n",
       " 'Explain the concept of Winsorized means and how they were used in estimating treatment effects in this study. Why was it necessary to censor 5% of the tails in this analysis?',\n",
       " 'Describe the statistical method used in this study to compare the treatment effects of fesoterodine, tolterodine ER, and placebo. How was the p-value calculated and what does the significance level of 0.0172 indicate in terms of the comparison between fesoterodine and tolterodine ER?',\n",
       " 'What was the primary purpose of the study evaluating the efficacy and safety of Etanercept and Methotrexate in Japanese subjects with rheumatoid arthritis?',\n",
       " 'Describe the primary outcome measure used in the study and explain how it was assessed in relation to disease progression and joint worsening.',\n",
       " 'What are the inclusion criteria for participants in this study on the treatment of rheumatoid arthritis in Japanese individuals?',\n",
       " 'What were the primary outcome time frame and statistical method used in the analysis of the study comparing the efficacy of Methotrexate and Etanercept in treating rheumatoid arthritis?',\n",
       " 'How was mTSS used consistently in the statistical analysis plan and study results?',\n",
       " 'Can you explain the significance of mTSS in the context of the study results?',\n",
       " 'What was the primary purpose of the study described in the context information provided?',\n",
       " 'How was the enrollment for the study conducted, and what was the total number of participants involved in the research?',\n",
       " 'What are the inclusion criteria for patients eligible to participate in the study on locally advanced/metastatic non-small cell lung cancer?',\n",
       " 'How was the difference in overall survival between treatment arms analyzed in the study, and what was the resulting p-value?',\n",
       " 'What was the primary purpose of the study involving FOLFIRI chemotherapy with or without sunitinib in patients with metastatic colorectal cancer?',\n",
       " 'What was the outcome of the study as determined by the independent Data Monitoring Committee (DMC) in June 2009, and how did Pfizer respond to these findings?',\n",
       " 'What is the primary outcome measure in this study on metastatic colorectal cancer patients receiving FOLFIRI treatment?',\n",
       " 'Describe the eligibility criteria for patients to participate in this study on metastatic colorectal cancer.',\n",
       " 'Explain the treatment regimen for patients in recruitment group 1, including the administration of FOLFIRI and the use of placebo during the study. How many courses of FOLFIRI were administered during each 6-week cycle?',\n",
       " 'Based on the statistical analysis provided, what was the p-value calculated for the comparison between the treatment group and the placebo group in terms of non-inferiority? What does this p-value indicate about the results of the study?',\n",
       " 'What were the primary objectives of the study comparing perceptions and satisfaction for two different delivery mechanisms for Etanercept in patients with rheumatoid arthritis?',\n",
       " 'How did the study aim to characterize patient attributes that may indicate when one device may result in greater patient satisfaction than another in the context of rheumatoid arthritis treatment?',\n",
       " 'What is the primary outcome measure of the study, and how is it assessed?',\n",
       " 'What are the inclusion criteria for participants in the study, and what are the exclusion criteria mentioned?',\n",
       " 'What were the null and alternative hypotheses tested in the study, and what was the significance level used for the non-inferiority test?',\n",
       " 'Using the information provided, calculate the 95% two-sided confidence interval for the mean difference (AI minus PFS) of subject satisfactions and determine if non-inferiority was demonstrated based on the lower limit of the confidence interval.',\n",
       " 'What is the primary outcome measure used in the study of the efficacy and safety of pregabalin compared to placebo for the treatment of post-surgical pain from hysterectomy?',\n",
       " 'What are the inclusion criteria for subjects participating in the study, specifically related to the type of surgery and expected duration of hospital stay post-surgery?',\n",
       " 'What are the exclusion criteria for subjects participating in the study on total abdominal hysterectomy? Provide specific examples of criteria that would disqualify a subject from participating.',\n",
       " \"Based on the recruitment details provided, compare and contrast the two recruitment groups (Pregabalin 150mg and Pregabalin 300mg) in terms of dosage and frequency. How does the statistical analysis of these groups support the study's objectives?\",\n",
       " 'What was the primary outcome measured in the study of Gemcitabine Plus AG-013736 versus Gemcitabine for advanced pancreatic cancer?',\n",
       " 'Why was the study prematurely discontinued, according to the detailed description provided in the context information?',\n",
       " 'What are the inclusion criteria for participants in this study on pancreatic adenocarcinoma?',\n",
       " \"How was death determined in this study, and what was the primary outcome time frame for assessing the participants' status?\",\n",
       " 'What were the two treatment arms in the study comparing temsirolimus versus sorafenib as second-line therapy in patients with advanced renal cell carcinoma who had failed first-line sunitinib?',\n",
       " 'What was the primary outcome measured in this study, and how was it defined?',\n",
       " 'What are the inclusion criteria for participants in this study on metastatic renal cell carcinoma (mRCC) receiving first-line sunitinib therapy?',\n",
       " 'What are the treatment regimens for the two recruitment groups in this study, and how long are participants expected to receive these treatments for?',\n",
       " 'What were the primary and secondary objectives of the study comparing patient satisfaction with the prefilled syringe (PFS) and the auto-injector (AI) for etanercept?',\n",
       " 'How were patient perceptions related to device attributes measured in the study, and what factors were considered in characterizing patient attributes that may indicate greater satisfaction with one device over another?',\n",
       " 'What is the primary outcome measure evaluated in this study for the treatment of psoriasis with Enbrel and Etanercept?',\n",
       " 'What are the inclusion criteria for participants in this study on the treatment of moderate to severe plaque psoriasis with Enbrel and Etanercept?',\n",
       " 'What are the two recruitment groups mentioned in the context information, and what is the difference in the administration method of Etanercept between these two groups?',\n",
       " 'Based on the group IDs provided, what statistical method was used to analyze the data, and what was the outcome in terms of non-inferiority testing?',\n",
       " 'What was the primary purpose of the study on Adjunctive Ziprasidone in the Treatment of Bipolar I Depression conducted by Pfizer?',\n",
       " 'Describe the intervention model and masking used in the study evaluating the efficacy and safety of flexible doses of oral Ziprasidone as add-on therapy with lithium, valproate, or lamotrigine in Bipolar I Depression.',\n",
       " 'What is the primary outcome measure in this study and how is it assessed?',\n",
       " 'What are the inclusion criteria for participants in this study, specifically regarding their diagnosis and medication history?',\n",
       " 'Explain the significance of the p-value provided in the context information. How does it relate to the null hypothesis and the conclusion drawn from the study?',\n",
       " 'Describe the statistical method used in the analysis of the data presented. What are the key components of this method and how do they contribute to the interpretation of the results?',\n",
       " 'What was the primary objective of the study on the efficacy and safety of IV diclofenac (DIV075V) for pain after elective orthopedic surgery?',\n",
       " 'How was the primary outcome, Sum of the Pain Intensity Differences (SPID) Over 24 Hours, measured in the study comparing diclofenac to placebo or Ketorolac tromethamine for post-operative pain relief?',\n",
       " 'What are the eligibility criteria for participants to be included in the study on pain reduction following orthopedic surgery?',\n",
       " 'Describe the dosages and administration schedules of DIC075V and ketorolac tromethamine for participants in the study.',\n",
       " 'What was the primary completion date of the study on the efficacy and safety of pregabalin (Lyrica) as monotherapy in patients with partial seizures?',\n",
       " 'Why was the study on pregabalin (Lyrica) as monotherapy in patients with partial seizures terminated, according to the detailed description provided in the context information?',\n",
       " 'What is the primary outcome measure of the study involving the use of Pregabalin in participants with epilepsy? Describe the criteria for participants to discontinue the study based on this outcome measure.',\n",
       " 'What are the inclusion criteria for participants in the study on Pregabalin for epilepsy treatment? Provide details on the eligibility requirements related to the diagnosis of epilepsy, seizure history, and current anti-epileptic drug treatment.',\n",
       " 'Explain the statistical method used in the analysis of the data provided in the context information. How was the p-value calculated and what does it indicate about the results?',\n",
       " 'Discuss the limitations and caveats mentioned in the context information regarding the study. How did the External Data Monitoring Committee (DMC) impact the study and what was the basis for the primary analysis reported?',\n",
       " 'What is the primary purpose of the study comparing anidulafungin and voriconazole in combination to voriconazole alone for the treatment of Invasive Aspergillosis?',\n",
       " 'Describe the intervention plan for the Arms group receiving Voriconazole and Anidulafungin in the study.',\n",
       " 'What are the inclusion criteria for participants in this study on the treatment of invasive aspergillosis with voriconazole and anidulafungin?',\n",
       " 'Describe the treatment regimen for participants in the Voriconazole/Anidulafungin group during the second week of the study.',\n",
       " 'Explain the statistical method used to analyze the data on all-cause mortality on Day 42 (Week 6) within each stratum. How was the treatment difference calculated and what was the significance level used for determining statistical significance?',\n",
       " 'Discuss the significance of the p-value of 0.0434 in the context of the study results. How does this p-value relate to the non-inferiority type and the tested hypothesis?',\n",
       " 'What was the primary outcome measured in the Fesoterodine Flexible Dose Study, and how was it calculated?',\n",
       " 'What were the inclusion criteria for patients to participate in the study evaluating the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder?',\n",
       " 'Explain the exclusion criteria for participants in the study on fesoterodine treatment for overactive bladder (OAB) symptoms. How do these criteria impact the selection of participants for the study?',\n",
       " 'Describe the recruitment process for participants in the study comparing fesoterodine and placebo for OAB symptoms. How were participants assigned to the placebo and fesoterodine groups, and what were the treatment protocols for each group?',\n",
       " 'What was the primary outcome measured in the study comparing pregabalin and levetiracetam in patients with partial seizures? Provide a brief description of how this outcome was determined.',\n",
       " 'According to the eligibility criteria, what are the requirements for subjects to be included in the study comparing pregabalin and levetiracetam as adjunctive therapy for reducing seizure frequency in patients with partial seizures?',\n",
       " 'What are the eligibility criteria for subjects to participate in the study on epilepsy treatment, specifically in terms of their diagnosis, treatment history, and current medication regimen?',\n",
       " 'Describe the treatment regimens for the two recruitment groups in the study, including the dosages and administration schedules for pregabalin and levetiracetam during the titration phase, maintenance phase, and optional continuation phase.',\n",
       " 'What is the parameter type being analyzed in the given context information?',\n",
       " 'What limitation was mentioned regarding the results for the BPRS in the study?',\n",
       " 'What was the primary purpose of the study evaluating prophylaxis treatment with B-domain deleted recombinant Factor VIII in children with Hemophilia A?',\n",
       " 'How was the Mean Annualized Bleed Rate (ABR) by Treatment calculated for the On Demand Cohort in the study?',\n",
       " 'What are the inclusion criteria for male subjects aged less than 6 years with moderately severe to severe hemophilia A in this study?',\n",
       " 'Describe the treatment regimen followed by participants in the Moroctocog Alfa (AF-CC) OD Cohort during Period 1 and Period 2 of the study.',\n",
       " 'Explain the treatment regimen followed by participants in Recruitment group 1 for routine prophylaxis therapy in this study. What was the dosage of moroctocog alfa (AF-CC) administered during Period 1 and Period 2?',\n",
       " 'In Recruitment group 1, a statistical analysis was conducted to compare the efficacy of on demand therapy versus routine prophylaxis therapy at 25 IU/kg. Describe the statistical method used for this analysis and interpret the reported p-value and confidence interval in the context of the study results.',\n",
       " 'What was the primary outcome measured in the study \"Fesoterodine \"add-on\" Male Overactive Bladder Study\" and how was it assessed?',\n",
       " 'What were the eligibility criteria for male participants in the study, specifically regarding age, medication, and symptoms of overactive bladder?',\n",
       " 'What are the exclusion criteria for this study involving fesoterodine treatment, and why are they important in determining eligibility for participation?',\n",
       " 'Describe the recruitment groups in this study, including the treatment regimens and adjustments made at the Week 4 visit. How do these groups differ in terms of medication administration and dosage adjustments?',\n",
       " 'What was the primary outcome measured in the \"Celebrex In Acute Gouty Arthritis Study\" and how was it assessed?',\n",
       " 'Describe the treatment regimens for the two arms in the study, including the dosage and duration of the medications used.',\n",
       " 'What are the inclusion criteria for participants in this study on acute gouty arthritis?',\n",
       " 'How was the primary analysis conducted in this study, and what factors were considered in the analysis?',\n",
       " 'What is the statistical method used in the study, and what type of parameter values were analyzed for each group comparison?',\n",
       " 'What limitations and caveats should be considered when interpreting the study results, particularly in relation to the data collection for the Patients Global Evaluation of study medication?',\n",
       " 'What is the primary purpose of the study \"Surgical Pain After Inguinal Hernia Repair (SPAIHR)\"?',\n",
       " 'What is the primary outcome measure used in the study, and how is it assessed?',\n",
       " 'What are the exclusion criteria for subjects participating in the study on surgery and pain control medication?',\n",
       " 'Describe the recruitment details for male subjects enrolled in the study on Pregabalin for pain management before and after surgery.',\n",
       " 'What statistical method was used to analyze the data in the given context information? Explain why this method was chosen for the analysis.',\n",
       " 'In the context information, it is mentioned that centers with fewer than 8 treated subjects were combined into pooled centers. How might this pooling of centers impact the interpretation of the study results, particularly in relation to the p-values reported?',\n",
       " 'What was the primary outcome measure in the study evaluating the efficacy and safety of pregabalin for pain associated with diabetic peripheral neuropathy?',\n",
       " 'What were the inclusion criteria for patients participating in the study, and what was one of the exclusion criteria mentioned in the context information provided?',\n",
       " 'Explain the pre-assignment details of the study, including how subjects were classified and randomly assigned to treatment groups based on creatinine clearance values.',\n",
       " 'Discuss the statistical analysis conducted in the study, including the significance level, p-values, and statistical method used. How were the treatment groups and creatinine clearance strata factored into the analysis?',\n",
       " \"What was the reason for the termination of the study comparing Inotuzumab Ozogamicin in combination with Rituximab versus defined investigator's choice in follicular non-Hodgkin's lymphoma?\",\n",
       " 'Describe the treatment arms in the study, including the interventions and dosing schedules for each arm.',\n",
       " 'What is the dosing regimen for R-FND in this clinical trial, including the specific drugs and their administration schedules?',\n",
       " 'What are the eligibility criteria for participants in this study, including requirements related to the type of lymphoma, prior treatment history, and laboratory values?',\n",
       " 'Explain the treatment regimens received by participants in Recruitment Group 0 (FG000) and Recruitment Group 1 (FG001) in the study. How do these regimens differ in terms of the drugs administered and the duration of each cycle?',\n",
       " 'What statistical method was used to analyze the data in this study, and what was the p-value obtained? Additionally, discuss the limitations and caveats of the study as mentioned in the context information.',\n",
       " 'What is the primary endpoint of the study comparing Bosutinib to Imatinib in subjects with newly diagnosed chronic phase Philadelphia Chromosome Positive CML?',\n",
       " 'Describe the intervention for Arms group 0 in the study, including dosage, administration, and duration of treatment.',\n",
       " 'Explain the criteria for achieving a complete cytogenetic response (CCyR) in patients with chronic phase Ph+ CML, as outlined in the context information. How is CCyR determined in terms of Ph+ metaphases and Bcr-Abl fusion product percentages?',\n",
       " 'Compare and contrast the eligibility criteria for inclusion and exclusion in the clinical trial for patients with chronic phase Ph+ CML. What are the key differences between the two sets of criteria, and why are they important in selecting participants for the study?',\n",
       " 'What was the reason for the termination of the study on CP-751,871 in combination with paclitaxel and carboplatin for patients with non-small cell lung cancer?',\n",
       " 'Describe the treatment arms in the study, including the interventions received by patients in each arm and the purpose of each arm in the trial.',\n",
       " 'What is the primary outcome measure in the study described in the context information? Provide a brief description of how this outcome is assessed and the time frame for assessment.',\n",
       " 'What are the eligibility criteria for patients to participate in the clinical trial involving Figitumumab, Paclitaxel, and Carboplatin? Provide examples of both inclusion and exclusion criteria mentioned in the document.',\n",
       " 'Explain the standard platinum-based doublet chemotherapy regimen used in the study, including the specific drugs administered and the treatment schedule.',\n",
       " 'What were the key findings of the study regarding the efficacy of CP-751,871 in the treatment of advanced non-adenocarcinoma non-small cell lung cancer (NSCLC)? What led to the early termination of the study?',\n",
       " 'What was the primary outcome measured in the clinical trial evaluating the efficacy and safety of fesoterodine in comparison to tolterodine extended release in patients with overactive bladder?',\n",
       " 'What were the inclusion criteria for adult subjects to participate in the 12-week, randomized, double-blind, placebo-controlled trial comparing fesoterodine to tolterodine extended release for overactive bladder?',\n",
       " 'What are the exclusion criteria for subjects participating in the study of fesoterodine, and why are these criteria important to consider?',\n",
       " 'Describe the recruitment details for participants with urgency incontinence Overactive Bladder (OAB) symptoms in the study. What were the different treatment groups and their respective descriptions?',\n",
       " 'Explain the statistical method used in the analysis of the treatment difference between fesoterodine and tolterodine ER at Week 12. How was the p-value adjusted in this analysis?',\n",
       " 'Why was the comparison between fesoterodine and tolterodine ER only performed if statistical significance favoring fesoterodine was achieved in the comparison with placebo? How was the overall alpha level maintained in this analysis?',\n",
       " 'What was the primary outcome measure in the study on neuromuscular changes in small for gestational age children during somatropin therapy, and how was it assessed?',\n",
       " 'Describe the intervention model and allocation method used in the study conducted by Pfizer on the effect of somatropin treatment in short children born small for gestational age.',\n",
       " 'Explain the eligibility criteria for participants in the study, including the specific age range, birth length/weight-SDS requirements, and growth velocity SDS criteria. Why were participants with prior GH treatment excluded from the study?',\n",
       " 'Compare and contrast the treatment regimens for the two recruitment groups (Somatropin and Control Arm) in terms of dosage, administration, and duration. How did the study design account for potential confounding variables such as baseline values and study duration in the analysis of the results?',\n",
       " 'What was the primary purpose of the study titled \"Genotropin Treatment In Very Young Children Born Small For Gestational Age\"?',\n",
       " 'What were the eligibility criteria for inclusion in the study, specifically regarding the age range, ethnicity, and birth characteristics of the subjects?',\n",
       " 'What are the exclusion criteria for participants in this study on small for gestational age (SGA) children, and why are these criteria important for the research?',\n",
       " 'Describe the recruitment process for the randomized controlled trial involving Genotropin and the untreated control group. How many participants were screened, and how many were ultimately randomized for the study?',\n",
       " 'What were the primary and secondary objectives of the study comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa in advanced renal cell carcinoma subjects?',\n",
       " 'Can you explain the primary outcome measure of the study, Progression-Free Survival (PFS), as defined in the context information provided?',\n",
       " 'Explain the eligibility criteria for participants in the study on advanced renal cell carcinoma (RCC) treatment. What were the key inclusion and exclusion criteria mentioned?',\n",
       " 'Describe the treatment regimens for the two recruitment groups in the study. What were the specific drugs administered and how often were they given to participants?',\n",
       " 'What was the primary purpose of the study titled \"Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder\" conducted by Pfizer?',\n",
       " 'Describe the eligibility criteria for participants in the study evaluating the safety and efficacy of Varenicline Tartrate for smoking cessation in subjects with schizophrenia and schizoaffective disorder.',\n",
       " 'Explain the eligibility criteria for participants in the study based on the provided context information. What are the specific criteria that must be met for individuals to be considered eligible to participate in the study?',\n",
       " 'Compare and contrast the treatment plans for the two recruitment groups (Varenicline and Placebo) in the study. What are the specific dosages and schedules for each group, and how do they differ in terms of administration?',\n",
       " 'What were the primary objectives of the study comparing celecoxib and tramadol in patients with chronic low back pain?',\n",
       " 'Describe the criteria used to determine a successful responder in the study based on the Numerical Rating Scale-Pain (NRS-Pain) at Week 6.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on chronic low back pain treatment?',\n",
       " 'Describe the recruitment groups and their respective treatment descriptions in the study comparing celecoxib and tramadol HCL for chronic low back pain.',\n",
       " 'What was the primary outcome measure in the study evaluating the efficacy and safety of bapineuzumab in patients with mild to moderate Alzheimer Disease?',\n",
       " 'What was the overall status of the study evaluating the efficacy and safety of bapineuzumab in Alzheimer Disease patients, and when was the primary completion date?',\n",
       " \"Explain the eligibility criteria for participants in the study of bapineuzumab for Alzheimer's Disease. What were the inclusion and exclusion criteria, and why were women of childbearing potential excluded from the study?\",\n",
       " 'Describe the primary outcome measure and the analysis method used in the study of bapineuzumab. How was the ADAS-Cog score calculated, and what did a negative change from baseline indicate in terms of cognitive impairment?',\n",
       " 'How was the Hochberg approach utilized in the analysis of the two dose levels (0.5 mg/kg and 1.0 mg/kg) of bapineuzumab in the study?',\n",
       " 'What were the limitations and caveats mentioned in the context information that may have impacted the interpretation of the study results?',\n",
       " 'What was the primary reason for the termination of the study on CP-751,871 in combination with erlotinib for patients with advanced non-small cell lung cancer of non-adenocarcinoma histology?',\n",
       " 'Describe the treatment plan for patients in Arm A of the study, which involved the combination of CP 751,871 and erlotinib.',\n",
       " 'What is the primary outcome measure in the study described in the context information? Provide a brief description of this outcome measure and the time frame for its assessment.',\n",
       " 'Describe the eligibility criteria for participants in the study. What are the inclusion criteria related to the type of non-small cell lung cancer, and what are some of the exclusion criteria mentioned?',\n",
       " 'What statistical method was used to analyze the data in the study mentioned in the context information?',\n",
       " 'What was the reported p-value for the study, and what significance level was used to determine statistical significance?',\n",
       " 'What is the primary outcome measure used in the study evaluating the safety and efficacy of Bapineuzumab in Alzheimer Disease patients?',\n",
       " 'Describe the study design, including the allocation, intervention model, masking, and enrollment count, of the trial evaluating Bapineuzumab in patients with mild to moderate Alzheimer Disease.',\n",
       " 'Explain the scoring system and items included in the ADAS-Cog/11 scale used in the study. How is cognitive impairment measured using this scale, and what does a negative change from baseline indicate?',\n",
       " 'Describe the eligibility criteria for participants in the study, including both inclusion and exclusion criteria. How were participants selected for enrollment, and what were the key requirements for their involvement in the research?',\n",
       " 'What was the primary purpose of the study comparing sunitinib in combination with prednisone versus placebo and prednisone in patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy?',\n",
       " 'How was the primary outcome, Overall Survival (OS), defined in this study, and what was the time frame for assessing this outcome?',\n",
       " 'What are the eligibility criteria for patients to participate in the clinical trial for progressive, metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy?',\n",
       " 'What were the key findings regarding the comparison between the treatment groups in terms of non-inferiority, as indicated by the p-value and hazard ratio in the clinical trial?',\n",
       " 'What is the primary outcome measured in the study on axitinib (AG-013736) as second-line therapy for metastatic renal cell cancer?',\n",
       " 'What was the overall status of the study on axitinib (AG-013736) as second-line therapy for metastatic renal cell cancer, and when was the completion date?',\n",
       " 'What are the eligibility criteria for patients to participate in the study on renal cell cancer treatment, specifically in terms of their cancer subtype, prior treatments, and timing of major surgeries or radiation?',\n",
       " 'Based on the group IDs provided, what was the statistical method used to compare progression-free survival (PFS) between the two treatment arms, and what was the hazard ratio (HR) value calculated for the comparison?',\n",
       " 'What was the primary purpose of the study evaluating Desvenlafaxine Succinate (DVS) Sustained Release for the treatment of Vasomotor Symptoms in menopausal women?',\n",
       " 'Describe the intervention plan for Arms group 0 in the study assessing the safety and efficacy of DVS SR for the treatment of Vasomotor Symptoms associated with menopause.',\n",
       " 'What were the inclusion criteria for participants in this study on the treatment of hot flushes in postmenopausal women?',\n",
       " 'How was the comparison between Desvenlafaxine Succinate Sustained Release (DVS SR) 100 mg and placebo conducted in terms of statistical analysis, and what was the result of this comparison?',\n",
       " 'What was the primary reason for the termination of the study comparing sunitinib malate versus sorafenib in patients with advanced hepatocellular carcinoma?',\n",
       " 'Describe the treatment plan for patients in Arm A (sunitinib arm) of the study, including dosing and criteria for discontinuation of treatment.',\n",
       " 'What are the eligibility criteria for participants to be included in this study on hepatocellular carcinoma treatment?',\n",
       " 'What dosing interruptions and/or reductions are allowed for the sorafenib intervention in this study?',\n",
       " 'What was the primary purpose of the study conducted by Pfizer in pediatric subjects with glaucoma?',\n",
       " 'Describe the primary outcome measure used in the Phase 3 study evaluating the efficacy and safety of latanoprost and timolol in pediatric subjects with glaucoma.',\n",
       " 'Explain the eligibility criteria for participants in the study on glaucoma treatment, including both the inclusion and exclusion criteria. How did these criteria help ensure the validity of the study results?',\n",
       " 'Describe the recruitment details provided in the context information. How did the randomization process contribute to the study design, and why was it important to stratify by age, diagnosis, and intraocular pressure of the study eye at baseline?',\n",
       " 'What was the primary purpose of the study titled \"Tanezumab in Osteoarthritis of the Knee\" conducted by Pfizer?',\n",
       " 'How was the efficacy of Tanezumab in patients with osteoarthritis of the knee measured in the study, according to the primary outcome described in the document?',\n",
       " 'Explain the eligibility criteria for participants in the study evaluating the effectiveness of tanezumab for osteoarthritis knee pain. What are the key inclusion and exclusion criteria that potential participants must meet?',\n",
       " 'Describe the primary outcome measure used in the study and how it is calculated. What is the significance of the WOMAC pain subscale score in assessing the efficacy of tanezumab for knee pain relief?',\n",
       " 'Explain the statistical method used in the study as described in the context information. How does ANCOVA help in analyzing the data in this particular research scenario?',\n",
       " 'Compare the results of the LS Mean Difference parameter between the two groups (OG000 and OG003) as presented in the context information. How do the confidence intervals and p-values contribute to the interpretation of the findings in terms of treatment effectiveness?',\n",
       " 'What was the primary purpose of the study on tanezumab in osteoarthritis of the hip conducted by Pfizer?',\n",
       " 'Describe the primary outcome measure used in the study, including its specific assessment and the timeframe for evaluation.',\n",
       " 'Explain the eligibility criteria for participants in the study on osteoarthritis of the hip, including the specific requirements related to pain levels, medication use, and willingness to undergo certain treatments.',\n",
       " 'Describe the primary outcome measures and time frame for assessment in the study comparing the effects of placebo and tanezumab on pain levels in individuals with osteoarthritis of the hip.',\n",
       " 'Explain the statistical method used in the analysis of the data presented in the context information. How does ANCOVA help in comparing the LS Mean Difference between different groups?',\n",
       " 'Discuss the significance of the LS Mean Difference value of -1.69 and -1.75, along with their corresponding confidence intervals, in the context of the study results. How do these values support the conclusion of superiority or other legacy non-inferiority in the study?',\n",
       " 'What was the primary purpose of the study titled \"Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis\" conducted by Pfizer?',\n",
       " 'Describe the primary outcome measure used in the study to evaluate the efficacy of celecoxib versus diclofenac SR in Chinese patients with Ankylosing Spondylitis.',\n",
       " 'Explain the eligibility criteria for participants in the study comparing Celecoxib 200 mg to Diclofenac SR 75 mg for the treatment of Ankylosing Spondylitis. What were the key inclusion and exclusion criteria?',\n",
       " 'Discuss the statistical analysis method used in the study and the results obtained. What was the p-value for the comparison between Celecoxib and Diclofenac, and how was non-inferiority determined in this analysis?',\n",
       " 'What was the primary outcome measure in the study on Sitaxsentan for subjects with pulmonary arterial hypertension? Provide a brief description of how this outcome measure was assessed.',\n",
       " 'What were the inclusion criteria for participants in the study on Sitaxsentan efficacy and safety in subjects with pulmonary arterial hypertension? Specifically, what were the diagnostic criteria for pulmonary arterial hypertension and the symptom classification required for inclusion in the study?',\n",
       " 'What are the exclusion criteria for this study involving patients with WHO functional class III symptoms? Why is previous exposure to an endothelin receptor antagonist (ETRA) such as sitaxsentan, bosentan, or ambrisentan considered an exclusion criterion?',\n",
       " 'Describe the recruitment groups for this study. What are the titles and descriptions of the two recruitment groups, and what is the purpose of each group in the study?',\n",
       " 'What is the primary objective of the study titled \"A Phase 3, Multi-Center, Randomized, Double-Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001 (NCT00795639)\"?',\n",
       " 'Why was the study on combination therapy (Sitaxsentan+Sildenafil) versus monotherapy (Sitaxsentan alone) terminated, according to the information provided?',\n",
       " 'What is the primary outcome measure of the study described in the context information? Provide a detailed explanation of how this outcome is defined and measured.',\n",
       " 'Describe the eligibility criteria for participants in the study. What are the specific inclusion and exclusion criteria mentioned in the document?',\n",
       " 'Explain the recruitment groups involved in the study, including the medications administered and dosages for each group. What was the purpose of comparing these specific groups in the study?',\n",
       " 'Discuss the statistical analysis conducted in the study, including the p-value, statistical method used, and the interpretation of the results. What limitations and caveats were mentioned in the context information that may impact the study findings?',\n",
       " 'What was the primary purpose of the study evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the treatment of Major Depressive Disorder?',\n",
       " 'Describe the primary outcome measure used in the study and explain its significance in assessing the efficacy of the treatment.',\n",
       " 'Explain the eligibility criteria for participants in the study, including the required scores on the Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) and the Clinical Global Impressions Scale-Severity (CGI-S). How were participants with a significant risk of suicide excluded from the study?',\n",
       " 'Describe the pre-assignment details of the study, including the number of potential participants screened, the number enrolled, and the treatment received during the screening period prior to randomization. How did this pre-assignment phase contribute to the overall study design?',\n",
       " 'What was the primary purpose of the study conducted by Pfizer on pregabalin in patients with idiopathic Restless Legs Syndrome (RLS)?',\n",
       " 'Describe the primary outcome measure used in the study to assess the severity of Restless Legs Syndrome symptoms in the participants.',\n",
       " 'What are the inclusion criteria for participants in this study on idiopathic Restless Leg Syndrome (RLS)?',\n",
       " 'Describe the treatment regimen for the recruitment group receiving Pregabalin 300 mg in the study.',\n",
       " 'What is the primary purpose of the study evaluating the effects of Bazedoxifene/Conjugated Estrogens on endometrial safety and postmenopausal osteoporosis?',\n",
       " 'Describe the intervention for Arms group 1 in the study, including the dosage and frequency of administration.',\n",
       " 'Explain the primary outcome of the study regarding endometrial hyperplasia assessment at Month 12. What were the two definitions used to determine the presence of hyperplasia, and how were the results summarized?',\n",
       " 'Describe the eligibility criteria for participants in the study. What were the inclusion criteria related to age, menopausal status, and uterine health? Additionally, what were some of the exclusion criteria mentioned, such as the use of certain medications and medical history restrictions?',\n",
       " 'What was the primary purpose of the study mentioned in the context information, and why was it terminated?',\n",
       " 'Can you explain the significance of the US FDA clinical hold on tanezumab osteoarthritis clinical studies and how it impacted the study mentioned in the document?',\n",
       " 'What is the primary outcome measure in this study on osteoarthritis and arthritis treatment, and how is it assessed?',\n",
       " 'What are the inclusion criteria for patients participating in this study on tanezumab and NSAID treatment for osteoarthritis of the knee or hip?',\n",
       " 'What are the exclusion criteria for participants in this study on osteoarthritis pain management? Provide at least three criteria mentioned in the context information.',\n",
       " 'Describe the treatment plan for participants in the recruitment group receiving tanezumab 10 mg with naproxen exposure. Include details about the dosages and administration schedule mentioned in the document.',\n",
       " 'What statistical method was used for the analysis in the study described in the context information?',\n",
       " 'Compare the results of the LS Mean Difference between group OG001 and group OG004 with the results of the LS Mean Difference between group OG000 and group OG002. What can be inferred from these comparisons?',\n",
       " 'In the analysis based on the ANCOVA model with treatment, baseline value, and index joint as covariates, what was the LS Mean Difference for the comparison between groups OG008 and OG009? Provide the confidence interval values as well.',\n",
       " 'What statistical method was used in the analysis comparing groups OG001 and OG003? Describe the non-inferiority type and provide the p-value for this comparison.',\n",
       " 'Explain the statistical method used in the analysis described in the context information. How does this method help in comparing the treatment groups?',\n",
       " 'Compare the results of the LS Mean Difference parameter for the treatment groups OG005 and OG009 with the corresponding confidence intervals. What conclusions can be drawn from this comparison in terms of non-inferiority or superiority?',\n",
       " 'What is the statistical method used in the study, and what was the p-value obtained from the analysis?',\n",
       " 'What is the confidence interval (CI) for the LS Mean Difference in the study, and what does the CI range suggest about the results in relation to the null hypothesis?',\n",
       " 'What is the primary purpose of the Phase 3 study comparing two doses of CP-690,550 vs. placebo for the treatment of Rheumatoid Arthritis?',\n",
       " 'Describe the primary outcome measure used in the study, specifically focusing on the criteria for achieving an American College of Rheumatology 20% (ACR20) response at Month 3.',\n",
       " 'What are the inclusion criteria for patients participating in the study on RA treatment with CP-690,550?',\n",
       " 'How were the different doses of CP-690,550 compared to placebo in terms of efficacy, and what statistical method was used for the analysis?',\n",
       " 'Explain the significance of the p-value \"<0.0001\" in the context of the statistical analysis conducted using the normal approximation method. How does this value impact the interpretation of the results?',\n",
       " 'Calculate the percent difference between the two groups mentioned in the context information, and determine if the confidence interval of 95% (with a two-sided approach) supports the conclusion drawn from the analysis. Justify your answer with reference to the lower and upper limits of the confidence interval.',\n",
       " 'What was the primary purpose of the study titled \"Tanezumab In Osteoarthritis Of The Knee (2)\" conducted by Pfizer?',\n",
       " 'How was the efficacy and safety of tanezumab compared with naproxen and placebo tested in patients with osteoarthritis in the study with National Clinical Identification NCT ID NCT00830063?',\n",
       " 'Explain the eligibility criteria for participants in the study, including both inclusion and exclusion criteria. How did these criteria help ensure the validity of the study results?',\n",
       " 'Describe the recruitment groups in the study, including the treatments received by participants in each group. How were the outcomes compared between these groups, and what statistical methods were used for analysis?',\n",
       " 'Explain how the 95% confidence interval was calculated for the LS mean difference in the first group, and what the lower and upper limits of the interval represent in this context.',\n",
       " 'Compare the p-values obtained from the ANCOVA analysis for the two groups mentioned in the document. Discuss the implications of these p-values in relation to the non-inferiority type specified for each group.',\n",
       " 'What was the primary purpose of the study titled \"Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia\" conducted by Pfizer?',\n",
       " 'How was the primary outcome of the study measured, and what specific scale was used to assess daily pain scores in patients with fibromyalgia?',\n",
       " 'Explain the eligibility criteria for participants in the study comparing placebo and pregabalin for fibromyalgia treatment. What were the inclusion and exclusion criteria that participants had to meet in order to be eligible for the study?',\n",
       " 'Discuss the recruitment details for the study comparing placebo and pregabalin for fibromyalgia treatment. How were participants assigned to either the Placebo group or the Pregabalin group, and what was the administration schedule for each treatment group?',\n",
       " 'What was the primary objective of the study conducted by Pfizer regarding two different Tick-Borne Encephalitis (TBE) vaccines in children aged 1-11 years?',\n",
       " 'Can you explain the vaccination schedule and interventions followed in the study, including the types of vaccines administered and the timing of each dose for the participants?',\n",
       " 'What are the inclusion criteria for male and female children to participate in the study regarding TBE vaccination?',\n",
       " 'What are the exclusion criteria for subjects to be excluded from participation in the study on TBE vaccination?',\n",
       " 'What were the two recruitment groups in the study, and what vaccines did participants receive in each group according to the conventional immunization schedule?',\n",
       " 'How was the non-inferiority of seropositive response rate tested in the study, and what was the p-value obtained from the statistical method used?',\n",
       " 'What was the primary purpose of the Phase 3 study of CP-690,550 in patients with active rheumatoid arthritis on background methotrexate conducted by Pfizer?',\n",
       " 'Describe the primary outcome measure used in the study to assess the efficacy of CP-690,550 in patients with rheumatoid arthritis.',\n",
       " 'What are the inclusion and exclusion criteria for participants in this study on rheumatoid arthritis treatment?',\n",
       " 'How was the statistical significance of the different doses of CP-690,550 compared to placebo determined in this study, and what were the results of the comparison?',\n",
       " 'What is the primary purpose of the Phase 3 study comparing CP 690,550, Humira, and placebo in patients with Rheumatoid Arthritis?',\n",
       " 'Can you explain the significance of including an active comparator, adalimumab, in the study design?',\n",
       " 'What are the inclusion criteria for patients participating in the study on rheumatoid arthritis treatment with CP-690,550?',\n",
       " 'Describe the primary outcome measure used in the study and explain how it is assessed in participants with rheumatoid arthritis.',\n",
       " 'What are the eligibility criteria for patients to participate in the study, specifically in relation to their history of infection, previous TNFi treatment, and contraindications for adalimumab therapy?',\n",
       " 'Can you explain the recruitment groups and their corresponding treatments in the study, including the dosages of CP-690,550 and adalimumab, as well as the administration schedule up to Month 12?',\n",
       " 'Explain the statistical method used in the analysis and how it relates to the calculation of the percent difference with a 95% confidence interval.',\n",
       " 'Discuss the significance of the p-value being less than 0.0001 in the context of the study and how it impacts the interpretation of the results.',\n",
       " 'What is the primary objective of the Phase 3 study involving CP-690,550 in patients with active rheumatoid arthritis?',\n",
       " 'Can you explain the significance of the completion date and verification date in the context of the study conducted by Pfizer on CP-690,550 for the treatment of rheumatoid arthritis?',\n",
       " 'What are the inclusion criteria for patients to participate in the clinical trial for Rheumatoid Arthritis involving CP-690,550?',\n",
       " 'Describe the primary outcome measure used in the study, including the specific criteria for achieving an ACR20 response at Month 6.',\n",
       " 'What are the two recruitment groups in the study, and what are the respective doses of CP-690,550 being administered to participants in each group?',\n",
       " 'What statistical method was used to analyze the data in this study, and what was the p-value obtained for the comparison between the two doses of CP-690,550?',\n",
       " 'What was the primary outcome measure in the study testing the efficacy and safety of tanezumab in patients with osteoarthritis of the hip or knee?',\n",
       " 'What was the overall status of the clinical study involving tanezumab in osteoarthritis patients conducted by Pfizer?',\n",
       " 'What is the total score range for the WOMAC pain subscale score in this study, and what does a higher score indicate?',\n",
       " 'What were the eligibility criteria for participants in this study, and what were some of the exclusion criteria mentioned?',\n",
       " 'Explain the statistical method used in the analysis described in the context information. How does ANCOVA help in comparing the treatment groups while controlling for covariates and random effects?',\n",
       " 'Compare the results of the LS Mean Difference between group OG001 and OG003 with a p-value of 0.009 to the results between group OG002 and OG003 with a p-value of 0.175. Discuss the implications of these findings in terms of treatment effectiveness and statistical significance.',\n",
       " 'What was the primary outcome measure in the study on tanezumab and nerve function in arthritis patients, and how was it assessed?',\n",
       " 'Why was the study on tanezumab terminated, and what were the implications of the US FDA clinical hold on the clinical trials involving tanezumab for osteoarthritis patients?',\n",
       " 'Explain the eligibility criteria for participants in the study of Tanezumab for osteoarthritis pain relief. What are some of the key inclusion and exclusion criteria that potential participants must meet or avoid?',\n",
       " 'Describe the primary outcome measures and time frame for the study on Tanezumab. How are the values of attributes scored and what do positive and negative scores indicate in terms of response to treatment?',\n",
       " 'What statistical method was used in the analysis of the data presented in the context information? What was the p-value obtained from this analysis?',\n",
       " 'What limitations and caveats were mentioned in the context information regarding the study? How did these limitations impact the study results?',\n",
       " 'What was the primary purpose of the study mentioned in the context information, and why was it terminated?',\n",
       " 'Can you explain the significance of the US FDA clinical hold on tanezumab osteoarthritis clinical studies and how it impacted the study mentioned in the document?',\n",
       " 'What is the primary outcome measure in this study on osteoarthritis treatment with tanezumab and diclofenac? Describe the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score and how it is assessed at Week 16.',\n",
       " 'What are the inclusion criteria for patients to participate in this study on osteoarthritis treatment with tanezumab and diclofenac? Explain the requirements related to the diagnosis of osteoarthritis, current medication regimen, pain and function levels, and use of non-study pain medications.',\n",
       " 'What are the exclusion criteria for participants in the study on osteoarthritis of the knee or hip, specifically related to medical history and conditions that may affect the assessment of pain associated with OA?',\n",
       " 'Describe the recruitment details for participants in the study, including the medication regimen they were required to follow prior to randomization.',\n",
       " 'What statistical method was used to analyze the data in the study mentioned in the context information?',\n",
       " 'What limitation affected the study mentioned in the context information, leading to the premature termination of further study drug dosing?',\n",
       " 'What was the primary purpose of the study evaluating on-demand treatment with Xyntha in Chinese subjects with hemophilia A?',\n",
       " 'Describe the primary outcome measure used in the study, specifically focusing on the Investigator Hemostatic Efficacy Assessment 8 Hours Post Infusion.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on Xyntha for hemophilia A treatment?',\n",
       " 'How were participants recruited for the study on Xyntha in China, and what was the treatment regimen they received during the active phase of the study?',\n",
       " 'What was the primary outcome measured in the study on the effects of Pregabalin on sleep maintenance in subjects with fibromyalgia?',\n",
       " 'What was the enrollment count for the study, and what were the arms groups involved in the intervention?',\n",
       " 'What are the inclusion criteria for subjects participating in the study on fibromyalgia and insomnia disorder?',\n",
       " 'How were the secondary outcome measures analyzed in the study, and what was the rationale behind this approach according to the limitations and caveats mentioned in the context information?',\n",
       " 'What is the primary purpose of the study described in the context information, and what is the study design used to evaluate the efficacy and safety of desvenlafaxine succinate sustained release in adults with Major Depressive Disorder?',\n",
       " 'Can you explain the treatment protocol for subjects participating in the study, including the duration of the open-label period, the criteria for withdrawal from the study, and the randomization process for subjects who demonstrate a stable response to treatment?',\n",
       " 'What is the primary outcome measure of the study and how is it defined? Provide details on the time frame for assessing this outcome.',\n",
       " 'Describe the eligibility criteria for participants in the study, including both inclusion and exclusion criteria. How many participants were enrolled in the Desvenlafaxine succinate sustained release open-label response phase?',\n",
       " 'In the study described, what was the treatment regimen for subjects in the \"DVS SR 50 mg (Open-label Phase)\" group during the 20-week open-label phase?',\n",
       " 'What statistical method was used to analyze the data in the study, and what was the significance level for declaring statistical significance?',\n",
       " 'What was the primary objective of the study on Quillivant XR oral suspension in pediatric patients with ADHD?',\n",
       " 'Describe the primary outcome measure used in the study and explain how it assessed the manifestations of ADHD in the participants.',\n",
       " 'What were the inclusion criteria for participants in this study on ADHD medication?',\n",
       " 'Describe the pre-assignment details of the study design, including the phases involved and any dose adjustments mentioned.',\n",
       " 'Explain the treatment plan for participants in recruitment group 1, including the dosing schedule and duration of each intervention period.',\n",
       " 'How were treatment comparisons for observed scores analyzed in the study, and what was the key finding in terms of the efficacy of NWP06 compared to placebo?',\n",
       " 'What is the primary purpose of the Phase 3 trial involving the investigational drug PF-02341066 in patients with advanced non-small cell lung cancer?',\n",
       " 'How many arms were involved in the study comparing PF-02341066 versus pemetrexed or docetaxel, and what were the intervention names for each arm?',\n",
       " 'What is the primary outcome measure in this clinical trial, and how is it defined and calculated?',\n",
       " 'What are the inclusion criteria for patients to be eligible for participation in this study, specifically regarding their diagnosis and prior treatment history?',\n",
       " 'What was the statistical significance level for the analysis conducted using the Log Rank method, and why was it set at a one-sided alpha of 0.025?',\n",
       " 'What limitations and caveats were mentioned in the study regarding the analysis of ALK fusion variants and protein expression, and why were these analyses not conducted?',\n",
       " \"What is the primary purpose of the study mentioned in the context information? Provide a brief explanation of the study's focus and objectives.\",\n",
       " 'Describe the primary outcome measure used in the study. What criteria need to be met for a participant to achieve the American College of Rheumatology 20% (ACR20) response at Month 3?',\n",
       " 'What were the inclusion criteria for participants in the study comparing CP-690,550 with placebo for the treatment of rheumatoid arthritis?',\n",
       " 'Describe the statistical method used to analyze the superiority of CP-690,550 10 mg and 5 mg compared to placebo in the study.',\n",
       " 'What was the primary outcome measured in the study on MDV3100 in patients with castration-resistant prostate cancer who had previously been treated with docetaxel-based chemotherapy?',\n",
       " 'What were the eligibility criteria for patients to participate in the phase 3 study comparing the clinical benefit of MDV3100 versus placebo in castration-resistant prostate cancer patients?',\n",
       " 'What are the eligibility criteria for participants to be included in the study of Enzalutamide versus Placebo in patients with certain cancer types?',\n",
       " 'What were the primary objectives of the study comparing Enzalutamide versus Placebo, and what were the key findings in terms of statistical significance and clinical outcomes?',\n",
       " 'What was the primary purpose of the study on tanezumab in patients with osteoarthritis of the knee or hip conducted by Pfizer?',\n",
       " 'Why was the study on tanezumab terminated in December 2010, according to the detailed description provided in the context information?',\n",
       " 'Explain the eligibility criteria for participants in the study based on the information provided. How did these criteria impact the selection of participants for the research?',\n",
       " 'Describe the primary outcome time frame for the study and discuss how the change in the primary time-point from Week 16 to Week 8 affected the analysis of the results.',\n",
       " 'What was the primary purpose of the study described in the context information provided?',\n",
       " 'Can you explain the primary outcome measure, Wake After Sleep Onset (WASO), as described in the study?',\n",
       " 'What are the inclusion criteria for participants in this study on restless legs syndrome?',\n",
       " 'Describe the intervention schedule for participants in the \"Placebo Then Pramipexole 0.5 mg Then Pregabalin 300 mg\" recruitment group.',\n",
       " 'Explain the significance of the PBO wash-out period of 7 days between each period in the study. How does this impact the validity of the results obtained?',\n",
       " 'Compare and contrast the statistical methods used in the analysis of Group IDs OG000 vs. OG002 and Group IDs OG000 vs. OG001. How do the results and confidence intervals differ between these comparisons?',\n",
       " 'What was the primary purpose of the study involving bapineuzumab in Alzheimer Disease patients, as described in the context information?',\n",
       " 'How was safety measured in the study, and what was the primary outcome related to safety that was assessed in the participants?',\n",
       " 'What were the eligibility criteria for participants in the extension study 3133K1-3002 of the bapineuzumab program?',\n",
       " 'Why were efficacy results obtained after Week 78 not presented in the study results of the bapineuzumab program extension study?',\n",
       " \"What was the primary purpose of the study described in the context information, and how long was each subject's participation expected to last?\",\n",
       " 'How was safety measured in the study, and what specific outcome was the primary focus in terms of adverse events reported by participants?',\n",
       " \"What are the inclusion criteria for subjects participating in this study's extension phase, as outlined in the context information?\",\n",
       " 'Describe the recruitment details of the study, including the number of centers involved, the countries where the study was conducted, and the reason for its early termination by the sponsor.',\n",
       " 'What is the primary purpose of the study evaluating the antibody response of the 13-valent pneumococcal conjugate vaccine 24 months after the toddler dose?',\n",
       " 'How many arms were involved in the study, and what intervention was administered in Arm group 0?',\n",
       " 'What are the inclusion criteria for participants in the study evaluating the Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration one month after receiving a single dose of the 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine?',\n",
       " 'Describe the recruitment groups and their corresponding descriptions in the study involving the administration of a single dose of the 13-valent pneumococcal conjugate (13vPnC) vaccine two years after completing a full schedule of pneumococcal conjugate vaccine doses.',\n",
       " 'Explain the significance of calculating the GMC ratio and the confidence interval for the GMC ratio in the context of comparing different pneumococcal vaccines for serotypes 4 and 6B. How does the GMC ratio help in assessing the effectiveness of the vaccines?',\n",
       " 'Compare and contrast the results of the GMC ratio calculations for serotypes 4 and 6B between groups OG000 and OG002. Discuss the implications of these findings in terms of vaccine efficacy and potential differences in immune response.',\n",
       " 'Explain the process of calculating the confidence interval (CI) for the geometric mean concentration (GMC) ratio in the context of the study mentioned in the document. Provide an example using one of the serotypes mentioned.',\n",
       " 'Discuss the significance of testing for non-inferiority in the context of the study described in the document. How does the determination of non-inferiority impact the interpretation of the results for vaccine efficacy?',\n",
       " 'Explain the significance of the GMC ratio in the context of the given information. How is it calculated and why is it important in comparing different measures?',\n",
       " 'Compare and contrast the non-inferiority testing results for Serotype 14 and Serotype 18C based on the GMC ratios provided in the document. Discuss the implications of the confidence intervals for each serotype.',\n",
       " 'Explain the significance of the GMC ratio in the context of the study mentioned in the document. How was the GMC ratio calculated for the different group comparisons?',\n",
       " 'Compare and contrast the results of the GMC ratio for Serotype 19F and Serotype 23F based on the confidence intervals provided in the document. Discuss any implications of these findings in the context of the study.',\n",
       " 'Explain the significance of the GMC ratio in the context of the given information. How is it calculated and what does it indicate about the measures being compared?',\n",
       " 'Compare and contrast the non-inferiority testing results for Serotype 23F and Serotype 1 based on the GMC ratio and confidence intervals provided in the document. What conclusions can be drawn from these results in terms of vaccine effectiveness?',\n",
       " 'Explain how the confidence interval for the geometric mean concentration (GMC) ratio was calculated for Serotype 3 in the given context information.',\n",
       " 'Compare the GMC ratios for Serotype 5 between different groups as described in the context information. What can be inferred from the confidence intervals provided for these comparisons?',\n",
       " 'What is the GMC ratio for Serotype 6A when comparing the measures of 13vPnC/13vPnC/13vPnC to 7vPnC/7vPnC/13vPnC? Provide the confidence interval values for this comparison.',\n",
       " 'How does the GMC ratio for Serotype 7F differ when comparing the measures of 13vPnC/13vPnC/13vPnC to 7vPnC/7vPnC/13vPnC compared to 7vPnC/13vPnC/13vPnC? Include the confidence interval values in your explanation.',\n",
       " 'Explain the significance of the GMC ratio in the context of the study mentioned in the document. How was the confidence interval (CI) for the GMC ratio calculated for different serotypes?',\n",
       " 'Discuss the non-inferiority type mentioned in the document and how it relates to the GMC ratio values for different group comparisons. How does the back transformation of CI based on the Student t distribution play a role in determining non-inferiority in this study?',\n",
       " 'What was the primary outcome measure in the study evaluating the efficacy of a novel ibuprofen formulation on fever in patients with an uncomplicated acute infection?',\n",
       " 'What were the inclusion criteria for subjects participating in the study, and what were the exclusion criteria that would disqualify individuals from participating?',\n",
       " 'Explain the eligibility criteria for participation in the study based on the provided context information. How does pregnancy, breast-feeding, serious medical or psychiatric disorders, and age factor into the eligibility requirements?',\n",
       " 'Discuss the recruitment groups and their respective descriptions in the study. What were the differences between the Placebo group and the Ibuprofen Sodium group in terms of dosage and treatment? Additionally, explain the statistical analysis method used to compare the two groups and the limitations mentioned in the study results.',\n",
       " 'What is the primary purpose of the study comparing the effectiveness and safety of CP-690,550 to methotrexate in patients with rheumatoid arthritis who have not previously received methotrexate?',\n",
       " 'Describe the primary outcome measure used in this study and explain its significance in evaluating the effectiveness of the experimental drug CP-690,550 compared to methotrexate.',\n",
       " 'What are the inclusion criteria for participants in this study on Rheumatoid Arthritis (RA) treatment with methotrexate? How are these criteria defined in terms of joint pain, joint swelling, and inflammatory markers?',\n",
       " 'Describe the treatment regimens for the two recruitment groups in the study, including the dosage and frequency of administration for CP-690,550 and methotrexate.',\n",
       " 'What was the primary purpose of the study mentioned in the context information, and why was it terminated?',\n",
       " 'Describe the primary outcome measure of the study and how it was assessed in participants with HIV neuropathy.',\n",
       " 'What are the inclusion criteria for participants in this study on HIV-associated Distal Symmetrical Polyneuropathy (DSP) with subjective sensory symptom of pain?',\n",
       " 'Describe the treatment regimen for participants in the Pregabalin group during the 16-week study period.',\n",
       " 'What statistical method was used in the study to analyze the data?',\n",
       " 'Why was the study terminated on April 2, 2012, according to the limitations and caveats provided?',\n",
       " 'What was the primary purpose of the study titled \"A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY\" conducted by Pfizer?',\n",
       " \"How was the primary outcome of the study measured, and what scale was used to assess the participants' diabetic peripheral neuropathy pain levels during the double-blind phase?\",\n",
       " 'Explain the eligibility criteria for patients to participate in the study on painful diabetic peripheral neuropathy. What are the inclusion and exclusion criteria mentioned in the document?',\n",
       " 'Describe the recruitment process for participants in the study on pregabalin treatment for diabetic peripheral neuropathy. What were the specific requirements for participants to be eligible for the double-blind treatment phase?',\n",
       " 'What was the primary purpose of the study titled \"Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation\" conducted by Pfizer?',\n",
       " 'How was the primary outcome of the study measured, and what specific parameter was used to assess the change from baseline in annual growth rate in the participants treated with Genotonorm?',\n",
       " 'Explain the eligibility criteria for participants in the study on growth hormone treatment. What are the inclusion and exclusion criteria specified for the subjects?',\n",
       " 'Discuss the recruitment groups and treatment descriptions in the study. What were the differences between the Genotonorm 0.7 and Genotonorm 1.4 continuous treatment groups, and how were they administered to the subjects?',\n",
       " 'What was the primary outcome measure used in the study evaluating a novel ibuprofen formulation in the treatment of episodic tension-type headache?',\n",
       " 'Describe the arms groups and interventions used in the study comparing the novel ibuprofen formulation to standard ibuprofen and placebo in the treatment of episodic tension-type headache.',\n",
       " 'What are the inclusion criteria for participants in this study on episodic tension-type headaches?',\n",
       " 'Based on the recruitment details provided, what are the differences between the placebo and ibuprofen sodium treatment groups in terms of dosage and composition?',\n",
       " 'What was the primary purpose of the study evaluating a novel ibuprofen formulation in the treatment of post-surgical dental pain?',\n",
       " 'Describe the primary outcome measure used in the study and explain how it was calculated.',\n",
       " 'Explain the eligibility criteria for participants in the study on post-operative pain relief following surgical extraction of third molars. What are the inclusion and exclusion criteria specified in the document?',\n",
       " 'The study compared the efficacy of ibuprofen sodium versus a placebo in managing post-operative pain. Based on the provided information, describe the recruitment groups, including the description of the placebo and ibuprofen sodium treatments. What statistical method was used to analyze the results, and what was the p-value obtained for the comparison between the two treatments?',\n",
       " 'What was the primary purpose of the study comparing 0.3 mg Pegaptanib Sodium to sham injections in subjects with diabetic macular edema?',\n",
       " 'Describe the issue that was reported during the study regarding the maintenance of treatment masking, as mentioned in the detailed description section.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on diabetic macular edema treatment with pegaptanib sodium?',\n",
       " 'What statistical method was used to analyze the data comparing the efficacy of pegaptanib sodium and sham injection in the treatment of macular edema, and what was the resulting p-value?',\n",
       " 'What was the primary objective of the study evaluating Azithromycin Plus Chloroquine and Sulfadoxine Plus Pyrimethamine combinations for intermittent preventive treatment of Falciparum Malaria in pregnant women in Africa?',\n",
       " 'Why was the study terminated after an interim analysis of efficacy data by an External Data Monitoring Committee, and what was the notification date to the investigators regarding this termination?',\n",
       " 'What are the eligibility criteria for pregnant women to participate in the study mentioned in the context information? Provide examples of both inclusion and exclusion criteria.',\n",
       " 'Describe the treatment regimen for participants in the \"Azithromycin + Chloroquine\" recruitment group as outlined in the recruitment details. How many treatments are administered and at what intervals?',\n",
       " 'What was the treatment regimen for participants in recruitment group 1, \"Sulfadoxine + Pyrimethamine\"? How many treatments were administered and at what intervals?',\n",
       " 'Why was the program terminated by Pfizer, according to the limitations and caveats mentioned in the document?',\n",
       " 'What was the primary purpose of the study comparing the new Genotropin Mark VII pen to the current Genotropin pen in pediatric and adult subjects?',\n",
       " 'Describe the arms groups and intervention plans for the participants in the study assessing the convenience and preference of the newly developed Genotropin Mark VII pen.',\n",
       " 'Explain the primary outcome of the study regarding the comparison between the Genotropin Pen and the new Genotropin Mark VII Injection Pen. What question was asked to participants to assess this outcome, and what were the response options provided to them?',\n",
       " 'Describe the eligibility criteria for participants in the study. What were the inclusion criteria for subjects, and what were the exclusion criteria? Additionally, why were subjects with Prader-Willi syndrome or chronic renal insufficiency excluded from the study?',\n",
       " 'What is the primary outcome measured in the clinical trial comparing the efficacy of crizotinib versus standard chemotherapy in patients with ALK positive lung cancer?',\n",
       " 'What was the overall status of the study as of the verification date in September 2017?',\n",
       " 'What are the eligibility criteria for patients to participate in the study comparing Crizotinib and chemotherapy for locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer with ALK gene locus involvement?',\n",
       " 'Describe the treatment regimens for the two recruitment groups in the study, including the dosages and administration schedules for Crizotinib and chemotherapy.',\n",
       " 'Explain the administration protocol for the combination treatment of pemetrexed and either cisplatin or carboplatin as described in the context information. What are the specific doses and timing of each drug infusion?',\n",
       " 'Based on the statistical analysis provided in the context information, discuss the significance of the p-value obtained from the 1-sided log rank test in comparing progression-free survival (PFS) between the two treatment arms. What does the hazard ratio of 0.454 indicate in terms of treatment efficacy?',\n",
       " 'What were the primary objectives of the study evaluating the effects and safety of treatment, treatment withdrawal, and re-treatment with CP-690,550 in subjects with moderate to severe chronic plaque psoriasis?',\n",
       " 'Can you explain the significance of comparing the efficacy responses of CP-690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of treatment and subsequent withdrawal of active treatment in the study conducted by Pfizer?',\n",
       " 'Explain the primary outcome measure in the study, which focuses on the Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period. How is the PASI score calculated and what does it indicate about the severity of psoriasis in participants?',\n",
       " 'Describe the treatment arms in the study for participants with Psoriasis. What are the differences between the two arms in terms of the duration and type of treatment received, as well as the intervention model and masking used in the study?',\n",
       " 'What are the inclusion criteria for participants in this study on plaque-type psoriasis, as outlined in the eligibility criteria section?',\n",
       " 'How were participants in the study divided into different recruitment groups based on the dosage of CP-690,550 they received during Period A (Initial Treatment)?',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'How is overall survival defined in the study, and what factors determine when overall survival data is censored for analysis?',\n",
       " 'What are the inclusion criteria for patients participating in the randomized, double-blind treatment period of the study? Provide at least three criteria mentioned in the document.',\n",
       " 'Explain the significance of the hazard ratio value of 0.706 in the study results, as described in the group IDs section of the context information. What does a hazard ratio of less than 1 favoring enzalutamide indicate in comparison to placebo?',\n",
       " 'Explain the significance of the p-value being less than 0.0001 in the context of the statistical analysis method used (Log Rank). How does this p-value impact the interpretation of the results?',\n",
       " 'Discuss the importance of considering limitations and caveats in a research study. In this specific case, why is it important to acknowledge any potential limitations or caveats despite the results being statistically significant?',\n",
       " 'What was the primary purpose of the study evaluating a novel ibuprofen formulation in the treatment of post-surgical dental pain?',\n",
       " 'Describe the primary outcome measure used in the study and explain how it was calculated.',\n",
       " 'What are the inclusion criteria for participants in the study on post-operative pain relief following surgical extraction of third molars?',\n",
       " 'Describe the recruitment groups and their respective descriptions in the study on the effectiveness of ibuprofen sodium for post-operative pain relief.',\n",
       " 'Explain the statistical method used in the analysis of the treatment difference between Acetaminophen and Placebo. How was the p-value calculated and what does it indicate about the results?',\n",
       " 'Describe the approach taken to control Type I error at a 5% significance level in the comparison of co-primary endpoints sequentially for IBU Na vs PBO, IBU Na vs APAP, and APAP vs PBO for SPRID 0-6 and time to meaningful relief. How was the significance of subsequent comparisons determined based on the results of preceding steps?',\n",
       " 'What is the primary objective of the study involving inotuzumab ozogamicin plus rituximab for relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not candidates for intensive high-dose chemotherapy?',\n",
       " \"Can you explain the significance of the study's termination status and its implications on the evaluation of the efficacy of the treatment combination?\",\n",
       " 'What is the primary outcome measure of the study described in the context information? Provide a brief explanation of how this outcome is defined and measured.',\n",
       " 'Describe the treatment arms in the study, including the interventions used in each arm and the number of cycles administered. How do the two arms differ in terms of treatment options for participants with Non-Hodgkin lymphoma?',\n",
       " 'Explain the two treatment options given to participants in the study, including the dosages and administration schedules for each option.',\n",
       " 'Discuss the statistical analysis conducted in the study, including the primary null hypothesis, the statistical method used, and the interpretation of the results based on the hazard ratio and confidence interval provided.',\n",
       " 'What was the primary outcome measured in the study \"Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens\"? Provide a brief description of how this outcome was assessed and the time frame for measurement.',\n",
       " 'What were the inclusion and exclusion criteria for participants in the study on the long-term efficacy of exemestane compared to megestrol acetate in the treatment of postmenopausal women with advanced breast cancer? Specifically, what was the key requirement for inclusion, and who was excluded from the study?',\n",
       " 'What are the eligibility criteria for participants in this study in terms of sex and age?',\n",
       " 'What were the recruitment groups and their respective descriptions in this study?',\n",
       " 'What is the primary completion date of the study comparing Etanercept against a placebo for Etanercept on a background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the treatment of early Spondyloarthritis patients who do not have X-ray structural changes?',\n",
       " 'What is the enrollment count for the study, and what is the intervention model used in the trial comparing Etanercept against a placebo for Etanercept on a background NSAID in the treatment of adult subjects with non radiographic axial Spondyloarthritis?',\n",
       " 'What is the primary outcome measure of the study and how is it defined?',\n",
       " 'What are the inclusion criteria for participants in the study?',\n",
       " 'Explain the null and alternative hypotheses in the context of the study comparing the efficacy of etanercept to placebo in achieving an ASAS 40 response after 12 weeks of treatment. What was the primary endpoint of the study and how was it tested?',\n",
       " 'Describe the statistical method used to analyze the Week 12 data in the study. What was the p-value obtained from the analysis, and how was statistical significance determined? Additionally, provide the 95% confidence interval for the mean difference between etanercept and placebo in achieving an ASAS 40 response.',\n",
       " 'What is the primary purpose of the study \"Once-A-Day Pregabalin For Partial Seizures\" conducted by Pfizer?',\n",
       " 'How was the efficacy of two different dosages of pregabalin CR dosed once daily compared to placebo in the study, and what was the primary outcome measure used to assess this efficacy?',\n",
       " 'What were the inclusion criteria for participants in the study on epilepsy with partial onset seizures?',\n",
       " 'Describe the recruitment group titled \"Pregabalin 330 mg\" and the dosing regimen followed during the study.',\n",
       " 'Explain the statistical method used in the study to calculate the p-value and the significance of the p-value obtained in the context of the ANCOVA model.',\n",
       " 'Discuss the fixed terms included in the ANCOVA model and their relevance in determining the treatment effect on the participants.',\n",
       " 'What was the primary outcome measured in the study on the multiple dose dental pain study of ibuprofen extended release, and how was it calculated?',\n",
       " 'Describe the intervention for Arms group 0 in the study, including the dosage and timing of administration for the ibuprofen 600 mg extended release caplets.',\n",
       " 'What are the inclusion criteria for subjects participating in the study on post-operative pain management following surgical removal of third molars?',\n",
       " 'Based on the group IDs provided, what was the primary outcome measure used to assess the efficacy of the placebo and ibuprofen treatments, and what was the statistical significance of the results?',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'Describe the primary outcome measure used in the study and how it is defined.',\n",
       " 'What are the inclusion criteria for patients participating in the study on pain management after healing from herpes zoster skin rash?',\n",
       " 'How was the recruitment conducted for the study on pregabalin controlled release and placebo in patients with persistent pain after herpes zoster skin rash?',\n",
       " 'What is the primary objective of the study mentioned in the context information?',\n",
       " 'Can you identify the key dates associated with the completion and verification of the study on AN2690 topical solution for onychomycosis of the toenail?',\n",
       " 'What is the primary outcome measure of the study on onychomycosis of toenails, and how is it defined?',\n",
       " 'Describe the intervention arms in the study, including the type of treatment and duration of application for each arm.',\n",
       " 'What were the eligibility criteria for participants in the study on distal subungual onychomycosis, and why were these criteria important for the research?',\n",
       " 'Describe the pre-assignment details of the study, including the treatment options and application instructions for participants. How did the study design aim to evaluate the effectiveness of the AN2690 Topical Solution, 5% compared to the Solution Vehicle?',\n",
       " 'What is the primary purpose of the study mentioned in the context information, and what is the primary outcome measure used to evaluate the efficacy of the treatment?',\n",
       " 'According to the eligibility criteria outlined in the document, what are the inclusion and exclusion criteria for patients participating in the study on the controlled release formulation of pregabalin for fibromyalgia treatment?',\n",
       " 'Describe the eligibility criteria for participants in the study, including any exclusion criteria and the minimum age requirement. How were participants selected for the double blind phase of the study?',\n",
       " 'Explain the dosing regimen for participants in the pregabalin (Single Blind Phase) group during the study. What was the consequence for participants who were unable to tolerate the optimized dose of study medication?',\n",
       " 'What is the main objective of the study mentioned in the context information, and what is the duration of the study?',\n",
       " 'Identify the lead sponsor of the study, the overall status of the study, and the primary completion date.',\n",
       " 'What is the primary outcome measure of the study on Psoriasis treatment with CP-690,550 at Week 16?',\n",
       " 'How is the Physician Global Assessment (PGA) of Psoriasis scored in this study, and what criteria define a positive response in terms of PGA score categories?',\n",
       " 'What is the primary outcome time frame for the study mentioned in the context information?',\n",
       " 'What are the eligibility criteria for participants in the study, specifically in terms of age, duration of diagnosis, and severity of psoriasis?',\n",
       " 'What statistical method was used for the analysis in the study described in the context information? Explain why this method was chosen and how it contributes to the validity of the results.',\n",
       " 'In the study, one of the comparisons had an odds ratio of 12.45 with a 95% confidence interval ranging from 9.01 to 31.88. Discuss the implications of this finding in terms of the effectiveness of the treatment being studied.',\n",
       " 'What is the primary objective of the study mentioned in the context information?',\n",
       " 'Can you identify the key dates associated with the completion and submission of the study mentioned in the context information?',\n",
       " 'What is the primary purpose of the study mentioned in the context information?',\n",
       " 'Can you explain the intervention model and masking used in the study?',\n",
       " 'What were the eligibility criteria for participants in the study on AN2690 Topical Solution for distal subungual onychomycosis?',\n",
       " 'How was the recruitment conducted for the study, including details on the treatment groups and the timeline of subject enrollment and completion?',\n",
       " 'What is the primary objective of the study mentioned in the context information?',\n",
       " 'Can you explain the overall status and timeline of the study conducted by Pfizer for patients with moderate to severe chronic plaque psoriasis?',\n",
       " 'What is the primary outcome measure of this study on Psoriasis treatment with CP-690,550?',\n",
       " 'How is the Physician Global Assessment (PGA) of Psoriasis scored in this study, and what criteria define a positive response in terms of PGA score?',\n",
       " 'What are the inclusion criteria for participants in this study on plaque psoriasis treatment?',\n",
       " 'How were the primary outcome measures reported in this study, and what was the significance of the statistical analysis method used?',\n",
       " 'What statistical method was used for the analysis in the study, and what significance level was set for testing each hypothesis against placebo?',\n",
       " 'For the comparison between two groups (OG000 and OG001), what was the p-value obtained, and what type of non-inferiority was tested in this case?',\n",
       " 'What was the primary purpose of the study titled \"Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy\" conducted by Pfizer?',\n",
       " 'How was the enrollment for the study structured in terms of the intervention groups, and what were the specific interventions administered to each group?',\n",
       " 'What is the primary outcome measure used in this study, and how is it assessed?',\n",
       " 'Describe the eligibility criteria for participants in this study, including both the inclusion and exclusion criteria.',\n",
       " 'What was the primary purpose of the study comparing on-demand treatment to a prophylaxis regimen of BeneFIX in subjects with moderately severe to severe Hemophilia B?',\n",
       " 'How was the annualized bleed rate (ABR) calculated in the study, and what was the primary outcome related to this calculation?',\n",
       " 'Explain the eligibility criteria for subjects to participate in the study, focusing on the requirements related to exposure days to factor IX products and the number of bleeding episodes, particularly joint bleeds, in the 12-month period before the Screening visit.',\n",
       " 'Describe the timeline of participation in the study, including the different periods involved (Screening, Period 1, Period 2, follow-up safety period), and the duration of each period. Additionally, discuss the recruitment details, including the number of enrolled participants, study centers, and countries involved in the research.',\n",
       " 'What is the primary objective of the Archer 1009 study comparing PF-00299804 to erlotinib in patients with advanced non-small cell lung cancer?',\n",
       " 'Can you explain the significance of the co-primary populations defined in the protocol for analyzing the primary objective of Progression Free Survival in the Archer 1009 study?',\n",
       " 'What is the primary outcome measure in the study comparing PF-00299804 and Erlotinib for the treatment of Non-Small Cell Lung Cancer?',\n",
       " 'What are the inclusion criteria for patients to be eligible for enrollment in the study, as outlined in the context information provided?',\n",
       " 'Explain the recruitment process for this study, including the number of participants, treatment arms, and the criteria for eligibility and randomization.',\n",
       " 'Discuss the statistical analysis conducted in this study, including the p-value, statistical method used, and the interpretation of the hazard ratio (HR) and confidence interval (CI) for the comparison between the Dacomitinib arm and Erlotinib arm.',\n",
       " 'What was the primary purpose of the \"Ibuprofen Sodium Tension Headache Study\" conducted by Pfizer?',\n",
       " 'Describe the primary outcome measure used in the study to compare the effectiveness of a novel ibuprofen formulation to placebo and standard ibuprofen in treating tension-type headache.',\n",
       " 'What are the inclusion criteria for participants in this study on episodic tension-type headache treatment?',\n",
       " 'Based on the group IDs provided, what was the statistical method used to analyze the treatment difference between Ibuprofen sodium and Ibuprofen (Motrin IB) for time to meaningful relief, and what was the p-value obtained from the analysis?',\n",
       " 'What is the primary purpose of the study mentioned in the context information? Provide a brief explanation of the study design and the intervention being tested.',\n",
       " \"Describe the primary outcome measure used in the study and explain how it is assessed. What is the significance of measuring the change from baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score?\",\n",
       " 'Explain the eligibility criteria for participants in the study on major depressive disorder (MDD) treatment. What were the inclusion and exclusion criteria specified for individuals aged 7 to 18 years with a primary diagnosis of MDD?',\n",
       " 'Discuss the primary outcome time frame and the statistical method used in the study comparing the efficacy of Placebo and DVS SR Low Dose in treating major depressive disorder. What was the p-value obtained from the analysis, and what does it indicate about the difference between the two treatment groups?',\n",
       " 'What is the primary outcome measure used in the study evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release versus placebo in children and adolescent outpatients with Major Depressive Disorder (MDD)? Describe how this outcome measure is assessed and interpreted.',\n",
       " 'Discuss the study design and methodology employed in the multicenter, randomized, double-blind, placebo-controlled study conducted to evaluate the efficacy, safety, and tolerability of Desvenlafaxine Succinate Sustained Release (DVS SR) in the treatment of children and adolescent outpatients with MDD. Include details about the arms groups, interventions, masking, and enrollment criteria.',\n",
       " 'Explain the eligibility criteria for participants in the study on major depressive disorder (MDD) treatment. What are the inclusion and exclusion criteria that were specified?',\n",
       " 'Discuss the recruitment groups involved in the study comparing Fluoxetine versus Placebo for the treatment of MDD. What were the treatment regimens for each group, and what were the key findings in terms of the adjusted mean difference between the two groups?',\n",
       " 'What was the primary purpose of the study on pregabalin in patients with fibromyalgia conducted by Pfizer?',\n",
       " 'How was the primary outcome of the study measured, and what was the specific endpoint assessed in relation to pain scores during the double-blind treatment period at Week 14?',\n",
       " 'What are the inclusion criteria for patients participating in the study on fibromyalgia treatment with pregabalin and placebo?',\n",
       " 'How was the recruitment process conducted for the study, and what were the details of the two recruitment groups (Pregabalin and Placebo)?',\n",
       " 'What statistical method was used in the analysis of the data, and what type of parameter was calculated? Provide the specific values for the parameter and its confidence interval.',\n",
       " 'Based on the provided information, what was the p-value obtained from the analysis, and what does this value indicate about the significance of the results?',\n",
       " 'What is the primary purpose of study A0081041 conducted by Pfizer in children ages 4-16 years with partial onset seizures?',\n",
       " 'How many arms groups were involved in the study, and what were the interventions administered in each group?',\n",
       " 'Explain the primary outcome measure of the study and how it is calculated. What is the significance of log-transforming the 28-day seizure rate for all partial onset seizures during the baseline phase?',\n",
       " 'Discuss the eligibility criteria for subjects to participate in the study. What are the inclusion and exclusion criteria that potential participants must meet or avoid in order to be enrolled in the trial?',\n",
       " 'What are the two recruitment groups in the study, and what doses of pregabalin were administered to participants in each group based on their weight and age?',\n",
       " 'What eligibility criteria were set for participants in the study, in terms of age, sex, and health status?',\n",
       " 'What was the primary purpose of the Phase 3b multicenter study of Pregabalin in fibromyalgia subjects with comorbid depression?',\n",
       " 'Describe the intervention for Arms group 0 in the study, including the dosage and duration of treatment with Pregabalin.',\n",
       " 'How are the endpoint mean pain scores for Period 1 and Period 2 defined in the study, and when are they measured?',\n",
       " 'Describe the recruitment process for participants in the double-blind, crossover study, including the treatment sequences and the number of participants recruited from different countries and study centers.',\n",
       " \"How was Satterthwaite's approximation used in the statistical analysis of the data?\",\n",
       " 'What was the significance level (p-value) obtained from the Mixed Models Analysis, and how does it impact the interpretation of the results?',\n",
       " 'What is the primary purpose of the clinical study mentioned in the context information?',\n",
       " 'Can you explain the significance of using DA-9501 (Dexmedetomidine) in patients undergoing surgery with epidural or spinal anesthesia without intubation under monitored sedation care?',\n",
       " 'What is the primary purpose of the study described in the context information?',\n",
       " 'What are the inclusion criteria for patients participating in the study mentioned in the context information?',\n",
       " 'What are some of the exclusion criteria for patients participating in the study, particularly in relation to their medical history and current health status?',\n",
       " 'Can you explain the different recruitment groups and their corresponding descriptions in the study, focusing on the dosages and administration details of the drugs being tested?',\n",
       " 'What type of statistical test was used in the study, and how was it applied (e.g. stratified by a specific variable)?',\n",
       " 'What was the reported p-value in the study, and what does a p-value of less than 0.001 indicate in terms of statistical significance?',\n",
       " 'What is the primary completion date of the study on Venlafaxine ER for Major Depressive Disorder (MDD)?',\n",
       " 'Describe the design of the study on Venlafaxine ER, including the treatment phases and follow-up visit evaluation.',\n",
       " 'What is the primary outcome measure of this study, and how is it assessed?',\n",
       " 'Describe the eligibility criteria for participants in this study.',\n",
       " 'Explain the exclusion criteria related to Axis II personality disorders and mental retardation according to DSM-IV diagnostic criteria. Why are subjects with these conditions excluded from the study?',\n",
       " 'Describe the pre-assignment details for subjects participating in the study, including the screening process, randomization, and treatment options. How were subjects confirmed to meet the entry criteria before being randomized to different treatment groups?',\n",
       " 'Explain the statistical method used in the analysis of the data provided in the context information. How does this method help in comparing the mean differences between the different treatment groups?',\n",
       " 'Discuss the significance of the p-value of 0.031 in the context of the study. How does this p-value indicate the strength of the relationship between the treatment groups and the outcome variables?',\n",
       " 'What is the primary purpose of the study described in the context information?',\n",
       " 'How was the average Diabetic Peripheral Neuropathy (DPN) pain measured in the study, and what was the time frame for data collection?',\n",
       " 'Explain the eligibility criteria for participants in the study on pregabalin treatment for diabetic neuropathy pain. What were the inclusion and exclusion criteria that participants had to meet in order to be eligible for the study?',\n",
       " 'Describe the recruitment details for the study, including the number of participants screened, randomized, and withdrawn before randomization. In which countries were the 47 centers located, and what were the key treatment periods and procedures for the participants in the study?',\n",
       " 'What was the primary purpose of the study titled \"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis\" conducted by Pfizer?',\n",
       " 'How was remission defined in the study, and what specific criteria were used to determine if a participant was in remission at Week 52?',\n",
       " 'Explain the components of the Mayo score and how they are used to measure disease activity in ulcerative colitis patients.',\n",
       " 'Describe the eligibility criteria for participants in the study, including both inclusion and exclusion criteria.',\n",
       " 'What statistical method was used to analyze the data in the study mentioned in the context information?',\n",
       " 'What was the difference in percentage between the groups being compared, and what was the confidence interval for this difference?',\n",
       " 'What is the primary outcome measure of the study evaluating the efficacy and safety of tofacitinib in patients with moderate to severe ulcerative colitis?',\n",
       " 'What is the overall status of the study evaluating the use of CP-690,550 in patients with ulcerative colitis, and when was the primary completion date of the study?',\n",
       " 'What are the inclusion criteria for subjects participating in the study on UC treatment with tofacitinib? How do these criteria ensure that the study participants have moderately to severely active UC?',\n",
       " 'How was the efficacy of tofacitinib at different dosages (10 mg BID and 15 mg BID) evaluated in the study? Provide details on the statistical method used and the significance of the p-value obtained.',\n",
       " 'What is the primary outcome measure of the study evaluating the efficacy and safety of tofacitinib in patients with moderate to severe ulcerative colitis?',\n",
       " 'What is the overall status of the study evaluating the efficacy and safety of tofacitinib in patients with moderate to severe ulcerative colitis conducted by Pfizer?',\n",
       " 'Explain the eligibility criteria for participants in the study on tofacitinib for ulcerative colitis. What are the inclusion and exclusion criteria that were specified for enrollment in the study?',\n",
       " 'Describe the primary outcome measure and time frame used in the study on tofacitinib for ulcerative colitis. What was the total score range for disease severity, and how were the scores calculated to assess the severity of the disease?',\n",
       " 'What is the primary purpose of the study comparing the effects of Intravenous Epoetin Hospira and Epoetin Alfa in patients with chronic renal failure requiring hemodialysis?',\n",
       " 'Describe the arms groups in the study, including the interventions and labels associated with each group.',\n",
       " 'Explain the eligibility criteria for patients with chronic renal failure and renal anemia to participate in the study, focusing on the requirements related to stable Epogen treatment, hemoglobin levels, dialysis regimen, and iron stores.',\n",
       " 'Discuss the exclusion criteria for patients with chronic renal failure and renal anemia to participate in the study, highlighting specific medical conditions, treatments, and health parameters that would disqualify a patient from being included in the research.',\n",
       " 'Explain the eligibility criteria for participants in the study comparing Epoetin Hospira and Epogen for the treatment of chronic renal failure.',\n",
       " 'Discuss the recruitment details for participants with chronic renal failure who were receiving Epoetin maintenance therapy prior to enrollment in the study.',\n",
       " 'What is the LS Mean Difference reported in the context information provided?',\n",
       " 'What is the confidence interval (CI) for the LS Mean Difference, and what does it suggest about the statistical significance of the results?',\n",
       " 'What is the primary purpose of the study described in the context information, and what is the brief title of the study?',\n",
       " 'How many arms groups were involved in the study, and what were the interventions provided in each arm group?',\n",
       " 'What are the inclusion criteria for hemodialysis patients with chronic renal failure and renal anemia to participate in the study, specifically regarding Epogen dosing, hemoglobin levels, dialysis stability, and iron stores?',\n",
       " 'Identify three exclusion criteria for patients to be considered ineligible for participation in the study, including specific medical conditions, treatments, and laboratory values.',\n",
       " 'What are some of the exclusion criteria for participation in the study involving Epoetin Hospira and Epogen?',\n",
       " 'Can you explain the recruitment details for participants with chronic renal failure who were receiving Epoetin maintenance therapy prior to enrollment in the study?',\n",
       " 'What was the dosing regimen for participants during the maintenance period of the study, and how long were they followed up after the last dose of study treatment?',\n",
       " 'Based on the group IDs provided, what was the non-inferiority margin considered relevant to demonstrate the equivalence of the two products, and what was the LS mean difference with its corresponding 95% confidence interval?',\n",
       " 'What was the primary purpose of the study conducted by Pfizer on the efficacy and safety of Pregabalin in treating patients with painful Diabetic Peripheral Neuropathy (DPN) who also experience pain on walking?',\n",
       " 'How was the primary outcome of the study, which focused on the average Diabetic Peripheral Neuropathy (DPN) pain based on a Numeric Rating Scale (NRS) over the last 7 days of each treatment period, assessed and recorded by the participants?',\n",
       " 'How was the endpoint mean pain score defined in the study, and what criteria were used to categorize pain severity?',\n",
       " 'Can you explain the recruitment process for participants in the study, including the number of participants screened, randomized, and the countries where the study was conducted?',\n",
       " 'What statistical method was used in the analysis of the data provided in the context information?',\n",
       " 'What was the calculated p-value for the analysis, and does it suggest a statistically significant difference between the groups being compared?',\n",
       " 'What is the primary objective of the study mentioned in the context information, and how is it being evaluated in children aged 6 to 17 years with bladder overactivity caused by a neurological condition?',\n",
       " 'Describe the arms groups and interventions used in the study to evaluate the safety and efficacy of fesoterodine in subjects with symptoms of detrusor overactivity associated with a neurological condition.',\n",
       " 'What is the primary outcome measure of the study at Week 12 in the Active Comparator Phase/Efficacy Phase?',\n",
       " 'What are the inclusion criteria for subjects participating in the study, specifically related to age and medical conditions?',\n",
       " 'Explain the statistical method used in the study to calculate the p-value for change from Baseline at Week 12. How does this method account for baseline factors such as maximum cystometric bladder capacity and weight?',\n",
       " 'Compare the results for the difference in Least square (LS) Mean between group OG000 and OG002 with the results for the difference in LS Mean between group OG001 and OG002. How do these findings contribute to the overall interpretation of the study results?',\n",
       " \"What is the primary completion date of the study comparing inotuzumab ozogamicin to investigator's choice of chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia?\",\n",
       " 'Who is the lead sponsor of the study and what is their organization class?',\n",
       " 'What is the primary outcome measure of the study for participants with Acute Lymphoblastic Leukemia?',\n",
       " 'Describe the intervention for Arm A in the study, including the dose, administration schedule, and total number of cycles.',\n",
       " 'What were the eligibility criteria for participants in this study? Provide examples of both inclusion and exclusion criteria.',\n",
       " 'Describe the treatment regimens for participants in the two recruitment groups, \"Inotuzumab Ozogamicin\" and \"Defined Investigator\\'s Choice of Chemotherapy.\" What were the differences in dosing and administration between the two groups?',\n",
       " 'What was the primary objective of the study involving the investigational drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in patients with moderate to severe chronic low back pain?',\n",
       " 'Describe the primary outcome measure used in the study, including how it was calculated and what it represents in terms of pain assessment.',\n",
       " 'Explain the eligibility criteria for participants in the study on the efficacy and safety of ALO-02 Extended-Release Capsules for chronic low back pain. What were the inclusion and exclusion criteria that participants had to meet in order to be eligible for the study?',\n",
       " 'Describe the recruitment process and treatment protocol for participants in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Study on ALO-02 Extended-Release Capsules. What were the different recruitment groups, and what was the treatment regimen for participants in each group during the study?',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'How many participants were enrolled in the study comparing Ceftazidime-Avibactam with Doripenem for treating complicated urinary tract infections in hospitalized adults?',\n",
       " 'Explain the difference in treatment interventions between Arms group 0 and Arms group 1 in the study, including the specific drugs used and their administration methods.',\n",
       " 'Describe the primary outcome measure of the study, focusing on the patient-reported symptomatic response at Day 5 and the criteria for determining non-inferiority.',\n",
       " 'Explain the eligibility criteria for patients participating in the study, including the age range, requirements for female patients, and criteria for urine culture results.',\n",
       " 'Describe the recruitment details provided in the document, including the treatment groups involved, the number of randomized patients in each protocol, and the combined total number of patients in the study.',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'How many participants were enrolled in the study comparing Ceftazidime-Avibactam with Doripenem for treating complicated urinary tract infections, including acute pyelonephritis?',\n",
       " 'Explain the difference in the intervention descriptions for Arms group 0 (Ceftazidime - Avibactam) and Arms group 1 (Doripenem) in the context of IV treatment for the study.',\n",
       " 'Describe the primary outcome measure for the study, focusing on the patient-reported symptomatic response at Day 5 and the criteria for concluding noninferiority.',\n",
       " 'Explain the inclusion criteria for patients participating in the study, focusing on the age range, sterilization requirements for female patients, and the presence of pyuria and positive urine culture.',\n",
       " 'Discuss the recruitment details provided in the context information, including the treatment groups (CAZ-AVI and doripenem), the number of randomized patients in each protocol, and the combined total of patients in the study.',\n",
       " 'What is the primary objective of the Phase III study comparing Crizotinib to chemotherapy regimens in East Asian non-small cell lung cancer patients with ALK gene alterations?',\n",
       " 'Can you provide the start date, primary completion date, and completion date of the clinical trial comparing Crizotinib to chemotherapy in previously untreated ALK positive East Asian non-small cell lung cancer patients?',\n",
       " 'What is the primary outcome measure of the study described in the context information? Provide a detailed explanation of how this outcome is defined and calculated.',\n",
       " 'What are the inclusion criteria for patients participating in the study? Specifically, what are the requirements related to the diagnosis of lung cancer and the presence of a specific genetic alteration?',\n",
       " 'What are the eligibility criteria for patients to participate in the study, specifically in terms of prior treatments, cardiac health, and medical conditions?',\n",
       " 'Describe the treatment regimens for participants in the Crizotinib arm and the Chemotherapy arm of the study, including dosages, administration methods, and maximum treatment durations.',\n",
       " 'Explain the administration protocol for pemetrexed, cisplatin, and carboplatin in the study described in the context information. What was the maximum duration of chemotherapy treatment allowed in this study?',\n",
       " 'What was the hypothesis being tested in the study, and what was the significance level required to detect a hazard ratio of 0.64 with 80% power? Additionally, based on the results provided, what can be concluded about the efficacy of crizotinib compared to chemotherapy in terms of hazard rate reduction?',\n",
       " 'What was the primary outcome measure used in the study on NWP09 in children with ADHD, and how was it assessed?',\n",
       " 'Describe the study design and methodology used in the evaluation of the safety and efficacy of the chewable formulation of extended-release methylphenidate in pediatric patients with ADHD.',\n",
       " 'Explain the eligibility criteria for children participating in the study on ADHD treatment with NWP09. What are the inclusion and exclusion criteria specified for the participants?',\n",
       " 'Discuss the recruitment details for the study, including the total number of participants enrolled, the randomization process, and the description of the two recruitment groups (Placebo and NWP09).',\n",
       " 'What is the primary outcome measure in the study on pregabalin for post-traumatic peripheral neuropathic pain, and how is it assessed?',\n",
       " 'Describe the eligibility criteria for subjects participating in the study on pregabalin for post-traumatic peripheral neuropathic pain.',\n",
       " 'Explain the exclusion criteria for subjects participating in the study on pregabalin treatment for post-traumatic neuropathic pain. How do these criteria ensure the validity and reliability of the study results?',\n",
       " 'Describe the recruitment details for the study on pregabalin treatment for post-traumatic neuropathic pain. How were participants randomized and what data was collected during the screening and taper periods?',\n",
       " 'What is the primary purpose of the study mentioned in the context information, and what is the brief title of the study?',\n",
       " 'Describe the arms groups involved in the study, including the intervention types, labels, and descriptions for each group.',\n",
       " 'What are the inclusion criteria for neonates in this study on persistent pulmonary hypertension of the newborn (PPHN)?',\n",
       " 'Describe the treatment protocol for participants in Part A of the study, including the dosage and administration of sildenafil and placebo.',\n",
       " 'Explain the statistical method used in the study mentioned in the context information. How does ANCOVA help in analyzing the data?',\n",
       " 'Discuss the significance of the p-value provided in the group IDs section. How does a p-value of 0.9850 impact the interpretation of the study results?',\n",
       " 'What is the primary objective of the study comparing Ceftazidime Avibactam plus Metronidazole to Meropenem for treating complicated intra-abdominal infections in hospitalized adults?',\n",
       " 'Can you identify the key dates associated with the completion and verification of the study, as well as the submission and update dates related to the research findings?',\n",
       " 'What is the primary purpose of the study described in the context information?',\n",
       " 'How is the primary outcome of the study defined and measured?',\n",
       " 'What are the inclusion criteria for patients participating in the study on intra-abdominal infections associated with peritonitis?',\n",
       " 'What was the primary objective of the study comparing Ceftazidime-Avibactam Plus Metronidazole to Meropenem in patients with intra-abdominal infections, and how was non-inferiority determined?',\n",
       " 'Explain the statistical method used in this study to calculate the risk difference (RD) between CAZ AVI and Meropenem clinical cure rates. How was the confidence interval (CI) calculated, and what does the CI range indicate about the results?',\n",
       " 'Based on the given information, what can be inferred about the comparison between CAZ AVI and Meropenem in terms of clinical cure rates? Provide a brief explanation of the parameter value, confidence interval, and statistical significance indicated by the p-value.',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'Describe the treatment regimen for the experimental group in the study, including the dosage and administration schedule of the drugs involved.',\n",
       " 'What is the primary outcome of the study as described in the context information? Provide a detailed explanation of how this outcome is measured and calculated.',\n",
       " 'What are the inclusion criteria for patients eligible to participate in the study based on the eligibility criteria provided? Explain why each criterion is important for selecting participants in this clinical trial.',\n",
       " 'Explain the treatment regimens for the two recruitment groups in the study on Palbociclib Plus Letrozole versus Placebo Plus Letrozole.',\n",
       " 'What statistical method was used to analyze the data in this study, and what was the reported p-value indicating the difference between the two treatment groups?',\n",
       " 'What is the primary purpose of the study described in the context information provided?',\n",
       " 'How many arms groups were involved in the study, and what were the intervention names for each group?',\n",
       " 'What is the primary outcome measure of the study, and how is it calculated?',\n",
       " 'What are the inclusion criteria for participants in the study, and why is it important for them to have a minimum number of Primary Generalized Tonic Clonic (PGTC) seizures during the baseline phase?',\n",
       " 'Explain the dosing regimens of Pregabalin for participants aged less than 17 years in the two recruitment groups mentioned in the document.',\n",
       " 'What statistical method was used to analyze the data in the Group IDs section, and what was the p-value obtained from the analysis?',\n",
       " 'What type of statistical analysis was used in the study, and what was the p-value obtained from the analysis?',\n",
       " 'What was the LS mean difference between the two groups being compared, and what was the confidence interval (CI) for this difference?',\n",
       " 'What is the primary completion date of the study comparing the efficacy of MEK162 versus Dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma?',\n",
       " 'How many patients were enrolled in the study, and what were the two arms they were randomized into for treatment?',\n",
       " 'What is the primary outcome measure in this clinical trial, and how is it defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1?',\n",
       " 'What are some of the key eligibility criteria for patients to be included in this clinical trial evaluating the use of MEK162 and dacarbazine for locally advanced, unresectable, or metastatic cutaneous melanoma?',\n",
       " 'What were the eligibility criteria for participants in the study on advanced unresectable or metastatic Neuroblastoma RAS viral oncogene homolog (NRAS) mutation-positive melanoma?',\n",
       " 'Describe the treatment regimens received by participants in the study, including the dosage and duration of binimetinib (MEK162) and dacarbazine, as well as the follow-up protocol after discontinuation of study treatment.',\n",
       " 'What is the primary completion date of the study \"ARCHER 1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC\"?',\n",
       " 'How many patients were randomized in a 1:1 ratio between dacomitinib (PF-00299804) and gefitinib in the study?',\n",
       " 'What is the primary outcome measure in this clinical trial involving patients with advanced NSCLC and EGFR-activating mutations? Describe the criteria used to determine disease progression based on this outcome measure.',\n",
       " 'What are the eligibility criteria for patients to be included in this study? Provide details on the specific requirements related to histology, EGFR mutations, prior treatment history, and overall health status.',\n",
       " 'Explain the pre-assignment details of the study, including the number of participants randomized, the treatment arms they were assigned to, and the outcomes observed after the last data cutoff date.',\n",
       " 'Discuss the recruitment details for the two treatment groups (Dacomitinib and Gefitinib) in terms of the dosage, administration, and duration of treatment specified for each group.',\n",
       " 'What was the primary objective of the study on topical Ibuprofen for delayed onset muscle soreness, and how was it conducted?',\n",
       " 'Describe the primary outcome measure used in the study and explain how it was assessed in participants.',\n",
       " 'Explain how the change from baseline in the time-weighted sum of muscle soreness with movement (MSM) over 0-24 hours is calculated in the study. What does a higher score indicate in this calculation?',\n",
       " 'Discuss the eligibility criteria for participants in the study, including both inclusion and exclusion criteria. Why is it important for participants to refrain from certain treatments during the study period?',\n",
       " 'What is the statistical method used in the study mentioned in the context information?',\n",
       " 'What is the LS Mean Difference value reported in the study, and what is the confidence interval for this parameter?',\n",
       " 'What is the primary purpose of the study comparing Ceftazidime-Avibactam versus Meropenem in hospitalized adults with nosocomial pneumonia, including ventilator-associated pneumonia?',\n",
       " 'How many participants were enrolled in the study, and what were the intervention arms used for the treatment of nosocomial pneumonia and ventilator-associated pneumonia?',\n",
       " 'What are the inclusion criteria for patients participating in the study, specifically regarding age, pregnancy status, onset of symptoms, and systemic signs?',\n",
       " 'Can you explain the primary outcome of the study in terms of what constitutes a clinical cure at the test-of-cure visit and the timeframe for this assessment?',\n",
       " 'What is the treatment regimen for recruitment group 0 (FG000) in the study, and how does it differ from the treatment regimen for recruitment group 1 (FG001)?',\n",
       " 'Based on the statistical analysis provided in the document, what was the calculated risk difference (RD) between the clinical cure rates of patients receiving CAZ-AVI and Meropenem, and was the non-inferiority margin met for the primary efficacy analysis?',\n",
       " 'What is the primary objective of the study evaluating the efficacy and safety of CP-690,550 in Asian subjects with moderate to severe plaque psoriasis?',\n",
       " 'What was the overall status of the study, and when were the primary completion date and completion date for the research on CP-690,550 in Asian subjects with moderate to severe chronic plaque psoriasis?',\n",
       " 'What is the primary outcome measure of this study on the treatment of psoriasis with Tofacitinib (CP-690,550)?',\n",
       " 'What are the inclusion criteria for participants in this study on the use of Tofacitinib for psoriasis treatment?',\n",
       " 'What are the eligibility criteria for subjects participating in the study on tofacitinib for the treatment of psoriasis?',\n",
       " 'Describe the recruitment groups and the dosages of tofacitinib administered to participants in each group up to Week 52 of the study.',\n",
       " 'What is the primary completion date of the study investigating the effectiveness and safety of tofacitinib in treating psoriatic arthritis, and what was the overall status of the study at that time?',\n",
       " 'Can you explain the purpose of using adalimumab as a comparator in the study on tofacitinib for psoriatic arthritis, and what was the lead sponsor of this research?',\n",
       " 'What is the primary outcome measure of the study, and when is it assessed?',\n",
       " 'What are the inclusion criteria for participants in the study regarding their diagnosis and previous treatment with disease-modifying anti-rheumatic drugs (DMARDs)?',\n",
       " 'What are the eligibility criteria for participants to be included in the study, specifically in terms of joint symptoms and skin lesions?',\n",
       " 'Describe the treatment regimen for participants in the \"Tofacitinib, 10 mg, Twice Daily\" recruitment group, including the dosages of tofacitinib and frequency of subcutaneous placebo administration.',\n",
       " 'What is the primary purpose of the study described in the context information?',\n",
       " 'Describe the primary outcome measure used in the study and how it is calculated.',\n",
       " 'Explain the eligibility criteria for participants in the study. What specific criteria needed to be met for inclusion, and what criteria would result in exclusion from the study?',\n",
       " 'Compare and contrast the two recruitment groups in terms of the treatment received by participants. What were the differences in the dosage and administration of tofacitinib between the two groups?',\n",
       " 'What is the primary outcome measure used in the study to assess driving performance in normal volunteer subjects after taking gabapentin, diphenhydramine, and triazolam compared to placebo?',\n",
       " 'What was the enrollment count for this clinical trial examining the next-day residual effects of gabapentin, diphenhydramine, and triazolam on simulated driving performance in normal volunteers?',\n",
       " 'What were the inclusion criteria for participants in the study on the effects of diphenhydramine citrate, gabapentin, triazolam, and placebo on driving performance?',\n",
       " 'Can you explain the pre-assignment details that were conducted before randomization in the study, and why they were important for the research outcomes?',\n",
       " ...]"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "queries = list(qa_dataset.queries.values())\n",
    "queries"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Faithfulness Evaluation Metric"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [],
   "source": [
    "from llama_index.core.evaluation import FaithfulnessEvaluator\n",
    "faithfulness_gpt4 = FaithfulnessEvaluator(llm=llm3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'What is the primary purpose of the study described in the context information?'"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "eval_query = queries[0]\n",
    "\n",
    "eval_query"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [],
   "source": [
    "response_vector = query_engine.query(eval_query)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [],
   "source": [
    "eval_result = faithfulness_gpt4.evaluate_response(response=response_vector)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# check passing parameter in eval_result if it passed the evaluation.\n",
    "eval_result.passing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [],
   "source": [
    "from llama_index.core.evaluation import EvaluationResult\n",
    "from llama_index.core import Response\n",
    "pd.set_option(\"display.max_colwidth\", 0)\n",
    "\n",
    "def display_eval_df(response: Response, eval_result: EvaluationResult) -> None:\n",
    "    if response.source_nodes == []:\n",
    "        print(\"no response!\")\n",
    "        return\n",
    "    eval_df = pd.DataFrame(\n",
    "        {\n",
    "            \"Response\": str(response),\n",
    "            \"Source\": response.source_nodes[0].node.text[:1000] + \"...\",\n",
    "            \"Evaluation Result\": \"Pass\" if eval_result.passing else \"Fail\",\n",
    "            \"Reasoning\": eval_result.feedback,\n",
    "        },\n",
    "        index=[0],\n",
    "    )\n",
    "    eval_df = eval_df.style.set_properties(\n",
    "        **{\n",
    "            \"inline-size\": \"600px\",\n",
    "            \"overflow-wrap\": \"break-word\",\n",
    "        },\n",
    "        subset=[\"Response\", \"Source\"]\n",
    "    )\n",
    "    display(eval_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_bd6eb_row0_col0, #T_bd6eb_row0_col1 {\n",
       "  inline-size: 600px;\n",
       "  overflow-wrap: break-word;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_bd6eb\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_bd6eb_level0_col0\" class=\"col_heading level0 col0\" >Response</th>\n",
       "      <th id=\"T_bd6eb_level0_col1\" class=\"col_heading level0 col1\" >Source</th>\n",
       "      <th id=\"T_bd6eb_level0_col2\" class=\"col_heading level0 col2\" >Evaluation Result</th>\n",
       "      <th id=\"T_bd6eb_level0_col3\" class=\"col_heading level0 col3\" >Reasoning</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_bd6eb_level0_row0\" class=\"row_heading level0 row0\" >0</th>\n",
       "      <td id=\"T_bd6eb_row0_col0\" class=\"data row0 col0\" >The primary purpose of the first study is to compare patient satisfaction with the prefilled syringe (PFS) and the auto-injector (AI), two different delivery devices for etanercept after 12 weeks of use. The secondary evaluation focuses on identifying patient and device attributes associated with patient satisfaction.\n",
       "\n",
       "The primary purpose of the second study is not explicitly stated in the context. However, it involves a Phase 3, randomized, double-masked, 12-week, parallel group study in pediatric subjects with Glaucoma, using the drug Timolol. The study seems to be comparing the effects of different treatments for glaucoma in children and adults.</td>\n",
       "      <td id=\"T_bd6eb_row0_col1\" class=\"data row0 col1\" >\"National Clinical Identification NCT ID\": \"NCT00482170\",\n",
       "\"Organization study identification\": \"0881A6-3326\",\n",
       "\"EudraCT number\": \"\",\n",
       "\"Organization\": \"Pfizer\",\n",
       "\"Organization class\": \"INDUSTRY\",\n",
       "\"Brief title\": \"Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept\",\n",
       "\"Official title\": \"A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Auto-injector and the Etanercept Prefilled Syringe) in Patients With Psoriasis.\",\n",
       "\"Overall status\": \"COMPLETED\",\n",
       "\"Start date\": \"2007-09\",\n",
       "\"Primary completion date\": \"2009-04\",\n",
       "\"Completion date\": \"2009-09\",\n",
       "\"Verification date\": \"2012-03\",\n",
       "\"Study first submitted date\": \"2007-06-01\",\n",
       "\"Results first submitted date\": \"2012-03-01\",\n",
       "\"Last update submitted date\": \"2012-03-01\",\n",
       "\"Last update posted date\": \"2012-03-30\",\n",
       "\"Lead sponsor\": \"Pfizer\",\n",
       "\"Lead sponsor class\": \"INDUSTRY\",\n",
       "\"Brief summary\": \"Prim...</td>\n",
       "      <td id=\"T_bd6eb_row0_col2\" class=\"data row0 col2\" >Pass</td>\n",
       "      <td id=\"T_bd6eb_row0_col3\" class=\"data row0 col3\" >YES</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x7fd91e95e810>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display_eval_df(response_vector, eval_result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/parkermoe/anaconda3/envs/capstone/lib/python3.11/site-packages/llama_index/core/evaluation/dataset_generation.py:212: DeprecationWarning: Call to deprecated class DatasetGenerator. (Deprecated in favor of `RagDatasetGenerator` which should be used instead.)\n",
      "  return cls(\n"
     ]
    },
    {
     "ename": "ValueError",
     "evalue": "Metadata length (1605) is longer than chunk size (1024). Consider increasing the chunk size or decreasing the size of your metadata to avoid this.",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "\u001b[1;32m/mnt/c/Users/Aluminum/Documents/Capstone/demos/eval_v4.ipynb Cell 46\u001b[0m line \u001b[0;36m4\n\u001b[1;32m      <a href='vscode-notebook-cell://ssh-remote%2B10.0.0.18/mnt/c/Users/Aluminum/Documents/Capstone/demos/eval_v4.ipynb#Y100sdnNjb2RlLXJlbW90ZQ%3D%3D?line=0'>1</a>\u001b[0m \u001b[39mfrom\u001b[39;00m \u001b[39mllama_index\u001b[39;00m\u001b[39m.\u001b[39;00m\u001b[39mcore\u001b[39;00m\u001b[39m.\u001b[39;00m\u001b[39mevaluation\u001b[39;00m \u001b[39mimport\u001b[39;00m DatasetGenerator\n\u001b[1;32m      <a href='vscode-notebook-cell://ssh-remote%2B10.0.0.18/mnt/c/Users/Aluminum/Documents/Capstone/demos/eval_v4.ipynb#Y100sdnNjb2RlLXJlbW90ZQ%3D%3D?line=2'>3</a>\u001b[0m question_generator \u001b[39m=\u001b[39m DatasetGenerator\u001b[39m.\u001b[39mfrom_documents(llama_documents)\n\u001b[0;32m----> <a href='vscode-notebook-cell://ssh-remote%2B10.0.0.18/mnt/c/Users/Aluminum/Documents/Capstone/demos/eval_v4.ipynb#Y100sdnNjb2RlLXJlbW90ZQ%3D%3D?line=3'>4</a>\u001b[0m eval_questions \u001b[39m=\u001b[39m question_generator\u001b[39m.\u001b[39;49mgenerate_questions_from_nodes(\u001b[39m5\u001b[39;49m)\n\u001b[1;32m      <a href='vscode-notebook-cell://ssh-remote%2B10.0.0.18/mnt/c/Users/Aluminum/Documents/Capstone/demos/eval_v4.ipynb#Y100sdnNjb2RlLXJlbW90ZQ%3D%3D?line=5'>6</a>\u001b[0m eval_questions\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/site-packages/llama_index/core/evaluation/dataset_generation.py:328\u001b[0m, in \u001b[0;36mDatasetGenerator.generate_questions_from_nodes\u001b[0;34m(self, num)\u001b[0m\n\u001b[1;32m    326\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mgenerate_questions_from_nodes\u001b[39m(\u001b[39mself\u001b[39m, num: \u001b[39mint\u001b[39m \u001b[39m|\u001b[39m \u001b[39mNone\u001b[39;00m \u001b[39m=\u001b[39m \u001b[39mNone\u001b[39;00m) \u001b[39m-\u001b[39m\u001b[39m>\u001b[39m List[\u001b[39mstr\u001b[39m]:\n\u001b[1;32m    327\u001b[0m \u001b[39m    \u001b[39m\u001b[39m\"\"\"Generates questions for each document.\"\"\"\u001b[39;00m\n\u001b[0;32m--> 328\u001b[0m     \u001b[39mreturn\u001b[39;00m asyncio\u001b[39m.\u001b[39;49mrun(\u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49magenerate_questions_from_nodes(num\u001b[39m=\u001b[39;49mnum))\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/site-packages/nest_asyncio.py:30\u001b[0m, in \u001b[0;36m_patch_asyncio.<locals>.run\u001b[0;34m(main, debug)\u001b[0m\n\u001b[1;32m     28\u001b[0m task \u001b[39m=\u001b[39m asyncio\u001b[39m.\u001b[39mensure_future(main)\n\u001b[1;32m     29\u001b[0m \u001b[39mtry\u001b[39;00m:\n\u001b[0;32m---> 30\u001b[0m     \u001b[39mreturn\u001b[39;00m loop\u001b[39m.\u001b[39;49mrun_until_complete(task)\n\u001b[1;32m     31\u001b[0m \u001b[39mfinally\u001b[39;00m:\n\u001b[1;32m     32\u001b[0m     \u001b[39mif\u001b[39;00m \u001b[39mnot\u001b[39;00m task\u001b[39m.\u001b[39mdone():\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/site-packages/nest_asyncio.py:98\u001b[0m, in \u001b[0;36m_patch_loop.<locals>.run_until_complete\u001b[0;34m(self, future)\u001b[0m\n\u001b[1;32m     95\u001b[0m \u001b[39mif\u001b[39;00m \u001b[39mnot\u001b[39;00m f\u001b[39m.\u001b[39mdone():\n\u001b[1;32m     96\u001b[0m     \u001b[39mraise\u001b[39;00m \u001b[39mRuntimeError\u001b[39;00m(\n\u001b[1;32m     97\u001b[0m         \u001b[39m'\u001b[39m\u001b[39mEvent loop stopped before Future completed.\u001b[39m\u001b[39m'\u001b[39m)\n\u001b[0;32m---> 98\u001b[0m \u001b[39mreturn\u001b[39;00m f\u001b[39m.\u001b[39;49mresult()\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/asyncio/futures.py:203\u001b[0m, in \u001b[0;36mFuture.result\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    201\u001b[0m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m__log_traceback \u001b[39m=\u001b[39m \u001b[39mFalse\u001b[39;00m\n\u001b[1;32m    202\u001b[0m \u001b[39mif\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_exception \u001b[39mis\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39mNone\u001b[39;00m:\n\u001b[0;32m--> 203\u001b[0m     \u001b[39mraise\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_exception\u001b[39m.\u001b[39mwith_traceback(\u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_exception_tb)\n\u001b[1;32m    204\u001b[0m \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_result\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/asyncio/tasks.py:277\u001b[0m, in \u001b[0;36mTask.__step\u001b[0;34m(***failed resolving arguments***)\u001b[0m\n\u001b[1;32m    273\u001b[0m \u001b[39mtry\u001b[39;00m:\n\u001b[1;32m    274\u001b[0m     \u001b[39mif\u001b[39;00m exc \u001b[39mis\u001b[39;00m \u001b[39mNone\u001b[39;00m:\n\u001b[1;32m    275\u001b[0m         \u001b[39m# We use the `send` method directly, because coroutines\u001b[39;00m\n\u001b[1;32m    276\u001b[0m         \u001b[39m# don't have `__iter__` and `__next__` methods.\u001b[39;00m\n\u001b[0;32m--> 277\u001b[0m         result \u001b[39m=\u001b[39m coro\u001b[39m.\u001b[39msend(\u001b[39mNone\u001b[39;00m)\n\u001b[1;32m    278\u001b[0m     \u001b[39melse\u001b[39;00m:\n\u001b[1;32m    279\u001b[0m         result \u001b[39m=\u001b[39m coro\u001b[39m.\u001b[39mthrow(exc)\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/site-packages/llama_index/core/evaluation/dataset_generation.py:313\u001b[0m, in \u001b[0;36mDatasetGenerator.agenerate_questions_from_nodes\u001b[0;34m(self, num)\u001b[0m\n\u001b[1;32m    311\u001b[0m \u001b[39masync\u001b[39;00m \u001b[39mdef\u001b[39;00m \u001b[39magenerate_questions_from_nodes\u001b[39m(\u001b[39mself\u001b[39m, num: \u001b[39mint\u001b[39m \u001b[39m|\u001b[39m \u001b[39mNone\u001b[39;00m \u001b[39m=\u001b[39m \u001b[39mNone\u001b[39;00m) \u001b[39m-\u001b[39m\u001b[39m>\u001b[39m List[\u001b[39mstr\u001b[39m]:\n\u001b[1;32m    312\u001b[0m \u001b[39m    \u001b[39m\u001b[39m\"\"\"Generates questions for each document.\"\"\"\u001b[39;00m\n\u001b[0;32m--> 313\u001b[0m     dataset \u001b[39m=\u001b[39m \u001b[39mawait\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_agenerate_dataset(\n\u001b[1;32m    314\u001b[0m         \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mnodes, num\u001b[39m=\u001b[39mnum, generate_response\u001b[39m=\u001b[39m\u001b[39mFalse\u001b[39;00m\n\u001b[1;32m    315\u001b[0m     )\n\u001b[1;32m    316\u001b[0m     \u001b[39mreturn\u001b[39;00m dataset\u001b[39m.\u001b[39mquestions\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/site-packages/llama_index/core/evaluation/dataset_generation.py:246\u001b[0m, in \u001b[0;36mDatasetGenerator._agenerate_dataset\u001b[0;34m(self, nodes, num, generate_response)\u001b[0m\n\u001b[1;32m    244\u001b[0m \u001b[39mif\u001b[39;00m num \u001b[39mis\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39mNone\u001b[39;00m \u001b[39mand\u001b[39;00m \u001b[39mlen\u001b[39m(query_tasks) \u001b[39m>\u001b[39m\u001b[39m=\u001b[39m num:\n\u001b[1;32m    245\u001b[0m     \u001b[39mbreak\u001b[39;00m\n\u001b[0;32m--> 246\u001b[0m index \u001b[39m=\u001b[39m SummaryIndex\u001b[39m.\u001b[39;49mfrom_documents(\n\u001b[1;32m    247\u001b[0m     [\n\u001b[1;32m    248\u001b[0m         Document(\n\u001b[1;32m    249\u001b[0m             text\u001b[39m=\u001b[39;49mnode\u001b[39m.\u001b[39;49mget_content(metadata_mode\u001b[39m=\u001b[39;49m\u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m_metadata_mode),\n\u001b[1;32m    250\u001b[0m             metadata\u001b[39m=\u001b[39;49mnode\u001b[39m.\u001b[39;49mmetadata,\n\u001b[1;32m    251\u001b[0m         )\n\u001b[1;32m    252\u001b[0m     ],\n\u001b[1;32m    253\u001b[0m     callback_manager\u001b[39m=\u001b[39;49m\u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mcallback_manager,\n\u001b[1;32m    254\u001b[0m )\n\u001b[1;32m    256\u001b[0m query_engine \u001b[39m=\u001b[39m index\u001b[39m.\u001b[39mas_query_engine(\n\u001b[1;32m    257\u001b[0m     llm\u001b[39m=\u001b[39m\u001b[39mself\u001b[39m\u001b[39m.\u001b[39mllm,\n\u001b[1;32m    258\u001b[0m     text_qa_template\u001b[39m=\u001b[39m\u001b[39mself\u001b[39m\u001b[39m.\u001b[39mtext_question_template,\n\u001b[1;32m    259\u001b[0m     use_async\u001b[39m=\u001b[39m\u001b[39mTrue\u001b[39;00m,\n\u001b[1;32m    260\u001b[0m )\n\u001b[1;32m    261\u001b[0m task \u001b[39m=\u001b[39m query_engine\u001b[39m.\u001b[39maquery(\n\u001b[1;32m    262\u001b[0m     \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mquestion_gen_query,\n\u001b[1;32m    263\u001b[0m )\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/site-packages/llama_index/core/indices/base.py:135\u001b[0m, in \u001b[0;36mBaseIndex.from_documents\u001b[0;34m(cls, documents, storage_context, show_progress, callback_manager, transformations, service_context, **kwargs)\u001b[0m\n\u001b[1;32m    132\u001b[0m \u001b[39mfor\u001b[39;00m doc \u001b[39min\u001b[39;00m documents:\n\u001b[1;32m    133\u001b[0m     docstore\u001b[39m.\u001b[39mset_document_hash(doc\u001b[39m.\u001b[39mget_doc_id(), doc\u001b[39m.\u001b[39mhash)\n\u001b[0;32m--> 135\u001b[0m nodes \u001b[39m=\u001b[39m run_transformations(\n\u001b[1;32m    136\u001b[0m     documents,  \u001b[39m# type: ignore\u001b[39;49;00m\n\u001b[1;32m    137\u001b[0m     transformations,\n\u001b[1;32m    138\u001b[0m     show_progress\u001b[39m=\u001b[39;49mshow_progress,\n\u001b[1;32m    139\u001b[0m     \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs,\n\u001b[1;32m    140\u001b[0m )\n\u001b[1;32m    142\u001b[0m \u001b[39mreturn\u001b[39;00m \u001b[39mcls\u001b[39m(\n\u001b[1;32m    143\u001b[0m     nodes\u001b[39m=\u001b[39mnodes,\n\u001b[1;32m    144\u001b[0m     storage_context\u001b[39m=\u001b[39mstorage_context,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    149\u001b[0m     \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs,\n\u001b[1;32m    150\u001b[0m )\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/site-packages/llama_index/core/ingestion/pipeline.py:127\u001b[0m, in \u001b[0;36mrun_transformations\u001b[0;34m(nodes, transformations, in_place, cache, cache_collection, **kwargs)\u001b[0m\n\u001b[1;32m    125\u001b[0m             cache\u001b[39m.\u001b[39mput(\u001b[39mhash\u001b[39m, nodes, collection\u001b[39m=\u001b[39mcache_collection)\n\u001b[1;32m    126\u001b[0m     \u001b[39melse\u001b[39;00m:\n\u001b[0;32m--> 127\u001b[0m         nodes \u001b[39m=\u001b[39m transform(nodes, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs)\n\u001b[1;32m    129\u001b[0m \u001b[39mreturn\u001b[39;00m nodes\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/site-packages/llama_index/core/node_parser/interface.py:115\u001b[0m, in \u001b[0;36mNodeParser.__call__\u001b[0;34m(self, nodes, **kwargs)\u001b[0m\n\u001b[1;32m    114\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39m__call__\u001b[39m(\u001b[39mself\u001b[39m, nodes: List[BaseNode], \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs: Any) \u001b[39m-\u001b[39m\u001b[39m>\u001b[39m List[BaseNode]:\n\u001b[0;32m--> 115\u001b[0m     \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mget_nodes_from_documents(nodes, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs)\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/site-packages/llama_index/core/node_parser/interface.py:75\u001b[0m, in \u001b[0;36mNodeParser.get_nodes_from_documents\u001b[0;34m(self, documents, show_progress, **kwargs)\u001b[0m\n\u001b[1;32m     70\u001b[0m doc_id_to_document \u001b[39m=\u001b[39m {doc\u001b[39m.\u001b[39mid_: doc \u001b[39mfor\u001b[39;00m doc \u001b[39min\u001b[39;00m documents}\n\u001b[1;32m     72\u001b[0m \u001b[39mwith\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mcallback_manager\u001b[39m.\u001b[39mevent(\n\u001b[1;32m     73\u001b[0m     CBEventType\u001b[39m.\u001b[39mNODE_PARSING, payload\u001b[39m=\u001b[39m{EventPayload\u001b[39m.\u001b[39mDOCUMENTS: documents}\n\u001b[1;32m     74\u001b[0m ) \u001b[39mas\u001b[39;00m event:\n\u001b[0;32m---> 75\u001b[0m     nodes \u001b[39m=\u001b[39m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m_parse_nodes(documents, show_progress\u001b[39m=\u001b[39;49mshow_progress, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs)\n\u001b[1;32m     77\u001b[0m     \u001b[39mfor\u001b[39;00m i, node \u001b[39min\u001b[39;00m \u001b[39menumerate\u001b[39m(nodes):\n\u001b[1;32m     78\u001b[0m         \u001b[39mif\u001b[39;00m (\n\u001b[1;32m     79\u001b[0m             node\u001b[39m.\u001b[39mref_doc_id \u001b[39mis\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39mNone\u001b[39;00m\n\u001b[1;32m     80\u001b[0m             \u001b[39mand\u001b[39;00m node\u001b[39m.\u001b[39mref_doc_id \u001b[39min\u001b[39;00m doc_id_to_document\n\u001b[1;32m     81\u001b[0m         ):\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/site-packages/llama_index/core/node_parser/interface.py:179\u001b[0m, in \u001b[0;36mMetadataAwareTextSplitter._parse_nodes\u001b[0;34m(self, nodes, show_progress, **kwargs)\u001b[0m\n\u001b[1;32m    177\u001b[0m \u001b[39mfor\u001b[39;00m node \u001b[39min\u001b[39;00m nodes_with_progress:\n\u001b[1;32m    178\u001b[0m     metadata_str \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_get_metadata_str(node)\n\u001b[0;32m--> 179\u001b[0m     splits \u001b[39m=\u001b[39m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49msplit_text_metadata_aware(\n\u001b[1;32m    180\u001b[0m         node\u001b[39m.\u001b[39;49mget_content(metadata_mode\u001b[39m=\u001b[39;49mMetadataMode\u001b[39m.\u001b[39;49mNONE),\n\u001b[1;32m    181\u001b[0m         metadata_str\u001b[39m=\u001b[39;49mmetadata_str,\n\u001b[1;32m    182\u001b[0m     )\n\u001b[1;32m    183\u001b[0m     all_nodes\u001b[39m.\u001b[39mextend(\n\u001b[1;32m    184\u001b[0m         build_nodes_from_splits(splits, node, id_func\u001b[39m=\u001b[39m\u001b[39mself\u001b[39m\u001b[39m.\u001b[39mid_func)\n\u001b[1;32m    185\u001b[0m     )\n\u001b[1;32m    187\u001b[0m \u001b[39mreturn\u001b[39;00m all_nodes\n",
      "File \u001b[0;32m~/anaconda3/envs/capstone/lib/python3.11/site-packages/llama_index/core/node_parser/text/sentence.py:153\u001b[0m, in \u001b[0;36mSentenceSplitter.split_text_metadata_aware\u001b[0;34m(self, text, metadata_str)\u001b[0m\n\u001b[1;32m    151\u001b[0m effective_chunk_size \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mchunk_size \u001b[39m-\u001b[39m metadata_len\n\u001b[1;32m    152\u001b[0m \u001b[39mif\u001b[39;00m effective_chunk_size \u001b[39m<\u001b[39m\u001b[39m=\u001b[39m \u001b[39m0\u001b[39m:\n\u001b[0;32m--> 153\u001b[0m     \u001b[39mraise\u001b[39;00m \u001b[39mValueError\u001b[39;00m(\n\u001b[1;32m    154\u001b[0m         \u001b[39mf\u001b[39m\u001b[39m\"\u001b[39m\u001b[39mMetadata length (\u001b[39m\u001b[39m{\u001b[39;00mmetadata_len\u001b[39m}\u001b[39;00m\u001b[39m) is longer than chunk size \u001b[39m\u001b[39m\"\u001b[39m\n\u001b[1;32m    155\u001b[0m         \u001b[39mf\u001b[39m\u001b[39m\"\u001b[39m\u001b[39m(\u001b[39m\u001b[39m{\u001b[39;00m\u001b[39mself\u001b[39m\u001b[39m.\u001b[39mchunk_size\u001b[39m}\u001b[39;00m\u001b[39m). Consider increasing the chunk size or \u001b[39m\u001b[39m\"\u001b[39m\n\u001b[1;32m    156\u001b[0m         \u001b[39m\"\u001b[39m\u001b[39mdecreasing the size of your metadata to avoid this.\u001b[39m\u001b[39m\"\u001b[39m\n\u001b[1;32m    157\u001b[0m     )\n\u001b[1;32m    158\u001b[0m \u001b[39melif\u001b[39;00m effective_chunk_size \u001b[39m<\u001b[39m \u001b[39m50\u001b[39m:\n\u001b[1;32m    159\u001b[0m     \u001b[39mprint\u001b[39m(\n\u001b[1;32m    160\u001b[0m         \u001b[39mf\u001b[39m\u001b[39m\"\u001b[39m\u001b[39mMetadata length (\u001b[39m\u001b[39m{\u001b[39;00mmetadata_len\u001b[39m}\u001b[39;00m\u001b[39m) is close to chunk size \u001b[39m\u001b[39m\"\u001b[39m\n\u001b[1;32m    161\u001b[0m         \u001b[39mf\u001b[39m\u001b[39m\"\u001b[39m\u001b[39m(\u001b[39m\u001b[39m{\u001b[39;00m\u001b[39mself\u001b[39m\u001b[39m.\u001b[39mchunk_size\u001b[39m}\u001b[39;00m\u001b[39m). Resulting chunks are less than 50 tokens. \u001b[39m\u001b[39m\"\u001b[39m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    164\u001b[0m         flush\u001b[39m=\u001b[39m\u001b[39mTrue\u001b[39;00m,\n\u001b[1;32m    165\u001b[0m     )\n",
      "\u001b[0;31mValueError\u001b[0m: Metadata length (1605) is longer than chunk size (1024). Consider increasing the chunk size or decreasing the size of your metadata to avoid this."
     ]
    }
   ],
   "source": [
    "from llama_index.core.evaluation import DatasetGenerator\n",
    "\n",
    "question_generator = DatasetGenerator.from_documents(llama_documents)\n",
    "eval_questions = question_generator.generate_questions_from_nodes(5)\n",
    "\n",
    "eval_questions"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Relevancy Evaluation Metric"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [],
   "source": [
    "from llama_index.core.evaluation import RelevancyEvaluator\n",
    "relevancy_gpt4 = RelevancyEvaluator(llm=llm3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Discuss the eligibility criteria for inclusion and exclusion of patients in the study comparing exemestane and tamoxifen therapy for adjuvant treatment of breast cancer. Why were patients with ER and PR negative primary tumors or unknown ER/PR status excluded from the study?'"
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "query = queries[3]\n",
    "\n",
    "query"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [],
   "source": [
    "response_vector = query_engine.query(query)\n",
    "\n",
    "# Relevancy evaluation\n",
    "eval_result = relevancy_gpt4.evaluate_response(\n",
    "    query=query, response=response_vector\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "eval_result.passing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [],
   "source": [
    "def display_eval_df(\n",
    "    query: str, response: Response, eval_result: EvaluationResult\n",
    ") -> None:\n",
    "    eval_df = pd.DataFrame(\n",
    "        {\n",
    "            \"Query\": query,\n",
    "            \"Response\": str(response),\n",
    "            \"Source\": response.source_nodes[0].node.text[:1000] + \"...\",\n",
    "            \"Evaluation Result\": \"Pass\" if eval_result.passing else \"Fail\",\n",
    "            \"Reasoning\": eval_result.feedback,\n",
    "        },\n",
    "        index=[0],\n",
    "    )\n",
    "    eval_df = eval_df.style.set_properties(\n",
    "        **{\n",
    "            \"inline-size\": \"600px\",\n",
    "            \"overflow-wrap\": \"break-word\",\n",
    "        },\n",
    "        subset=[\"Response\", \"Source\"]\n",
    "    )\n",
    "    display(eval_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_9eaa0_row0_col1, #T_9eaa0_row0_col2 {\n",
       "  inline-size: 600px;\n",
       "  overflow-wrap: break-word;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_9eaa0\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_9eaa0_level0_col0\" class=\"col_heading level0 col0\" >Query</th>\n",
       "      <th id=\"T_9eaa0_level0_col1\" class=\"col_heading level0 col1\" >Response</th>\n",
       "      <th id=\"T_9eaa0_level0_col2\" class=\"col_heading level0 col2\" >Source</th>\n",
       "      <th id=\"T_9eaa0_level0_col3\" class=\"col_heading level0 col3\" >Evaluation Result</th>\n",
       "      <th id=\"T_9eaa0_level0_col4\" class=\"col_heading level0 col4\" >Reasoning</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_9eaa0_level0_row0\" class=\"row_heading level0 row0\" >0</th>\n",
       "      <td id=\"T_9eaa0_row0_col0\" class=\"data row0 col0\" >Discuss the eligibility criteria for inclusion and exclusion of patients in the study comparing exemestane and tamoxifen therapy for adjuvant treatment of breast cancer. Why were patients with ER and PR negative primary tumors or unknown ER/PR status excluded from the study?</td>\n",
       "      <td id=\"T_9eaa0_row0_col1\" class=\"data row0 col1\" >The eligibility criteria for inclusion in the study required postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, who have been treated with tamoxifen continuously for between 2 and 3 years and one month, and are still free of disease. The exclusion criteria included patients with unresectable breast cancer and those with ER negative primary tumors. \n",
       "\n",
       "The study did not provide a specific reason for excluding patients with ER negative primary tumors or unknown ER/PR status. However, it's generally known that the effectiveness of both tamoxifen and exemestane is often dependent on the presence of hormone receptors such as estrogen receptors (ER) and progesterone receptors (PR). These drugs work by blocking these receptors or reducing their numbers, thereby slowing or stopping the growth of cancer cells. Therefore, patients with ER negative tumors, which do not have these receptors, or those with unknown ER/PR status, may not respond to these treatments, which could affect the results of the study.</td>\n",
       "      <td id=\"T_9eaa0_row0_col2\" class=\"data row0 col2\" >\",\n",
       "\"Primary outcome time frame\": \"Baseline up to Month 36\",\n",
       "\"Eligibility criteria\": \"Inclusion Criteria:\n",
       "* postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease\n",
       "Exclusion Criteria:\n",
       "* unresectable breast cancer\n",
       "* ER negative primary tumor\",\n",
       "\"Eligibility of healthy volunteer\": \"False\",\n",
       "\"Eligibility sex\": \"FEMALE\",\n",
       "\"Eligibility minimum age\": \"30 Years\",\n",
       "\"Eligibility standard age\": \"['ADULT', 'OLDER_ADULT']\",\n",
       "\"Pre-assignment details\": \"Main study also included 3 sub-studies only for the purpose of tolerability assessment: endometrial status, bone metabolism and quality of life (QoL). Out of 4740 enrolled participants, data for 16 participants from a center were excluded since it was considered unreliable. Results are reported for remaining 4724 participants.\",\n",
       "\"Recruitment details\": \"The publication describing ...</td>\n",
       "      <td id=\"T_9eaa0_row0_col3\" class=\"data row0 col3\" >Pass</td>\n",
       "      <td id=\"T_9eaa0_row0_col4\" class=\"data row0 col4\" >YES</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x7fd90453a5d0>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display_eval_df(query,response_vector, eval_result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [],
   "source": [
    "import random\n",
    "from llama_index.core.evaluation import BatchEvalRunner\n",
    "\n",
    "llm35 = OpenAI(temperature=0, model=\"gpt-3.5-turbo-16k-0613\")\n",
    "query_engine = vector_index.as_query_engine(llm=llm35)\n",
    "#lmm35 = OpenAI(temperature=0, model=\"gpt-3.5-turbo-16k-0613\")\n",
    "\n",
    "num_samples = 10\n",
    "batch_eval_queries = random.sample(queries, num_samples)\n",
    "\n",
    "# Initiate BatchEvalRunner to compute FaithFulness and Relevancy Evaluation.\n",
    "runner = BatchEvalRunner(\n",
    "    {\"faithfulness\": faithfulness_gpt4, \"relevancy\": relevancy_gpt4},\n",
    "    workers=8,\n",
    ")\n",
    "\n",
    "# Compute evaluation\n",
    "eval_results = await runner.aevaluate_queries(\n",
    "    query_engine, queries=batch_eval_queries\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.8"
      ]
     },
     "execution_count": 85,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "faithfulness_score = sum(result.passing for result in eval_results['faithfulness']) / len(eval_results['faithfulness'])\n",
    "\n",
    "faithfulness_score"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.5"
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "relevancy_score = sum(result.passing for result in eval_results['relevancy']) / len(eval_results['relevancy'])\n",
    "\n",
    "relevancy_score"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "capstone",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
